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Ischaemic	 heart	 disease	 remains	 the	 leading	 cause	 of	 death	worldwide	 and	 its	 major	 manifestation	 is	 through	 an	 acute	myocardial	infarction	(AMI).		This	usually	presents	as	an	ST	segment	elevation	 myocardial	 infarction	 (STEMI),	 where	 an	 acute	 plaque	rupture	 leads	 to	 a	 thrombotic	 occlusion	 of	 the	 coronary	 artery	rendering	 the	 myocardium	 ischaemic	 that	 eventually	 leads	 to	 cell	death.		The	most	effective	strategy	of	treating	this	is	via	percutaneous	coronary	 intervention	(PCI)	whereby	the	thrombus	 is	aspirated	and	stent	is	implanted	within	the	narrowed	segment	of	the	artery.		Other	treatment	options	include	thrombolysis	or	emergent	coronary	artery	bypass	 grafting	 (CABG)	 surgery.	 	 Although	 reperfusion	 is	 a	 pre-requisite	 for	 myocardial	 salvage,	 the	 process	 itself	 is	 capable	 of	inducing	 cell	 death	 in	 addition	 to	 that	 caused	 by	 myocardial	ischaemia	 -	 a	 process	 termed	 ‘lethal	 reperfusion	 injury’.  New	treatment	 strategies	 are	 required	 to	 protect	 the	 heart	 against	 the	detrimental	 effects	 of	 acute	 ischaemia-reperfusion	 injury	 (IRI).	Stromal	cell-derived	factor	1α	(SDF-1α	or	CXCL12),	acting	through	its	cognate	receptor	on	target	cell	membranes	has	been	recognised	and	demonstrated	 in	 animal	 models	 to	 limit	 myocardial	 infarction	 size	
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following	 acute	 ischaemia	 reperfusion	 injury.	 	 We	 have	 already	established	that	SDF-1α	is	an	important	humoral	factor	mediating	the	effects	 of	 remote	 ischaemic	 conditioning	 (RIC)	 such	 as	 reducing	infarction	size	in	a	rat	 in	vivo	model	as	well	as	improving	functional	recovery	 of	 rat	 cardiac	 papillary	 muscle	 in	 an	 ex	 vivo	 model.		Whether,	SDF-1α	can	protect	human	heart	tissue	is	not	known,	and	is	investigated	here	using	 isolated	human	atrial	 trabeculae	exposed	 to	simulated	IRI.	
A	 human	 atrial	 trabecular	 model	 utilising	 simulated	 ischaemia-reperfusion	 injury	was	 used	 to	 reiterate	 the	 existence	 of	 ischaemic	preconditioning	in	human	tissue.		The	model	was	characterised	using	various	stabilisation,	simulated	ischaemia	and	reperfusion	times	and	the	 challenges	 encountered	 with	 this	 model	 are	 discussed.	 Human	atrial	 trabeculae	 obtained	 during	 elective	 cardiac	 surgery	 were	suspended	 in	 organ	 baths	 and	 superfused	 with	 modified	 Tyrode’s	solution.	 	Using	 the	optimum	stabilisation,	 simulated	 ischaemia	and	reperfusion	 times,	 these	 trabeculae	 were	 then	 subjected	 to	 an	ischaemic	insult.		Some	of	these	were	preceded	by	a	preconditioning	protocol	 whilst	 others	 were	 pretreated	 with	 SDF-1α	 prior	 to	 the	simulated	ischaemic	insult.		The	end	point	for	the	human	model	was	the	 functional	recovery	of	myocardial	contractility.	 	Unlike	previous	
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experiments,	the	trabeculae	were	stretched	to	the	peak	of	the	Frank-Starling	curve	prior	to	assignment	to	various	protocols.		The	effect	of	reduced	number	of	stretches	is	also	compared	to	multiple	stretches.	
The	 results	 of	 this	 study	 demonstrate	 that	 (a)	 ischaemic	preconditioning	 is	 effective	 in	 a	 human	model	 despite	 evolution	 of	advancing	medical	therapy,	(b)	contrary	to	earlier	data,	I	was	unable	to	 demonstrate	 that	 stretch	 caused	 preconditioning	 of	 the	 human	myocardium,	 (c)	 SDF-1α	 act	 as	 a	 preconditioning	 mimetic	 and	protects	 it	 from	 lethal	 reperfusion	 injury	 and	 (d)	 the	 protection	appears	to	be	mediated	through	its	cognate	CXCR4	receptors	and	at	least	 partly	 via	 activation	 of	 intracellular	 kinases	 such	 as	extracellular	signal-regulated	kinases	(ERK).			
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Data	 from	 the	Quality	 and	Outcomes	 Framework	 (QOF)	 report	 that	2.3	million	 people	 in	 the	 United	 Kingdom	 (UK),	 live	 with	 coronary	heart	 disease	 (CHD).	 	 The	 highest	 and	 lowest	 prevalence	 being	 in	Scotland	and	Northern	Ireland	respectively.		£4.3	billion	pounds	was	spent	 treating	 cardiovascular	 disease	 (CVD)	 through	 Clinical	Commissioning	 Groups	 (CCGs)	 through	 the	 National	 Health	 Service	(NHS)	England	between	2012/2013.		CVD	remains	one	of	the	leading	causes	of	mortality	and	morbidity	within	the	UK	as	well	as	globally.		In	 2014,	 CVD	 accounted	 for	 27	 percent	 of	 all	 UK	 deaths	 while	malignancies	 lead	 the	charts	at	29	percent.	 	Though	CVD	exists	 in	a	variety	 of	 forms,	 CHD	 represents	 majority	 of	 deaths	 representing	almost	45	percent	due	to	CVD.			In	2014,	15	percent	and	10	percent	of	male	 and	 female	 deaths	 were	 from	 CHD	 totaling	 at	 69,000	 deaths.		Thus,	 CHD	by	 far	 is	 the	biggest	 single	 cause	 of	 death	 in	 the	UK.	 	 In	men,	 CHD	 also	 represents	 the	 single	 most	 common	 cause	 of	premature	 death	 (defined	 as	 death	 before	 the	 age	 of	 75	 years)	accounting	for	around	16,	800	deaths	(15	percent	of	male	premature	deaths).	
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On	a	global	basis,	figures	from	the	World	Health	Organisation	(WHO)	clearly	 shows	CVD	 to	be	 the	 leading	cause	of	death	with	more	 than	17.5	million	deaths	due	to	CVD	in	2012	(31%	of	all	global	deaths);	7.4	million	deaths	were	due	 to	CHD	despite	 advances	 in	 treatment	 and	overall	reduction	in	mortality	over	the	years	(1).	
	
1.2 A	historical	perspective	of	coronary	heart	disease		
Angina	 pectoris	 is	 derived	 from	 the	 Latin	 angina	 “infection	 of	 the	
throat”;	Latin	pectus	“chest”	(2).	
CHD	represents	a	spectrum	of	disease	 from	angina,	unstable	angina	and	 myocardial	 infarction	 (3).	 	 William	 Heberden	 first	 described	classical	 angina	 pectoris	 in	 1768	 before	 presenting	 it	 to	 the	 Royal	College	of	Physicians	 in	1768	prior	 to	 its	appearance	 in	 the	Medical	Transactions	 of	 the	 College	 in	 1772	 (4).	 	 	 Both	 typical	 and	 variant	anginas	were	described	that	still	hold	true	today.		Although	Heberden	was	one	of	the	earlier	physicians	to	describe	angina	pectoris,	there	is	also	a	case	described	 in	 the	memoirs	of	 the	Earl	of	Clarendon	1632	(5).	 	During	that	period	of	 time,	pathophysiology	was	unknown	and	treatment	consisted	of	bed	rest,	bloodletting	and	a	tincture	of	opium,	or	a	combination	thereof.	 	 	Towards	the	end	of	the	century	in	1799,	
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Caleb	H	Parry	hypothesised	that	angina	pectoris	(then	referred	to	as	Syncope	 Anginosa)	 was	 due	 to	 coronary	 ossification	 (calcification)	and	that	it	predominated	in	men	aged	50	years	and	above	and	rarely	occurred	 in	 women	 and	 children	 (6).	 	 During	 the	 18th	 and	 19th	century,	 medical	 knowledge	 focused	 on	 clinical	 observation	 and	clinical	 dissection	 before	 the	 emergence	 of	 Cardiovascular	 Sciences	towards	 the	 end	 of	 the	 19th	 century	 and	 beginning	 of	 20th	 century	where	 an	 interplay	 between	 science	 and	 medicine	 was	 sought	 to	better	understand	the	biology	of	cardiovascular	disease.	
Following	 Heberdens	 first	 description	 of	 angina,	 it	 took	 almost	 a	century	 for	 pathologists	 to	 describe	 thrombotic	 occlusions	 in	addition	 to	 coronary	 ossification	 in	 relation	 to	 coronary	 artery	disease.	
Towards	 the	 end	 of	 the	 19th	 century,	 vascular	 biologist	 discovered	occlusion	 of	 the	 coronary	 artery	 in	 dogs	 caused	 “quivering”	 of	 the	ventricles	 that	was	 rapidly	 fatal	 (7,	 8).	 	 In	 1879	 pathologist	 Ludvig	Hektoen	concluded	coronary	thrombosis	as	the	underlying	cause	for	a	 myocardial	 infarction	 (9).	 	 In	 1910,	 a	 pair	 of	 Russian	 physicians	trained	in	pathology	described	a	series	of	post	mortem	that	resulted	from	a	clinical	picture	of	myocardial	 infarction	(10).	 	Following	 this	James	 Herrick	 described	 total	 bed	 rest	 as	 a	 treatment	 for	 this	
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condition	(11)	before	utilising	electrocardiography	(ECG)	to	diagnose	it	 (12).	 	 This	 was	 the	 standard	 of	 care	 to	 diagnose	 and	 treat	 this	condition	 until	 the	 mid	 20th	 century	 when	 further	 rapid	 advances	were	made.			
In	 1948,	 the	 Framingham	 Heart	 Study	 studied	 the	 lifestyle	 of	 the	residents	 in	Massachusetts	 and	 published	 their	 findings	 “Factors	 of	Risk	in	the	Development	of	Coronary	Heart	Disease”	(13).		The	study	was	 the	 first	 to	 report	 hypertension	 and	 hyperlipidaemia	 as	 risk	factors	 for	 the	 development	 of	 coronary	 artery	 disease	 (CAD).	 	 As	part	of	their	observation,	investigators	also	noted	the	development	of	ischaemic	heart	disease	in	women	later	in	life	compared	to	men	(13).		National	 programs	 were	 subsequently	 rolled	 out	 to	 educate	physicians	 and	 the	 public	 that	 led	 a	 significant	 reduction	 in	 age-related	cardiac	deaths.	
In	1961	coronary	care	units	were	established.	 	Prior	to	this	patients	who	 were	 fortunate	 enough	 to	 survive	 a	 myocardial	 infarct	 were	admitted	 anywhere	within	 a	 hospital	 and	 usually	 as	 far	 as	 possible	from	 the	 nurses	 station	 in	 order	 to	 allow	 them	 complete	 rest.		Unfortunately	the	death	rate	was	as	high	as	30%,	most	likely	due	to	some	 form	of	 arrhythmia.	 	 Since	 the	 development	 of	 coronary	 care	units,	 inpatient	 mortality	 has	 reduced	 by	 half	 owing	 to	 continuous	
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cardiac	 monitoring,	 cardio-pulmonary	 resuscitation	 and	 external	defibrillation	(14).		
Back	 in	 1628,	 William	 Harvey	 set	 stage	 for	 the	 physiology	 of	cardiovascular	 system	 to	 flourish.	 	 In	 his	 publication	 of	 De	 Motu	
Cordis	in	1628,	he	described	the	cardiac	function	and	circulation	(15).			French	 physiologist	 Claude	 Bernard	 during	 the	 19th	 century	progressed	to	measure	pressures	within	cardiac	chambers	and	great	vessels	(16).		This	followed	suit	by	Werner	Forssman	who	undertook	cardiac	 catheterisation	 on	 himself	 resulting	 in	 the	 first	 human	cardiac	 catheterisation	 (17).	 	 Further	 exploration	 together	 with	Andre	Frederic	Cournand	and	Dickinson	W	Richards	(18)	led	to	all	3	being	 awarded	 the	 Nobel	 Prize	 in	 1958.	 	 Since	 then	 cardiac	catheterisation	 developed	 in	 1958.	 	 This	 was	 combined	 with	 left	ventriculography	 to	 study	 coronary	 artery	 disease	 that	 became	 the	gold	 standard	 for	 defining	 coronary	 anatomy	 and	 a	 platform	 for	surgical	treatment	by	way	of	coronary	revascularisation	(19).		
It	was	the	pioneering	work	of	Dotter	and	Judkin	that	lead	to	the	field	of	percutaneous	coronary	intervention	with	Andreas	Grüntzig	(1939-1985)	becoming	 the	 father	of	 such	 intervention	(20).	Grüntzig,	who	was	a	German	radiologist	was	taught	the	angioplasty	technique	from	Dotter	 following	a	 lecture	 in	Germany	and	then	went	on	to	perform	
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the	 first	 coronary	 balloon	 angioplasty	 on	 a	 human	 being	 with	excellent	 final	 angiographic	 results	 that	 remained	 patent	 at	 its	 10th	anniversary.		Subsequently	bare	metal	stents	(BMS)	evolved	followed	by	drug	eluting	stents	(DES),	which	are	utilised	mainly	today	(21).		
By	the	1970s,	in-hospital	mortality	had	reduced	from	30%	to	around	15%	and	in	the	first	year	following	hospital	discharge	approximately	10%	 of	 patients	 of	 died	 from	 left	 ventricular	 failure	 that	 resulted	from	larger	index	infarctions.		It	was	later	discovered,	through	animal	studies,	 that	 improving	 the	 balance	 between	 myocardial	 oxygen	supply	 and	 demand	 could	 reduce	 infarct	 size	 (22).	 	 By	 1976,	Cardiologists	 were	 able	 to	 unblock	 occluded	 coronary	 vessels	 with	the	 use	 of	 intravenous	 infusions	 of	 streptokinase,	which	 acted	 as	 a	thrombolytic	 agent,	which	 essentially	 dispersed	 the	 clot	 (23).	 	 	 The	Italian	Group	for	the	Study	of	Streptokinase	in	Myocardial	Infarction	(GISSI)	was	 the	 first	 human	 clinical	 trial	 involving	 11,712	 patients,	demonstrating	 a	 reduction	 in	 early	 mortality	 in	 the	 setting	 of	 an	acute	 infarction	(18%	relative	risk	reduction;	13%	to	10.7%	21-day	hospital	mortality)	(24).		The	reduction	was	further	pronounced	with	the	addition	of	aspirin	to	streptokinase	as	demonstrated	in	the	ISIS	II	trial	 (25).	 	 Interestingly,	 survival	 advantages	 produced	 by	 the	combination	of	fibrinolytic	therapy	and	one	month	of	aspirin	started	
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Ischaemia	 (Greek	 ischein	 “to	 restrain”	 +	 haima	 “blood”)	 is	 the	restriction	of	blood	supply	to	an	organ	or	tissue.		It	occurs	when	the	blood	 supply	 is	 inadequate	 to	meet	 the	 tissues	metabolic	 demands	resulting	 in	 hypoxia,	 insufficiency	 of	 metabolic	 substrates	 and	accumulation	 of	metabolic	waste	 that	 ultimately	 affect	 cell	 survival	(33).		It	may	occur	in	a	variety	of	circumstances	(decreased	supply	or	increased	demand)	but	 in	 relation	 to	 the	myocardial	 ischaemia,	 the	coronary	vessel	typically	becomes	either	partially	or	totally	occluded	resulting	in	an	imbalance	between	the	supply	and	demand	of	oxygen	and	essential	nutrients	to	the	myocardium.		Atherosclerotic	disease	is	the	most	 common	cause	of	myocardial	 ischaemia.	 	 It	 can	have	both	stable	 and	 unstable	 elements	 during	 which	 activated	 vascular	 wall	inflammation	 may	 lead	 to	 a	 myocardial	 infarction	 that	 may	 go	undetected	or	present	 for	 the	 first	 time	as	 sudden	 cardiac	death	or	with	 severe	 haemodynamic	 deterioration	 (34).	 	 Clinical	 features	 of	ischaemia	 result	 from	 this	 supply-demand	 imbalance	 and	 patients	often	 present	 with	 a	 variety	 of	 symptoms	 including	 diffuse	discomfort	in	the	chest,	shoulders	and	upper	extremities	that	tend	to	be	 associated	 with	 autonomic	 features	 of	 nausea,	 vomiting	 and	diaphoresis.	 	 	 The	 duration	 and	 severity	 of	 ischaemia	 often	
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determines	the	clinical	manifestation	that	spans	from	cardiac	angina	(less	than	20	minutes)	to	a	full	thickness	myocardial	infarction	(more	than	20	minutes).		Maroko	and	colleagues	first	identified	reperfusion	as	 the	 most	 effective	 approach	 for	 salvaging	 acutely	 ischaemic	myocardium	 (35),	 (36).	 	 In	 their	 animal	 study,	 they	 examined	 the	relationship	 between	 epicardial	 ST	 segment	 elevation	 15	 minutes	after	 coronary	 artery	 occlusion	 and	 myocardial	 creatine	phosphokinase	 activity	 (CPK)	 and	 histologic	 appearance	 24	 hours	later	 and	 were	 able	 to	 conclude	 that	 myocardial	 tissue	 can	 be	salvaged	if	the	infarct	related	coronary	artery	was	reperfused	within	a	timely	manner.		Treatment	of	ischaemia	consists	of	medical	therapy	to	 control	 symptoms	 in	 situations	 where	 angina	 remains	 stable	 or	else	 patients	 undergo	 some	 form	 of	 coronary	 revascularisation.		Currently,	this	can	be	achieved	either	through	primary	percutaneous	coronary	intervention	(PPCI),	thrombolysis	where	PPCI	facilities	are	unavailable	 in	a	 timely	manner,	or	 surgical	 revascularisation	 that	 is	referred	to	as	coronary	artery	bypass	grafting	(CABG)	–	This	is	often	necessary	 when	 there	 is	 a	 technical	 challenging	 lesion	 or	 there	 is	severe	disease	involving	either	the	left	main	stem	coronary	artery	or	there	is	involvement	of	two	or	more	vessels	(37).	
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Although	 reperfusion	 largely	 abolishes	 ischaemia	 in	 the	 infarct	related	 artery	 (IRA)	 territory,	 it	 also	 results	 in	 the	 activation	 of	processes	 that	 appear	 to	 be	 deleterious	 thus	 making	 myocardial	reperfusion	 a	 “double	 edged	 sword”.	 	 Some	 of	 these	 processes	include:	
	





• Production	 of	 oxygen	 derived	 free	 radical	 that	 may	 damage	ischaemic	myocytes	
• Post	ischaemic	depression	of	myocardial	function	“stunning”	
	




Patients	 encountering	 an	 acute	 ST	 segment	 elevation	 myocardial	infarction	are	 treated	with	 timely	reperfusion	 therapy,	namely	PPCI	or	thrombolysis	as	mentioned	earlier	in	section	1.3.			
The	concept	of	 restoring	blood	supply	 to	an	 ischaemic	myocardium	and	paradoxically	causing	harm	was	first	postulated	by	Jennings	and	colleagues	 in	 1960	 and	 was	 termed	 lethal	 reperfusion	 injury	 (39).		Since	its	recognition	it	has	become	an	integral	term	when	describing	myocardial	injury	following	an	infarct.		The	injury	results	in	death	of	cardiomyocytes	 that	 were	 viable	 immediately	 before	 myocardial	reperfusion	(40-42).	
	
1.4.1 Clinical	manifestation	of	coronary	reperfusion	





The	 observation	 that	 reperfusion	 induced	 arrhythmias	 may	 occur	when	 coronary	 blood	 flow	 is	 restored	 to	 areas	 of	 acute	 ischaemic	myocardium	 by	 coronary	 occlusion	 was	 originally	 made	 in	experimental	 laboratory	 in	 the	 19th	 century	 by	 Cohnheim	 and	 Von	Schulthess-Rechberg	 (43)	 and	 later	 described	 in	 1935	 by	 Tennant	and	Wiggers	(44).		There	are	various	types	of	arrhythmias	described	in	literature	including	ventricular	tachycardia,	ventricular	premature	complexes	and	idioventricular	rhythm.	 	These	usually	self	terminate	or	are	easily	treated	(45).		
	
1.4.1.2	Myocardial	stunning	
Heyndrickx	 et	 al	 in	 1975	 described	 myocardial	 stunning	 as	 a	prolonged	 post	 ischaemic	 dysfunction	 of	 viable	 tissue	 salvaged	 by	reperfusion	(46).	 	 	Reperfusion	of	an	 ischaemic	myocardium	results	in	 a	 prolonged	 period	 of	 contractile	 dysfunction	 albeit	 reversible.		The	myocardium	 is	 referred	 as	 ‘stunned’	 and	 requires	 a	 prolonged	period	 of	 time	 to	 gain	 full	 functional	 recovery.	 	 This	 can	 be	 seen	where	 there	 is	 global	 ischaemia	 (such	 as	 cardiac	 arrest	 or	 cardiac	
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• External	 capillary	 compression	 by	 cardiomyocytes	 swelling	and	endothelial	cells	





It	manifests	as	no	or	sluggish	blood	flow,	impaired	myocardial	blush	and	a	characteristic	coronary	flow	velocity	profile	(54).		Interestingly,	amongst	 patients	 who	 have	 undergone	 emergency	 coronary	intervention,	30-40%	have	evidence	of	microvascular	obstruction	on	myocardial	 contrast	 echocardiography	 despite	 having	 normal	coronary	 blood	 flow	 in	 the	 infarct	 related	 coronary	 artery	 during	coronary	angiography	(55,	56).		The	presence	of	this	phenomenon	is	usually	 indicative	 of	 larger	 infarcts,	 lower	 LV	 ejection	 fractions,	adverse	 LV	 remodelling	 and	 worse	 clinical	 outcomes	 (57,	 58).	 	 It	remains	 unclear	 whether	 microvascular	 dysfunction	 (MVD)	 is	independently	responsible	 for	cardiomyocytes	death	or	a	marker	of	severe	myocardial	 ischaemia	 reperfusion	 injury.	 	 Unfortunately,	 no	effective	 therapy	 exists	 to	 diminish	 MVD	 in	 patients	 who	 have	undergone	coronary	angioplasty.	
	
1.4.1.4	Lethal	myocardial	ischaemia	reperfusion	injury	
The	 first	 description	 of	 myocardial	 reperfusion	 injury	 stems	 from	Jennings	 seminal	 paper	 in	 1960	 that	 suggested	 the	 process	 of	restoring	 blood	 supply	 to	 an	 ischaemic	 myocardium	 can	paradoxically	 induce	 injury	 thus	 attenuating	 the	 benefits	 of	
	 51	
myocardial	 reperfusion.	 They	 reported	 histological	 features	 of	reperfused	canine	ischaemic	myocardium	that	included	cell	swelling,	myofibril	contracture,	disruption	of	sarcolemma	and	the	appearance	of	calcium	phosphate	particles	within	the	mitochondria	(39).	
During	 this	 process,	 there	 is	 death	 of	 cardiomyocytes	 that	 were	viable	 immediately	 prior	 to	 reperfusion.	 	 This	 phenomenon	 partly	explains	why	despite	fully	restoring	blood	in	an	infarct	related	artery	(IRA)	 in	 a	 timely	 fashion	 using	 the	 latest	 stents,	 antiplatelet	 and	antithrombotic	therapy,	death	rate	can	still	be	as	high	as	10%	and	the	heart	failure	incidence	follow	an	acute	infarct	can	be	as	high	as	25%.	
Reperfusion	 injury	 has	 been	 the	 subject	 of	 a	 wide	 range	 of	experimental	 studies	 to	 explore	 the	 mechanisms	 implicated	 in	 its	pathogenesis;	 infarct	 models	 in	 animals	 suggest	 that	 this	phenomenon	may	 be	 responsible	 for	 up	 to	 50%	of	 the	 final	 infarct	size	and	within	 these	experimental	models	a	number	of	approaches	have	 demonstrated	 a	 degree	 of	 protection	 from	 lethal	 reperfusion	injury	 (40).	 	 Unfortunately	 these	 strategies	 have	 poorly	 translated	from	 bench	 to	 clinical	 practice	 to	 be	 applied	 to	 real	 patients.			Therefore,	 it	 is	 clear	 that	 further	 laboratory	and	clinical	 studies	are	warranted	 to	 further	 explore	 reperfusion	 injury	 so	 that	 these	 new	developments	 can	 potentially	 improve	 the	 prognosis	 following	 a	
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myocardial	infarction	and	reduce	the	risk	of	developing	heart	failure	at	 a	 later	 stage.	 	 The	 degree	 of	 myocardial	 injury	 resulting	 from	reperfusion	injury	in	humans,	has	yet	to	be	quantified.	




Restoration	 of	 blood	 flow	 to	 a	 previously	 ischaemic	 myocardium	leads	to	production	of	reactive	oxygen	species	(ROS)	by	a	variety	of	sources	(endothelial	cells,	neutrophils,	electron	transport	chain)	that	cause	 cardiomyocyte	 injury	 and	 death	 through	 a	 variety	 of	mechanism	 including	 but	 not	 limited	 to	 direct	 DNA	 damage,	 cell	membrane	interference	and	denaturing	of	enzymes.	
	
1.4.2.2	Calcium	overload	
Intracellular	 calcium	 overload	 occurs	 during	 ischaemia	 by	mechanisms	described	earlier.	 	At	 the	onset	of	 reperfusion,	 calcium	
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overload	 is	 further	 amplified	 through	 ROS-mediated	 injury	 to	sarcoplasmic	 reticulum	 and	 correction	 of	mitochondrial	membrane	potential	 (mitochondrial	 re-energisation).	 	 The	 latter	 permits	regaining	of	the	mitochondrial	membrane	potential	enabling	calcium	to	enter	into	mitochondria	through	specific	mitochondrial	uniporters	that	 eventually	 cause	 opening	 of	 the	 mitochondrial	 permeability	transition	pore	(MPTP).		
Opening	 of	 the	 MPTP	 results	 in	 the	 mitochondrial	 membrane	becoming	permeable	 to	molecules	 less	 than	1.5	kDa.	This	promotes	swelling	 of	 the	 matrix	 and	 disruption	 to	 mitochondria.	 	 The	uncoupling	of	oxidative	phosphorylation	leads	to	a	reduction	in	ATP,	without	which	a	cell	may	not	undergo	repair	following	an	ischaemic	encounter.		Oxidative	stress	along	with	elevated	phosphate	elevation	and	depletion	of	adenine	nucleotide	all	 increase	sensitivity	of	MPTP	to	calcium.		Opening	of	this	pore	therefore	culminates	in	necrotic	cell	death	during	reperfusion	(59).	
	
1.4.2.3	Rapid	restoration	of	physiological	pH	(pH	paradox)	




1.4.2.4	 Mitochondrial	 permeability	 transition	 pore	 (MPTP)	
opening	
The	MPTP	remains	a	very	important	therapeutic	target	with	respect	to	reperfusion	injury.	 	The	MPTP	is	a	non-selective	channel	found	in	the	inner	mitochondrial	membrane.		When	it	opens,	cell	death	ensues	due	 to	 mitochondrial	 depolarisation,	 uncoupling	 of	 oxidative	phosphorylation	culminating	in	the	depletion	of	ATP	(61,	62).		It	is	an	important	promoter	of	cell	death,	as	many	mediators	of	reperfusion	injury	 appear	 to	 act	 on	 it.	 	 The	 accumulation	 of	 lactic	 acid	 during	anaerobic	 respiration	 acts	 to	 protect	 cardiomyocytes	 during	 acute	ischaemia	 through	 inhibition	 of	 the	 MPTP	 opening	 and	hypercontracture	 of	 the	 cell.	 	 During	 reperfusion,	MPTP	opens	 as	 a	result	of	 calcium	overload,	oxidative	stress	and	rapid	pH	correction	(63).	 	 Inhibition	 of	 this	 pore	 has	 generated	 a	 tremendous	 research	interest	and	as	such,	experimental	studies	have	reported	a	significant	reduction	 of	 infarct	 sizes	 in	 both	 animal	 and	 human	 models	 of	
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simulated	ischaemia-reperfusion	injury	models	using	agents	such	as	cyclosporine	 A	 (64)	 which	 is	 otherwise	 known	 for	 its	 common	immunosuppressant	property	in	clinical	practice.		
	
1.4.3	Coronary	atherosclerosis	





• 	Progress	 to	 total	 or	 near	 total	 coronary	 vessel	 occlusion	resulting	in	an	acute	coronary	event.		
There	 are	 several	 factors	 that	 determine	 how	 the	 ruptured	 TCFA	behaves	 including	the	actual	volume	and	composition	of	the	plaque,	degree	 of	 luminal	 narrowing,	 cap	 tear	 size	 and	 thrombotic	 milieu	(prothrombotic	 nature	 of	 the	 blood).	 	 	 Interestingly,	 it	 has	 been	demonstrated	 in	 patients	 with	 sudden	 cardiac	 death	 that	 repeated	cycles	 of	 asymptomatic	 coronary	 thrombosis	 occur,	 which	 become	integrated	into	the	vessel	wall	prior	to	the	fatal	event	(65).	
An	 alternative	 aetiology	 for	 coronary	 thrombosis	 is	 when	 plaque	erosion	occurs.		This	is	when	a	thrombus	forms	on	a	defect	within	the	endothelial	 layer	 that	 covers	 the	 plaque.	 	 The	 plaque	 itself	 is	 not	thinned	like	TCFAs	and	may	not	necessarily	be	inflamed.		This	type	of	coronary	 thrombosis	 tends	 to	 be	 prevalent	 in	 smokers	 due	 to	 the	prothrombotic	milieu	nature	of	smoking.				
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The	 gradual	 process	 of	 atherosclerosis	may	 become	 accelerated	 by	plaque	haemorrhage.		This	occurs	when	thin	blood	vessels	with	poor	integrity	 grow	 from	 the	 vasa	 vasorum	 situated	 in	 the	 most	 outer	layer	 (adventitia)	 of	 blood	 vessels	 into	 the	 more	 inner	 layers	 and	rupture	 leading	to	enlargement	of	plaque	(whilst	 trying	to	meet	 the	increasing	 demand	 of	 the	 thickening	 inner	 blood	 vessel).	 	 This,	however,	 does	 not	 necessarily	 lead	 to	 obliteration	 of	 the	 vessel	lumen.	 	 In	 1987,	 Seymour	 Glagov	 published	 his	 seminal	 article	describing	 the	phenomenon	of	vascular	modelling	which	now	bears	its	name	(66).	 	 In	 the	Glagov’s	phenomenon,	arteries	are	 thought	 to	alter	their	size	and	shape	in	relation	to	plaque	burden.		This	positive	remodelling	essentially	maintains	the	vessels	luminal	orifice	thereby	maintaining	blood	flow	to	the	area	it	supplies	despite	an	increase	in	plaque	 burden.	 	 This	 relationship	 between	 plaque	 burden	 and	luminal	orifice	has	been	shown	to	be	maintained	with	plaque	burden	up	to	45	percent.	 	Thereafter	lumen	size	becomes	affected	(negative	remodelling),	 due	 its	 inability	 to	 positively	 remodel	 through	expansion	to	accommodate	the	increasing	plaque	burden	(67).	
Following	 this,	 as	 the	 disease	 evolves,	 the	 luminal	 diameter	 of	 the	coronary	artery	becomes	progressively	narrowed	to	varying	degrees	until	 up	 to	 the	 point	 where	 the	 patient	 perceives	 angina.		
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Interestingly,	 atherosclerosis	 tends	 to	 form	 particularly	 in	 the	proximal	segments	of	main	coronary	vessels	especially	at	the	point	of	arterial	 bifurcation	 where	 blood	 flow	 haemodynamics	 becomes	altered	 (68).	 	 This	 slow	 progression	 of	 atherosclerosis	 may	 be	interrupted	 by	 rapid	 progression	 related	 to	 either	 asymptomatic	plaque	 disruption	 resulting	 in	 the	 formation	 of	 a	 non-occlusive	intraluminal	thrombus	or	may	result	in	plaque	haemorrhage.	
	
1.4.3.1	What	happens	during	an	acute	myocardial	infarction?	
The	 formation	 of	 thrombus	 eventually	 results	 in	 symptomatic	coronary	occlusion.	 	Plaque	rupture	 is	responsible	between	66-75%	of	fatal	myocardial	infarctions	based	on	post-mortem	evaluation.	 	In	patients	presenting	acutely	for	primary	coronary	intervention,	up	to	84%	have	total	coronary	occlusion	with	the	remainder	having	a	near	total	 occlusion	 where	 flow	 to	 distal	 vessel	 remains	 to	 a	 limited	degree.	 	 Quite	 often,	 the	 thrombus	 extracted	 during	 a	 primary	procedure	 is	 organised	 indicating	 its	 formation	 prior	 to	 the	development	of	angina.			
From	a	clinical	perspective,	an	acute	myocardial	infarction	is	either	a	non	 ST	 segment	 elevation	 myocardial	 infarction	 (NSTEMI)	 or	 a	 ST	
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segment	 elevation	 myocardial	 infarction	 (STEMI).	 	 The	 former	 is	three	 times	more	 frequent,	 has	 a	 lower	 incidence	 of	 total	 coronary	occlusion	and	coronary	angiography	often	demonstrates	a	significant	flow-limiting	lesion	in	the	order	equal	to	or	greater	than	70%	luminal	narrowing.	 	 Conversely,	 STEMI	 patients	 frequently	 have	 totally	occluded	coronary	vessels	with	greater	myocardial	necrotic	 risks	 in	comparison.		There	is	also	a	higher	degree	of	plaque	rupture	seen	in	STEMIs	when	compared	to	NSTEMIs	where	plaque	erosion	seems	to	predominate	when	 coronary	vessels	 are	 evaluated	during	 the	acute	presentation	using	optical	computed	tomography.	
	
1.4.3.2 Cellular	 pathophysiology	 of	 myocardial	 ischaemic	
injury		
The	 coronary	 vessel	 that	 supplies	 a	 particular	 territory	 determines	the	area	at	 risk	of	myocardial	 ischaemia.	 	During	an	acute	coronary	occlusion,	 prolonged	 ischaemia	 (more	 than	 20	 minutes)	 leads	 to	 a	“wave	front”	of	cell	death	that	begins	in	the	subendocardium,	which	then	expands	transmurally	to	involve	the	epicardium	(69).	
Deprivation	of	nutrients	and	oxygen	 leads	 to	a	 cascade	of	 reactions	that	 culminates	 in	 rapid	metabolic	 and	 biochemical	 changes	within	
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the	cardiomyocytes;	oxidative	phosphorylation	comes	to	a	standstill	leading	 to	 mitochondrial	 membrane	 depolarisation,	 ATP	 depletion	and	inhibition	of	myocardial	contractile	function.	
Cell	 metabolism	 switches	 from	 aerobic	 to	 anaerobic	 glycolysis	resulting	 in	 increased	 production	 of	 lactic	 acid	 that	 translates	 to	 a	reduction	 in	 both	 intracellular	 and	 extracellular	 pH	 making	 the	environment	 more	 acidic.	 	 To	 compensate	 for	 this	 anomaly,	 the	Na+/H+	 exchanger	 brings	Na+	 into	 the	 cell	while	 extruding	H+.	 	 The	3Na+/2K+/ATPase	 also	 ceases	 to	 function	 during	 ischaemia	 when	ATP	 generation	 is	 affected.	 	 The	 ensuing	 intracellular	 Na+	 overload	(normally	 the	major	 extracellular	 cation)	 triggers	 the	 2Na+/Ca++	 to	function	in	reverse	mode	to	carry	Ca++	 into	the	cell	whilst	extruding	Na+	 out	 of	 the	 cell	 leading	 to	 intracellular	 calcium	 overload.	 	 With	continuing	ischaemia,	waste	metabolites	accumulate	instigating	to	an	increase	 in	 osmolality	 of	 the	 intracellular	 environment	 leading	 to	 a	flow	of	water	along	this	gradient	causing	cellular	swelling.		Thus,	the	net	 consequence	 is	 that	 of	 an	 intracellular	milieu	which	 is	 acidotic,	with	elevated	Ca++	and	is	swollen	from	the	inflow	of	water	(70).		The	initial	 acidotic	 environment	 generated	 as	 a	 result	 of	 ischaemia	 also	inhibits	 the	 opening	 of	 the	 mitochondrial	 permeability	 transition	
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pore	 (MPTP)	 and	 prevents	 cardiomyocytes	 contraction	 during	 this	time.	
As	 mentioned	 earlier	 the	 contractile	 function	 of	 cardiomyocytes	becomes	 affected	during	 ischaemia	when	ATP	 synthesis	 comes	 to	 a	halt	 as	 oxidative	 phosphorylation	 ceases	 leading	 to	 mitochondrial	membrane	 depolarisation.	 	 In	 an	 attempt	 to	 maintain	 the	mitochondrial	 membrane	 potential,	 the	 F1F0	 ATPase	 works	 in	reverse	mode	using	energy	derived	from	hydrolysis	of	ATP	leading	to	an	 increase	 in	 mitochondrial	 inorganic	 phosphates.	 	 The	 result	 is	further	 depletion	 of	 ATP	 and	 hastening	 of	 myocardial	 contractile	function	(71).			
Reperfusion	causes	 further	damage.	 	The	pathological	mechanism	is	described	below.	
	
1.4.3.3 Cellular	 pathophysiology	 of	 myocardial	 reperfusion	
injury	
When	vessel	patency	is	re-established	in	the	infarct	related	coronary	artery,	 the	 changes	 seen	 are	 spectacular;	 the	 3Na+/2K+/ATPase	becomes	 reactivated	 to	 actively	 pump	 Na+	 into	 the	 extracellular	space	with	the	return	of	oxygen	and	glucose.		The	Na+	gradient	that	is	
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established	 across	 the	 cell	 membrane	 permits	 the	 Na+/Ca++	exchanger	 to	 work	 in	 normal	 mode	 (forward	 direction)	 thereby	extruding	Ca++	out	and	bridging	Na+	 into	cells.	 	 In	 cells	 subjected	 to	prolonged	 ischaemia,	 however	 the	 3Na+/2K+/ATPase	 is	 unable	 to	reactivate	leading	to	persistent	high	intracellular	Na+	concentrations.		In	 such	 cases,	 the	 Na+/Ca++	 pump	 continues	 to	 function	 in	 reverse	mode	to	exchange	 intracellular	Na+	 for	extracellular	Ca++.	 	With	that	in	mind,	 the	 return	 of	 oxidative	 phosphorylation	 and	 generation	 of	free	 ATP	 in	 an	 environment	 rich	 in	 cytosolic	 Ca++	 will	 cause	cardiomyocytes	hypercontracture	(72).				
Moreover,	reperfusion	leads	to	a	rapid	correction	of	the	extracellular	acidic	 pH	 as	 excess	 H+	 are	 removed	 -	 that	 encourages	 the	 Na+/H+	exchanger	 to	 extrude	H+	 for	Na+.	 	 This	 build	 up	 of	 intracellular	Na+	causes	 the	 Na+/Ca++	 exchanger	 to	work	 in	 reverse	mode	 to	 further	increase	 intracellular	Ca++	(72).	 	Eventually	 this	process	will	 further	augment	hypercontracture	of	 the	cardiomyocytes	as	pH	normalises.		It	 is	 thought	 that	 the	 initial	 low	 pH	 environment	 of	 ischaemic	cardiomyocytes	 acts	 as	 a	 protective	 mechanism	 to	 inhibit	 muscle	contraction;	this	is	abolished	when	the	pH	is	normalised	at	the	onset	of	reperfusion	when	ATP	becomes	readily	available	to	endorse	hyper	contracture	 in	 the	 presence	 of	 high	 calcium	 concentration	 (72).	 	 In	
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addition	 to	 the	 electrolyte	 imbalance,	 the	 accumulated	 waste	metabolites	are	eliminated	from	the	extracellular	environment	by	the	return	of	fluid	flow,	creating	an	osmotic	gradient,	which,	 in	addition	to	 the	 high	 cytosolic	 calcium	 environment	 cause	 cell	 swelling	 from	water	moving	along	the	osmotic	gradient.	










Physiological	 restoration	 of	 the	 pH	 through	 reactivation	 of	 Na+/H+	exchanger	 and	 washout	 of	 lactic	 acid	 leads	 to	 reversal	 of	 MPTP	closure	 and	 inhibition	 of	 contracture.	 	 During	 reperfusion,	 the	mitochondrial	 potential	 is	 also	 restored	 thus	 calcium	 is	 driven	 into	the	 mitochondria	 which	 itself	 trigger	 off	 MPTP	 opening.	 	 Within	several	hours	after	the	onset	of	reperfusion,	neutrophils	accumulate	within	the	infarcted	myocardium	in	response	to	the	chemoattractant	nature	of	ROS,	activated	compliment	system	and	cytokine	release.	
	
There	 is	 a	 huge	 reward	 to	 be	 gained	 through	 understanding	 the	mechanism	 underpinning	 myocardial	 ischaemia	 reperfusion	 injury	and	applying	this	knowledge	in	treating	patients	presenting	with	a	ST	segment	 elevation	 myocardial	 infarction	 amongst	 other	 disease	processes	 concerning	 reperfusion	 injury.	 	 Besides	 timely	 and	effective	reperfusion	therapy,	another	important	aspect	would	be	to	abolish,	 or	 at	 least	 minimise	 the	 detrimental	 effects	 of	 ischaemia	reperfusion.		In	this	regard,	the	work	by	Murry	et	al	provided	a	new	
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“A	 brief	 period	 of	 ischaemia	 followed	 by	 reperfusion	 renders	 the	heart	more	 resistant	 to	 injury	 from	 a	 subsequent	 longer	 ischaemic	insult	rather	than	accentuating	the	injury”	(73)	
This	 experimental	 technique	 essentially	 produces	 resistance	 to	 the	loss	of	blood	supply,	and	thus	oxygen,	to	tissues	of	many	types.	
	
1.5.1	First	description	of	ischaemic	preconditioning	
A	 major	 breakthrough	 in	 the	 ischaemia-reperfusion	 story	 was	 the	work	 carried	 out	 by	 Murry,	 Jennings	 and	 Reimer	 on	 ischaemic	preconditioning.	 	 This	 was	 first	 published	 in	 their	 seminal	 paper	titled	 “Preconditioning	with	 ischaemia:	a	delay	of	 lethal	 cell	 injury	 in	
ischemic	 myocardium”	 (74).	 	 Their	 studies	 were	 based	 on	 their	previous	 experimental	 work	 where	 they	 had	 demonstrated	 that	 a	brief	 episode	 of	 ischaemia	 reduced	 the	 rate	 at	 which	 ATP	 was	
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depleted	 during	 subsequent	 ischaemic	 episodes.	 	 By	 interspersing	the	 ischaemic	 episodes	 with	 normal	 perfusion,	 they	 felt	 that	 the	myocardium	gained	benefit	by	the	process	of	catabolite	washing	that	would	have	accumulated	during	ischaemia.			
In	 their	 landmark	 experiment,	 they	 hypothesised	 that	 several	 brief	ischaemic	episodes	may	protect	the	heart	from	the	deleterious	effects	of	a	myocardial	infarction	and	thus	reduce	infarct	size.		Indeed,	they	were	 able	 to	 demonstrate	 this	 in	 canine	 hearts.	 	 In	 an	 open	 chest	model,	the	control	group	of	five	dogs	were	subjected	to	40	minutes	of	circumflex	 vessel	 occlusion	 while	 in	 the	 intervention	 group,	 the	 7	dogs	 were	 subjected	 to	 four	 cycles	 of	 5	 minutes	 circumflex	 vessel	occlusion			interrupted	by	5	minutes	of	reperfusion	prior	to	receiving	40	minutes	of	 uninterrupted	 circumflex	occlusion.	 	All	 groups	were	then	 allowed	 4	 days	 of	 reperfusion	 before	 histological	 analysis	 of	area	 at	 risk	 took	 place.	 	 They	 reported	 that	 preconditioning	 with	simulated	 ischaemia	 (now	 termed	 ischaemic	 preconditioning)	paradoxically	reduced	infarct	size	by	75%	of	that	seen	in	the	control	groups	 (see	 figure	1	below)	 (72).	 	Moreover	 they	 found	 that	 the	40	minutes	of	simulated	ischaemia	lead	to	a	severe	depletion	of	ATP	and	cell	death	in	the	control	group	whereas	in	the	preconditioned	group,	the	same	 level	of	ATP	depletion	occurred	except	 that	 the	end	result	
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did	 not	 culminate	 in	 cell	 death.	 	 Interestingly,	 the	 authors	 also	observed	during	their	experiments	that	during	successive	application	of	 5	 minutes	 ischaemia,	 ST	 segment	 changes	 were	 less	 dramatic	when	 compared	 to	 the	 initial	 occlusion.	 	 This	 was	 independent	 of	collateral	blood	flow.	
	
	




As	 important	 as	 it	 may	 seem,	 application	 of	 such	 intervention	 into	clinical	practice	would	prove	extremely	difficult	owing	to	the	fact	that	predicting	the	onset	of	myocardial	infarction	is	impossible.		However,	it	can	be	hypothesised	from	this	study	that	patients	who	experience	anginal	episodes	prior	to	their	index	myocardial	infarction	will	have	a	greater	degree	of	myocardial	salvage	through	reperfusion	therapy	when	 compared	 to	 patients	 who	 experience	 a	 sudden	 onset	myocardial	infarction.		This	is	discussed	in	section	1.5.8	ahead.	





In	 the	original	 study	conducted	by	Murry	et	al	 (74),	a	 second	study	was	 carried	 out	 using	 the	 identical	 preconditioning	 protocol	 (4x5	min	 coronary	 occlusion	 interspersed	 with	 5	min	 reperfusion)	 with	the	 exception	 that	 the	 sustained	 coronary	 occlusion	 was	 3	 hours	rather	 than	 40	 minutes	 (72).	 	 In	 this	 second	 group	 there	 was	 no	difference	 observed	 between	 the	 infarct	 size	 in	 the	 preconditioned	and	control	groups	proving	the	concept	that	preconditioning	acted	to	delay	 cell	 death.	 	 However,	 there	 is	 a	 limitation	 as	 to	 how	 much	ischaemia	 cells	 may	 withstand	 before	 irreversible	 injury	 occurs	leading	 to	 cell	 death.	 	Nao	et	 al	 (80)	demonstrated	 this	 in	 a	 similar	canine	 model	 to	 Murry	 where	 the	 protection	 conferred	 by	preconditioning	 was	 maintained	 with	 60	 minutes	 of	 coronary	occlusion	but	lost	with	90	minutes	of	occlusion.	
Following	the	pivotal	study	by	Murry	et	al,	and	confirmatory	studies,	experiments	were	aimed	at	manipulating	the	varying	components	of	the	 preconditioning	 protocol	 (now	 referred	 to	 as	 classical	preconditioning)	–	specifically,	 the	brief	antecedent	preconditioning	stimulus,	 the	duration	of	 intervening	 reperfusion	between	 the	brief	and	 sustained	 ischaemia	 and	 the	 duration	 of	 the	 subsequent	
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prolonged	 index	 (test)	 ischaemia	 in	 an	 attempt	 to	 assess	 their	individual	significance	in	attaining	cardioprotection	(81).	
	
1.5.3	Preconditioning	stimulus	
Original	 studies	 employed	 numerous	 cycles	 of	 ischaemic	preconditioning	 prior	 to	 the	 index	 ischaemic	 event	 to	 demonstrate	cardioprotection;	 it	 has	 since	 been	 demonstrated	 even	 a	 single	preconditioning	 stimulus	with	90	seconds	 ischaemia	may	 lower	 the	threshold	 to	 induce	cardioprotection	(82).	 	 	At	 the	other	extreme,	 if	the	duration	of	the	preconditioning	stimulus	itself	is	large	enough	to	induce	cell	death,	 then	 it	 is	needless	 to	 say	 that	 this	will	not	 confer	cardiac	 protection	 and	 in	 fact	 may	 increase	 infarct	 size	 when	compared	to	time-matched	controls.	 	Similarly,	increasing	the	cycles	of	 the	 stimulus	mat	 not	 necessarily	 enhance	 the	 stimulus	 and	may	even	result	in	a	loss	of	efficacy.		
Evidence	 from	 dog	 and	 rabbit	 models	 shows	 that	 even	 a	 small	stimulus	 such	 as	 1.5	 mins	 to	 2.5	 mins	 provides	 an	 effective	preconditioning	 stimulus	 (83).	 	 In	 other	 examples,	 even	 a	 short	period	 of	 coronary	 stenosis	 (15	 mins)	 and	 transient	 imbalance	 of	myocardial	 oxygen	 supply/demand	 (such	 as	 rapid	 pace	 induction)	
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have	 been	 shown	 to	 protect	 rabbit	 and	 dog	 heart	 from	 subsequent	prolonged	ischaemia	proving	that	complete	coronary	occlusion	is	not	necessary	to	induce	cardioprotection.		
Further	 studies,	 with	 a	 few	 exceptions,	 have	 also	 concluded	 that	repeated	bouts	of	preconditioning	ischaemia	do	not	necessarily	yield	a	cumulative	“dose	dependent”	effect;	Li	et	al	(84),	for	example,	found	no	additional	benefit	with	6	or	12	bouts	of	preconditioning	ischaemia	when	 controlled	 with	 a	 group	 of	 dogs	 who	 received	 a	 single	preconditioning	stimulus.		In	fact,	there	may	even	be	a	loss	in	efficacy	of	 the	 preconditioning	 stimulus	with	 repeated	 cycles	 of	 antecedent	ischaemia.	 	 This	 was	 certainly	 the	 case	 when	 Cohen	 subjected	conscious	rabbits	 to	40-65,	5	minute	occlusions	over	3-4	days	prior	to	 the	 index	 ischaemia	and	 found	no	protection	 (85).	 	 Interestingly,	rabbits	may	even	lose	benefit	from	the	preconditioning	stimulus	in	as	few	 as	 6-8	 repeated	 bouts	 of	 antecedent	 ischaemia.	 	 However,	 this	resistance	to	protection	can	be	reversed.		Cohen	et	al,	discovered	that	if	 these	 repeated	bouts	of	antecedent	 ischaemic	were	 followed	by	a	rest	period	 and	 then	 subjected	 to	 a	 further	bout	of	 brief	 ischaemia,	the	cardioprotection	would	be	re-established	(81).	
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1.5.4	 Time	 interval	 between	 preconditioning	 stimulus	 and	
sustained	ischaemia		








Kuzuya	 (88)	 et	 al	 discovered	 this	 second	 “enhanced	 resistance	 to	infarction”	whilst	studying	with	rabbits	and	dogs.			
Marber	assessed	 the	 role	of	heat	 shock	protein	 (HSP)	 in	 relation	 to	myocardial	salvage;	in	his	experiments	he	subjected	rabbits	to	either	ischaemic	 preconditioning	 (four	 5	 minute	 coronary	 ligation	interspersed	with	 10	minute	 reperfusion)	 or	 thermal	 pretreatment	with	body	 temperature	elevation	 to	42oC	 for	15	minutes,	 each	with	corresponding	controls.	 	Twenty-four	hours	 later	 the	 rabbits	hearts	were	subjected	 to	a	period	of	 coronary	occlusion	 for	 thirty	minutes	and	 reperfused	 for	 120	minutes	 before	 being	 euthanised	 and	 their	hearts	assessed	for	HSP	estimation	or	 infarct	size.	 	HSP	assessed	by	Western	 blotting	 confirmed	 elevation	 in	 both	 preconditioned	 and	heat	 treated	 (with	 preferential	 elevation	 in	 the	 former	 group	 of	rabbits)	 when	 comparison	 was	 made	 to	 their	 respective	 controls.		Likewise,	infarct	size,	as	a	percentage	of	volume	at	risk,	was	reduced	in	both	intervention	groups.	 	The	authors	were	able	to	conclude	the	association	 of	 heat	 shock	 protein	 induced	 by	 thermal	 or	 sublethal	ischaemic	injury	was	associated	with	myocardial	salvage	(89).	
Kuzuya	 et	 al	 confirmed	 similar	 findings	 in	 an	 open	 chest	 canine	model.		In	their	group	of	dogs,	the	left	anterior	descending	artery	was	subjected	 to	 90	 minutes	 of	 occlusion	 followed	 by	 5	 hours	 of	
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reperfusion	either	immediately	or	24	hours	following	treatment	with	ischaemic	 preconditioning	 (4	 cycles	 of	 5	 minutes	 sublethal	ischaemia).	 	 The	 sizes	 of	 infarct	 were	 smaller	 and	 similar	 in	 both	groups	 when	 compared	 to	 their	 time-matched	 controls.	 	 No	difference	in	infarct	size	between	control	and	intervention	group	was	observed	when	the	index	infarct	was	applied	3	or	12	hours	following	the	preconditioning	stimulus	(90).	
It	should	be	noted	that	although	the	second	window	of	protection	is	significant	 and	 present	 universally,	 it	 is	 not	 as	 potent	 as	 early	 or	classical	 preconditioning	 (91).	 	 This	 is	 demonstrated	 in	 figure	 2	previously.	
The	 second	window	of	 protection	 is	 now	 thought	 to	 arise	 from	 the	upregulation	 of	 the	 72-kDA	 inducible	 heat	 shock	 protein	 (hsp72i),	increased	 transcription	 or	 functional	 upregulation	 of	 antioxidant	enzyme	 systems	 (superoxide	 dismutase,	 catalase	 and	 glutathione	peroxidase),	 increase	 cyclooxygenase-2	 expression	 (with	concomitant	 rise	 in	 prostaglandins)	 in	 addition	 to	 nitric	 oxide	synthase	 	 (iNOS)	 amongst	 activation	 of	 other	 transcription	 factors	(92).		It	is	thought	that	the	particular	time	delay	was	obligatory	based	upon	 the	 prerequisite	 that	 de	 novo	 stress	 protein	 synthesis	 would	require	a	specific	time	period	in	become	fully	expressed.	
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1.5.5	Duration	of	index	ischaemia		
Preconditioning	 itself	does	not	prevent	cardiomyocyte	cell	necrosis;	it	serves	to	delay	cell	death	as	evident	in	Murrys	original	study	where	a	 sustained	 ischaemic	 insult	 for	 3	 hours	 abolished	 the	cardioprotective	 benefits	 achieved	 from	 antecedent	 ischaemia	 that	was	seen	during	a	shorter	occlusion	of	40	minutes	(72).		Studies	have	since	 proved	 the	 efficacy	 of	 preconditioning	 to	 uphold	 where	 the	insult	lasts	anywhere	between	30	to	90	minutes	but	not	when	this	is	extended	to	3	hours.	 	Ultimately,	 if	 the	preconditioning	intervention	is	not	combined	with	timely	reperfusion,	then	the	protection	is	lost.			
	
1.5.6	Other	aspects	of	preconditioning		
Ischaemic	 preconditioning	 not	 only	 protects	 against	 reperfusion	injury	but	also	protects	against	other	detrimental	effects	of	ischaemia	including	 arrhythmias	 and	 post	 ischaemia	 contractile	 dysfunction.		Animal	models	have	shown	a	reduction	in	reperfusion	arrhythmias	in	rats,	canine	and	porcine	models	of	ischaemia-reperfusion.		Unlike	the	second	 window	 of	 protection,	 ischaemic	 preconditioning	 does	 not	appear	to	alter	the	bell	shaped	relationship	between	the	antecedent	duration	 of	 ischaemia	 and	 severity	 of	 the	 arrhythmia.	 	 This	 may	
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suggest	that	two	different	mechanistic	processes	exist	for	arrhythmia	and	size	of	infarction.	
Cohen’s	 group	 first	 demonstrated	 that	 preconditioning	 protects	against	 contractile	 impairment	 in	 a	 rabbit	 model	 of	 ischaemia	reperfusion	 (85)	 and	 this	 was	 shortly	 followed	 by	 the	 work	 of	Przyklenk	 who	 was	 able	 to	 demonstrate	 improved	 systolic	improvement	 in	 a	model	 of	 regional	 ischaemia	 (79).	 	 Furthermore,	Caves	group	were	able	to	demonstrate	similar	findings	in	a	rat	model	of	global	ischaemia	where	enhanced	functional	recovery	was	seen	in	association	with	 a	 reduction	 in	 enzyme	 leakage,	 all	 suggesting	 that	preconditioning	served	to	reduce	necrosis	(93).	
	
1.5.7	Mechanism	of	preconditioning	
With	all	this	in	mind,	the	next	step	was	to	determine	the	mechanism	of	 preconditioning.	 	 In	 an	 attempt	 to	 understand	 the	 processes	involved	 in	 preconditioning,	 investigators	 have	 now	 spent	 three	decades	 pursuing	 this	 subject.	 	 The	 exact	 mechanism	 by	 which	preconditioning	 takes	 effect	 remains	 yet	 to	 be	 fully	 elucidated	particularly	 its	 memory	 aspect;	 some	 possible	 mechanisms	 have	been	suggested.		What	we	do	know	is	despite	variability	with	regards	
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to	 the	duration	of	preconditioning	stimulus	and	 the	 lasting	effect	of	this,	 the	 actual	 intracellular	 mechanism	 is	 probably	 similar	 in	 all	species.	 	 Many	 papers	 have	 proposed	 an	 explanation	 through	triggers,	mediators	and	effectors.				
	
1.5.7.1	Trigger	pathway	
The	 most	 widely	 accepted	 theory	 for	 the	 mechanism	 is	 that	ischaemia	 provokes	 the	 release	 of	 endogenous	 ligands	 or	autocoids	that	 trigger	 protection	 by	 binding	 to	 their	 respective	 cardiac	myocytes	 cell	 surface	 receptors	 including	 G	 protein-coupled	 and	growth	factor	receptors.		This	mediates	a	complex	signalling	cascade	that	 eventually	 converge	 onto	 one	 or	more	 end	 effectors	 to	 confer	protection	(92).		






Adenosine,	for	example,	is	a	purine	nucleoside	that	is	produced	from	the	metabolism	 of	 adenosine	 triphosphate	 (ATP).	 	 During	 stressful	situations	 (such	as	 antecedent	 ischaemia),	ATP	utilisation	 increases	resulting	in	higher	levels	of	adenosine,	which	then	acts	via	adenosine	A1	receptors	to	mediate	protection.		The	adenosine	receptors	are	G-protein	 coupled	 receptors	 (GPCR)	 with	 4	 subtypes	 -	 A1,	 A2a,	 A2b,	and	A3.	 	They	have	all	been	shown	to	mediate	cardioprotection	(94,	95).		Activation	of	both	A1	and	A3	receptors	prior	to	lethal	ischaemia	has	been	demonstrated	in	several	experimental	models	to	attenuate	ischaemia	reperfusion	injury.		Adenosine	receptor	activation	reduces	cell	death	through	the	activation	of	mitochondrial	ATP	dependent	K	channel	(KATP)	as	well	as	 through	mitogen-activated	protein	kinases	(MAPK)	 and	 protein	 kinase	 C	 (PKC)	 (96)	 –	 These	 are	 discussed	ahead.		
	To	support	this,	Liu	et	al	(97),	investigated	this	in	rabbits.		They	were	able	 to	 demonstrate	 that	 a	 5-minute	 intracoronary	 infusion	 of	 an	adenosine	 receptor	 agonist	 afforded	 the	 same	 degree	 of	cardioprotection	 as	 seen	 in	 rabbits	 subjected	 to	 a	 protective	preconditioning	 protocol.	 	 Furthermore,	 they	 were	 also	 able	 to	demonstrate	 that	 2	 non-specific	 adenosine	 receptor	 blockers	 were	
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able	 to	 antagonise	 the	 protection	 mediated	 through	 ischaemic	preconditioning	(97).	
	
GPCR:	Opioid	
Schultz	 and	 colleagues	 (98)	 worked	 with	 male	 Wistar	 rats	 using	naloxone,	a	non-selective	opioid	receptor	antagonist,	to	demonstrate	the	 role	 of	 opioid	 receptors	 in	 the	 involvement	 of	 ischaemic	preconditioning.	 	 	 In	 their	 seminal	paper,	pre-treating	 the	 rats	with	naloxone	 prior	 to	 or	 immediately	 after	 a	 preconditioning	 protocol	abolished	 the	 protective	 effects	 of	 preconditioning	 (98)	 seen	 with	opioids,	 which	 are	 now	 thought	 to	 act	 via	 kappa	 and	 delta	 opioid	receptors	(99).		
	
GPCR:	Bradykinin	
Evidence	 for	 the	 role	 of	 bradykinin	 in	 myocardial	 preconditioning	comes	 from	 the	work	of	Wall	 et	 al	 (100)	who	evaluated	 the	 role	of	bradykinin	 in	 an	 open	 chest	 rabbit	 model	 of	 acute	 coronary	occlusion.	 	 Rabbits	 who	 received	 preconditioning	 (5-minutes	ischaemia	 followed	 by	 10-minutes	 reperfusion)	 or	 an	 intra-arterial	
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infusion	of	bradykinin	were	protected	from	the	insult	of	a	30-minute	coronary	occlusion.		This	was	abolished	in	the	presence	of	HOE	140,	a	potent	bradykinin	receptor	antagonist	(100).	
Other	 triggers	of	G	protein	coupled	receptors	 include	angiotensin	 II	(101),	 catecholamines	 (102),	 endothelin	 (103),	 urocortin,	adrenomedullin	and	glucagon-like	peptide	(104).		
	
Growth	factor	receptors	
Growth	 factor	 receptors	 have	 also	 been	 implicated	 in	 triggering	cardioprotection	(105).	 	Examples	of	 ligands	acting	on	this	receptor	include	 insulin,	 insulin-like	 growth	 factor,	 fibroblast	 growth	 factor,	granulocyte	 colony	 stimulating	 factor,	 erythropoietin	 and	adipocytokines	 (95).	 	 Atrial	 natriuretic	 peptide	 (ANP)	 has	 been	shown	to	trigger	 ligand	specific	ANP	receptors	(106).	 	Furthermore,	mechanical	 stimuli	 (107)	 and	 heat	 (89)	 have	 been	 described	 to	trigger	preconditioning	amongst	other	 substances	 including	volatile	anaesthesia,	statins	and	metformin	(95).	
Although	numerous	 substances	 listed	above	act	 to	mimic	 ischaemic	preconditioning,	blocking	their	receptors	does	not	necessarily	lead	to	blocking	their	preconditioning	effects	unlike	those	seen	in	the	above	
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experiments	concerning	adenosine,	opioids	and	bradykinin.	 	Clearly,	ischaemic	 preconditioning	 is	 much	 more	 complex	 than	 a	 single	trigger	 being	 released	 and	 occupying	 its	 receptor	 to	 mediate	 a	protective	 effect.	 	 Undoubtedly,	 there	 is	 a	 large	 interplay	 between	these	 various	 substances	 in	 order	 to	mediate	 a	 common	 effect;	 cell	survival.			





or	 suprathreshold	 preconditioning	 stimuli.	 	 Adapted	 from	
Morris	et	al	(108).	
	
It	can	be	seen	that	5	minutes	of	ischaemia	is	required	to	achieve	the	threshold	 for	 preconditioning	 (1st	 panel),	 but	 this	 is	 not	 achieved	when	the	duration	of	ischaemia	is	lowered	to	3	minutes	(panel	2).		In	the	 3rd	 panel,	 blocking	 the	 effects	 of	 bradykinin	 with	 HOE	 140	prevents	 the	 suprathreshold	 5	 minutes	 ischemia	 reaching	 the	threshold	 necessary	 to	 protect	 the	 cell.	 	 Finally,	 in	 panel	 4,	 a	
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subthreshold	 ischaemic	 stimulus	 with	 3	 minutes	 hypoxia	 in	 the	presence	of	 an	angiotensin	 converting	enzyme	 inhibitor	 (ACEi)	 that	increase	 bradykinin	 levels,	 confers	 protection.	 	 This	 clearly	demonstrates	 the	 interplay	 amongst	 these	 receptors.	 	 Based	 upon	this,	 blocking	 a	 particular	 receptor	 only	 serves	 to	 raise	 the	preconditioning	threshold.			
Finally,	 although	 other	 Gi	 receptors	 are	 expressed	 on	cardiomyocytes,	 triggering	 of	 which	 can	 induce	 a	 preconditioning	state,	 these	 other	 receptors	 do	 not	 seem	 to	 partake	 in	 ischaemic	preconditioning	probably	because	the	agonist	to	these	receptors	are	not	produced	in	sufficient	quantities	by	the	ischaemic	myocardium.	
	
1.5.7.2	Intracellular	Mediators	of	Preconditioning	
Once	 preconditioning	 has	 been	 triggered,	 complex	 arrays	 of	intracellular	 cascade	 of	 events	 are	 enrolled	 that	 recruit	 a	 series	 of	prosurvival	kinases,	which	form	part	of	an	anti-apoptotic	mechanism	for	 cellular	 protection.	 	 These	 kinases	 undergo	 some	 form	 of	 post-translational	modification	 and	 then	 convey	 cardioprotective	 signals	to	 the	mitochondria	 that	 leads	 to	 the	 generation	of	 reactive	oxygen	species	 that	 activate	 protein	 kinases	 such	 as	 Akt,	 Erk	 1/2,	 protein	
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kinase	 C	 and	 tyrosine	 kinase.	 These	 provide	 the	 required	 memory	allowing	 the	 ischaemic	 preconditioning	 effect	 to	 last	 the	 initial	 few	hours	as	seen	 in	classical	preconditioning,	which	 is	 the	 focus	of	 this	thesis.	 	 To	 achieve	 the	 second	 window	 of	 protection,	 a	 series	 of	transcription	factors	(AP-1,	hypoxia-inducible	factor	1	alpha,	nuclear	factor	 kB,	 nuclear	 factor	 erythroid2-related	 factor	 2)	 and	 signal	transducer	 and	 activator	 of	 transcription	 (STAT)	 become	 activated	by	these	kinases	to	enable	the	production	of	distal	mediators	(such	as	prostaglandin	G/H	synthase	(COX-2),	heat	shock	proteins	e.g.	Hsp72	and	 inducible	 nitric	 oxide	 synthase)	 that	 produces	 the	 second	window	 of	 protection,	 12-24	 hours	 following	 the	 initial	preconditioning	 stimulus.	 	 It	 is	 now	 known	 that	 the	 protection	afforded	 through	 ischaemic	 preconditioning	 is	 mediated	 through	several	signalling	pathways	 including	the	reperfusion	 injury	salvage	kinase	 pathway	 (RISK-	 comprising	 of	 PI3-kinase/Akt	 and	 Erk)	 and	the	 Survivor	 Activator	 Factor	 Enhancement	 (SAFE)	 pathway	(comprising	–	TNF	alpha,	JAK-STAT	3)	(109)	
In	 this	 regard,	 the	 activation	 of	 phosphatidylinositol-3-OH-kinase	(PI3K)-Akt	and	p42/p44	extra-cellular	signal-regulated	kinases	(Erk	1/2),	 at	 the	 onset	 of	 reperfusion	 has	 been	 shown	 to	 protect	 cells	against	 the	 detrimental	 effects	 of	 lethal	 reperfusion	 injury.	 	 These	
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innate	 pro-survival	 kinases	 have	 been	 collectively	 termed	 together	and	 form	 part	 of	 the	 Reperfusion	 Injury	 Salvage	 Kinase	 (RISK)	pathway,	by	Yellon’s	laboratory	(110).		
	
Phoshatidylinositol-3-OH-kinase	(PI3K)-Akt	signalling	cascade	
In	response	to	various	receptor	activation,	 the	(PI3K)-Akt	signalling	cascade	 is	 activated	 where	 it	 phosphorylates	 a	 whole	 host	 of	substrates	 including	 those	 involved	 in	 glycogen	 &	 protein	metabolism	 (glycogen	 synthase	 kinase-3),	 glucose	 metabolism	(GLUT4	 vesicles),	 apoptotic	 proteins	 (BAD,	 BAX,	 BIM,	 p53	 and	caspases),	 transcription	 factors,	 p70S6K,	 eNOS	 and	 PKC	 (111).		Protection	against	 ischaemia-reperfusion	 injury	 is	achieved	 through	activation	 of	 the	 serine-threonine	 kinase,	 Akt,	 which	 itself	 is	triggered	by	PI3	kinase.	
The	 involvement	 of	 PI3	 kinase	 was	 first	 suggested	 by	 Tong	 et	 al	(112).		In	their	isolated	perfused	rat	heart	model,	the	preconditioned	hearts	in	the	presence	of	a	potent	PI3	kinase	inhibitor,	wortmannin,	lost	 protection	 as	 demonstrated	 by	 a	 significant	 reduction	 in	 the	recovery	 of	 left	 ventricular	 developed	 pressure	 (LVDP)	 (102).		Yellon’s	 group	 later	 confirmed	 this	 in	 a	 similar	model	 group	where	
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they	were	 able	 to	 demonstrate	 the	 benefits	 of	 preconditioning	was	lost	in	the	presence	of	inhibitors	of	PI3-kinase	(113).	
	
p42/p44	extra-cellular	signal-regulated	kinases	(Erk	1/2)	
Similar	 to	 the	 (PI3K)-Akt	 signalling	 cascade,	 once	 triggered	 in	 the	context	 of	 ischaemia-reperfusion,	 protection	 against	 cell	 death	 is	achieved.	 	This	 family	of	 serine-threonine	kinases	 forms	part	of	 the	mitogen-activated	 protein	 kinases	 (MAPKs)	 and	 is	 involved	 in	 the	regulation	 of	 cell	 proliferation,	 differentiation	 and	 survival	 in	response	 to	 occupation	 of	 G	 protein-coupled	 and	 tyrosine	 kinase	receptors.	
The	 exact	mechanism	 through	which	damage	 limitation	 is	 achieved	remains	largely	unknown	however	part	explanation	is	their	ability	to	phosphorylate	 and	 inactivate	 pro-apoptotic	 proteins.	 	 To	demonstrate	 a	 few,	 direct	 or	 indirect	 phosphorylation	 of	 pro-apoptotic	proteins	via	the	RISK	pathway,	prevents	them	from	binding	to	 its	 effector	 mitochondria	 (BAD),	 inhibiting	 some	 form	 of	conformational	shape	change	 that	 is	essential	 for	mediating	 its	pro-apoptotic	 influence	 (BAX),	 reducing	 the	 actual	 expression	 of	 pro-apoptotic	 protein	 (BIM)	 or	 causing	 their	 degradation	 through	
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intermediaries	(p53),	 thus	mediating	cellular	protection	(110).	 	Akt,	on	 the	 other	 hand,	 has	 been	 identified	 to	 inhibit	 mitochondrial	transition	 permeability	 pore	 opening.	 	 By	 doing	 so,	 mitochondrial	cytochrome	 c	 (required	 to	 activate	 caspases)	 release	 from	 the	mitochondrial	 intermembranous	 space	 into	 the	 cytosol	 is	 inhibited	thereby	 allowing	 mitochondrial	 membrane	 potential	 to	 remain	unaltered	 and	 allowing	 cell	 survival.	 	 The	 PI3-Akt	 has	 also	 been	shown	to	activate	protein	kinase	C	(PKC)	that	has	been	shown	to	also	inactivate	 pro-apoptotic	 factors.	 	 This	 partly	 demonstrates	 the	complex	array	of	cellular	reaction	that	takes	place	to	minimise	harm	to	cells	during	ischaemia	reperfusion	injury.	
	
Protein	kinase	C	
Protein	 kinase	 C	 (PKC)	 is	 thought	 to	 be	 a	 common	 component	 for	many	 intracellular	 signal	 transduction	 pathways	 (114).	 It	 was	Professor	 Downey	 and	 colleagues	 who	 identified	 PKC	 as	 the	 first	cytosolic	 mediator	 of	 conditioning	 whilst	 investigating	 the	mechanism	underlying	preconditioning	(97).	 	His	group	was	able	to	counteract	 the	 benefits	 of	 preconditioning	 with	 the	 use	 of	 several	PKC	 inhibitors.	 	 It	was	Downey’s	 group	who	 first	 proposed	 that	 an	
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endogenous	 ligand	 (such	 as	 adenosine	A1)	 binding	 to	 its	 specific	 G	protein-coupled	 receptor,	 located	 on	 cell	 surface,	 activated	phospholipase	 C	 (PLC);	 the	 net	 result	 was	 a	 breakdown	 of	phosphatidylinositol	 4,5	 bisphosphonate	 and	 phosphatidyl	 choline	into	 inositol	 1,4,5-triphosphate	 and	 diacyl	 glycerol	 (DAG).	 	 	 DAG	would	 then	 act	 as	 a	 second	 messenger	 to	 cause	 phosphorylation,	activation	and	translocation	of	the	enzyme	PKC.	 	This	 in	turn	would	phosphorylate	a	 secondary	effector	 leading	 to	 the	protective	effects	of	preconditioning	(105,	115).	
	
Mitogen-Activated	Protein	Kinases	
There	are	many	MAP	kinases	described	 in	 literature	 (116)	amongst	which	 p38	 plays	 an	 important	 role	 in	 ischaemic	 preconditioning.		This	kinase	was	investigated	by	Yellon’s	group	(117),	where	isolated	rat	 hearts	 in	 the	 Langendorff	 model	 were	 subjected	 to	 35	minutes	regional	 ischaemia	 followed	 by	 2	 hours	 reperfusion.	 	 A	pharmacological	inhibitor	of	p38	MAPK	was	administered	at	various	stages	 of	 the	 experiment	 including	 during	 the	 preconditioning	protocol	or	 just	prior	 to	and	15	minutes	 into	 index	 ischaemia.	They	were	able	to	demonstrate	that	not	only	p38	MAPK	protects	the	heart	
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from	 lethal	 ischaemia	 reperfusion	 injury	but	 the	 temporal	aspect	of	p38	 was	 crucial;	 p38	 MAPK	 becomes	 activated	 during	 index	ischaemia	 and	 therefore	 the	 protection	 afforded	 by	 ischaemic	preconditioning	 becomes	 abrogated	 when	 the	 inhibitor	 is	 given	during	 this	 phase.	 	 They	 were	 also	 able	 to	 demonstrate	 that	 p38	MAPK	given	in	the	non	preconditioned	heart	prior	to	and	during	the	ischaemia	had	no	effect.			
Various	isoforms	of	p38	exist	(alpha/beta)	and	have	opposing	roles.		The	alpha	is	thought	to	become	activated	during	preconditioning	and	is	 thought	 to	 mediate	 preconditioning	 through	 increased	phosphorylation	of	heat	shock	proteins.			
	
Survivor	Activating	Factor	Enhancement	(SAFE)	pathway	




The	 mitochondria	 are	 thought	 to	 be	 the	 key	 mediator	 of	cardioprotection	in	the	context	of	ischaemia	reperfusion	injury.		They	are	where	most	of	 the	signalling	cascade	merges.	 	Mitochondria	are	double	membrane	bound	organelles	that	act	as	the	‘powerhouse’	for	cells.	 	 Through	 a	 series	 of	 reactions,	 they	 produce	 adenosine	triphosphate	(ATP)	that	acts	as	a	source	of	energy	for	cells.			
The	 basic	 structure	 of	 the	 mitochondria	 consists	 of	 an	 outer	mitochondrial	 membrane	 that	 envelopes	 the	 entire	 rod	 shaped	organelle,	 the	 intermembrane	space,	 the	 inner	membrane	 that	 folds	over	many	times	to	form	cristae,	and	the	matrix	that	contains	fluid.	
	
Mitochondrial	Permeability	Transition	Pore	
The	mitochondrial	permeability	 transition	pore	 is	a	channel	 located	within	the	inner	mitochondrial	membrane.		When	the	pore	is	opened,	the	inner	mitochondrial	membrane	potential	is	lost	leading	to	matrix	swelling,	 rupture	 of	 the	 outermost	 membrane	 and	 release	 of	cytochrome	C	from	the	intermembrane	space	into	the	cytoplasm	that	leads	 to	 processes	 that	 culminate	 in	 cell	 death.	 	 The	 MPTP	 was	previously	 thought	 to	 be	 a	 complex	 of	 voltage-dependent	 anion	
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channels	 located	 on	 the	 outer	 membrane	 that	 interacted	 with	adenine	 nucleotide	 translocase	 of	 the	 inner	 membrane,	 which	 was	regulated	by	cyclophilin	D	from	within	the	matrix.		The	MPTP	is	now	thought	to	be	formed	from	F0F1	that	consists	of	a	F0	domain,	which	is	 integral	to	the	inner	mitochondrial	membrane	and	the	F1	domain	located	 on	 the	 periphery	 of	 the	 membrane	 where	 the	 protons	 are	moving.	 	 The	 F-ATPase	 utilises	 a	 proton	 gradient	 to	 drive	 ATP	synthesis.	 	 It	 allows	 the	 passive	 movement	 of	 protons	 along	 an	electrochemical	 gradient	 and	 uses	 energy	 released	 from	 transport	reactions	to	release	newly	produced	ATP.			
During	 myocardial	 ischaemia	 and	 reperfusion,	 the	 MPTP	 opens	resulting	in	depolarisation	of	the	inner	mitochondrial	membrane.			As	with	conditioning,	paradoxically,	transient	MPTP	opening	serves	as	a	physiological	 function	 and	 plays	 a	 role	 in	 ROS	 homeostasis	 and	calcium	 release;	 and	 this	 has	 been	 shown	 to	 exert	 a	 positive	cardioprotective	 effects	 during	 ischaemic	 preconditioning	 (120).		From	 experimental	 studies	 it	 is	 clear	 that	 cyclophilin	 D	 (located	 in	the	mitochondrial	matrix)	is	involved	in	MPTP	opening;	it	lowers	the	threshold	 at	which	MPTP	 is	 opened	 in	 the	presence	 of	 calcium	and	inorganic	phosphates.		In	that	regard,	cyclosporine	A,	an	inhibitor	of	cyclophilin	 D,	 therefore	 an	 inhibitor	 of	 MPTP	 opening,	 has	 been	
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demonstrated	to	attenuate	infarct	size	in	experimental	studies	in	the	context	 of	 ischaemia	 and	 reperfusion.	 	 However,	 less	 success	 was	achieved	 in	patients	 in	 the	 setting	of	acute	myocardial	 infarction	or	during	elective	coronary	artery	bypass	grafting	surgery.					
	
Role	of	K+ATP	channels	in	preconditioning	
Following	 the	 first	 description	 of	 K+ATP	 channels	 in	 ventricular	cardiomyocytes	 by	 Noma	 in	 cardiac	 ventricular	 myocytes	 (121),	importance	 has	 been	 placed	 upon	 their	 role	 as	 mediators	 of	preconditioning;	this	has	been	demonstrated	in	experimental	models	ranging	from	isolated	cells	and	hearts	to	whole	animals.	
It	is	widely	accepted	that	these	channels	play	a	key	role	in	mediating	protection	and	it	was	Gross	and	collaborators	who	first	proposed	this	(122).	 	 Studies	 have	 since	 demonstrated	 its	 role	 in	 preconditioning	by	 producing	 or	 inhibiting	 cardioprotection	 using	 the	 channel	openers	 or	 blockers	 respectively.	 	 In	 subsequent	 experimental	studies,	 adenosine	 receptor	 activation	 has	 been	 shown	 to	 be	upstream	of	K+ATP	 activation	 as	 glibenclamide	 (potent	K+ATP	 channel	blocker)	 has	 been	 shown	 to	 attenuate	 cardioprotection	 induced	through	adenosine	A1	receptor	activation	(123).	
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There	 are	 2	 distinct	 K+ATP	 channels,	 each	 with	 unique	pharmacological	 profiles	 despite	 similarities	 in	 their	 structure.		There	 are	 those	 that	 reside	 on	 the	 cell	 surface	 (sarcolemmal)	 and	those	 located	 on	 the	 inner	 mitochondrial	 membrane	 (124).	 	 For	example,	 5-hydroxydecanoate	 has	 been	 shown	 to	 inhibit	 the	mitochondrial	channels	at	micromolar	range	but	has	failed	to	do	the	same	to	 the	sarcolemmal	channels	at	any	concentrations.	 	Similarly,	potent	openers	of	K+ATP	channels	such	as	diazoxide	are	almost	a	1000	times	 more	 potent	 opening	 mitochondrial	 K+ATP	 channels	 when	compared	to	sarcolemmal	channels	(125).		
An	early	hypothesis	was	 that	cardioprotection	was	mediated	by	 the	sarcolemmal	channels	by	shortening	the	duration	of	action	potential.		We	now	know	that	most	of	the	evidence	hinges	on	the	mitochondrial	K+ATP	as	mediators	of	cardioprotection	in	conditioning.			
Marban	and	colleagues	(126)	first	identified	the	involvement	of	K+ATP	channels,	 located	 within	 the	 inner	 mitochondrial	 membranes	 in	cardioprotection.	 	 Opening	 of	 the	mitochondrial	 K+ATP	 channels	will	drive	 K+	 (and	 water)	 into	 mitochondria	 along	 its	 electrochemical	gradient	 (as	H+	 ions	 are	 extruded);	K+/H+	 exchanger	 located	on	 the	inner	 membrane	 then	 exchange	 the	 entered	 K+	 with	 extra-mitochondrial	H+.		Theoretically,	the	K+	entering	cells	would	naturally	
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uncouple	 the	 mitochondrion	 therefore	 resulting	 in	 reduced	 ATP	production.		However	the	actual	degree	of	uncoupling	resulting	from	this	 is	 minimal	 therefore	 ATP	 production	 is	 minimally	 affected.		Several	theories	exist	to	explain	why	opening	of	these	K+	channels	is	protective,	but	in	essence,	the	mitochondria	are	made	more	resistant	to	calcium	entry.	
These	 particular	 channels	 are	 modulated	 by	 intracellular	concentrations	of	ATP	and	contribute	 to	action	potential	shortening	and	 prevention	 of	 intracellular	 calcium	 overload	 during	 ischaemia.		Therefore	 low	 levels	 of	 ATP	 (as	 seen	 during	 ischaemia)	 causes	opening	 of	 these	 channels	 allowing	 efflux	 of	 potassium	 ions	 that	hastens	 the	rate	of	 contractile	arrest	 through	reducing	 the	duration	of	 action	 potential	 and	 inhibiting	 calcium	 entry	 into	 cells.	 	 This	ultimately	leads	to	the	preservation	of	intracellular	ATP	therefore	are	protective	to	cells.		In	experimental	studies,	specific	K+ATP	antagonists	such	as	the	sulphonylureas	(Glibenclamide/Tolbutamide)	have	been	shown	to	block	the	effects	of	preconditioning	and	similarly,	opening	these	 channels	 with	 agents	 such	 as	 Nicorandil	 has	 shown	 to	precondition	the	myocardium.	





To	date	preconditioning	has	been	shown	to	abrogate	infarct	size	in	a	wide	range	of	experiments	and	has	been	successfully	reproduced	in	many	species	 studied	but	 the	question	 remained	as	 to	whether	 this	can	 be	 applied	 to	 humans.	 	 Experiments	 in	 humans	 are	 important	because	experimental	findings	on	ischaemic	preconditioning	may	not	necessarily	 be	 extrapolated	 to	 humans	 because	 of	 differences	 in	mechanism	 between	 species.	 	 Evidence	 for	 preconditioning	 in	humans	 mostly	 come	 from	 indirect	 evidence	 because	 logistics	 and	ethical	 reason	 prevent	 us	 from	 meeting	 the	 strict	 experimental	conditions	where	preconditioning	utilises	infarct	size	as	an	end	point	(127).	 	 However,	 Yellon’s	 group	 were	 able	 to	 demonstrate	 the	efficacy	of	IPC	in	humans	undergoing	coronary	artery	bypass	grafting	(128).		
There	is	compelling	evidence	for	the	existence	of	preconditioning	in	the	 human	 myocardium,	 mainly	 derived	 mainly	 from	 ex	 vivo	experiments	 involving	 human	 atrial	 trabeculae	 (129),	 ventricular	
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The	human	atrial	trabecular	model	of	ischaemia	and	reperfusion	has	been	developed	and	studied	extensively	in	Yellon’s	laboratory	at	the	Hatter	 Cardiovascular	 Institute.	 	 Briefly,	 atrial	 trabeculae	 isolated	from	 right	 atrial	 appendage	 harvested	 during	 cardiac	 surgery	undergo	various	preconditioning	protocols	and	 it	has	been	possible	to	demonstrate	 attenuation	 in	 ischaemic	 injury.	 	 Some	 studies	have	used	 rapid	 atrial	 pacing	 as	 a	 preconditioning	mimetic	 whilst	many	have	 used	 simulated	 ischaemia	 as	 their	 preconditioning	 stimulus.		
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The	 end	 points	 of	 these	 studies	 are	 reflected	 by	 an	 increase	 in	functional	recovery	following	an	ischaemic	insult.			







Findings	 Reference	3	 mins	 rapid	 atrial	pacing	followed	by	12	mins	reoxygenation	 Ability	 to	precondition	 and	involvement	 of	adenosine	in	PC	
Walker	DM	et	al	1995	
3	 mins	 simulated	ischaemia	 followed	by	 7	 mins	reoxygenation	
Role	of	protein	kinase	C	and	ATP	dependent	K	channel	 Speechly-D	et	al	1995	3	 mins	 (or	 1.5	 mins	subthreshold	ischaemia)	 followed	by	 7	 mins	reoxygenation	
Involvement	 of	bradykinin	 in	 PC	 and	interplay	 amongst	various	triggers	in	PC	
Morris	et	al	1997	
3	 mins	 simulated	ischaemia	 followed	by	 7	 mins	reoxygenation	
Role	 of	 ATP	dependent	 K	channels	in	PC	 Carr	et	al	1997	3	 mins	 simulated	ischaemia	 followed	by	 7	 mins	reoxygenation	 in	patients	±	Nicorandil		
Role	 of	 ATP	dependent	 K	channels	 in	 PC.	Addition	 of	 PC	abrogates	recovery.	
Carr	et	al	1997	
3	 mins	 simulated	ischaemia	 followed	by	 7	 mins	reoxygenation	
Role	 of	 adenosine	A1	and	 A3	 receptors	 in	PC	 Carr	et	al	1997	3	 mins	 simulated	ischaemia	 followed	by	 7	 mins	reoxygenation	
Role	 of	 delta	 opioid	receptor	 stimulation	in	PC	 Bell	et	al	2000	3	 mins	 simulated	ischaemia	 followed	by	 7	 mins	reoxygenation	
Role	of	MPTP	in	PC	 Shanmuganathan	 et	al	2005	
4	 x	 60	 sec	 post	conditioning		 Recruitment	 of	 RISK	in	post	conditioning	 Sivaraman	et	al	2007	4	 mins	 simulated	ischaemia	 followed	by	 16	 mins	reperfusion	
Role	 of	 various	isoforms	 of	 PKC	 in	preconditioning	 Sivaraman	et	al	2009	
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4	 mins	 simulated	ischaemia	 followed	by	 16	 mins	reperfusion	
Diabetics	 requiring	 a	stronger	PC	stimulus	 Sivaraman	et	al	2010	
Table	 1.1.	 	 Summary	 of	 atrial	 trabecular	models	 at	 the	 Hatter	
Cardiovascular	Institute.	
	




The	 first	 study	 to	demonstrate	preconditioning	exists	 in	 the	human	myocardium	 comes	 from	 our	 laboratory	 where	 we	 were	 able	 to	demonstrate	this	in	a	cohort	of	patients	undergoing	coronary	artery	bypass	 grafting	 (118).	 	 In	 this	 study,	 after	 establishing	cardiopulmonary	 bypass,	 patients	 would	 undergo	 2	 cycles	 of	
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preconditioning	 by	 way	 of	 3	 minutes	 of	 aortic	 cross	 clamping	interspersed	by	2	mins	of	reperfusion	whilst	the	heart	was	paced	at	90	 beats	 per	 minute.	 	 The	 index	 ischaemia	 was	 applied	 when	 the	heart	 underwent	 cross	 clamp	 fibrillation	 during	 distal	 aortic-coronary	 anastomosis	 for	 10	minutes.	 	 Needle	myocardial	 biopsies	taken	 from	the	 left	ventricular	 free	wall	were	 taken	at	various	 time	intervals	 including	 before	 the	 application	 of	 preconditioning	protocol,	 following	 the	 preconditioning	 protocol	 and	 following	 the	ischaemic	 insult	 (cross	 clamp	 fibrillation).	 	 The	 investigators	 were	able	 to	 demonstrate	 a	 reduction	 of	 ATP	 in	 the	 specimen	 taken	following	the	preconditioning	protocol	but	more	importantly,	similar	to	 earlier	 experiments	 of	 Murry	 et	 al,	 were	 able	 to	 demonstrate	myocardial	preservation	of	ATP	(40).			Many	small	clinical	trials	have	since	been	conducted	to	confirm	that	preconditioning	can	be	applied	to	 the	 human	 myocardium	 through	 measuring	 various	 biomarkers	including	 troponin	 and	 creatine	 kinase.	 	 Gaunts’	 group	 went	 on	 to	perform	a	systematic	review	and	meta-analysis	 involving	22	clinical	trials	to	evaluate	whether	preconditioning	had	any	benefits	in	terms	of	 clinical	 outcomes.	 	 To	 no	 surprise,	 the	 meta-analysis	 concluded	that	 although	 statistically	 insignificant	 (p=0.17)	 there	 was	 a	reduction	 in	 death,	 inotropic	 use	 was	 reduced;	 postoperative	
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ventricular	 arrhythmias	 were	 significantly	 reduced	 as	 were	 the	duration	of	ITU	stay	(139).			
	
Preconditioning	during	percutaneous	coronary	intervention	
Percutaneous	coronary	 intervention	 (PCI)	 involves	balloon	 inflation	of	a	coronary	lesion	in	order	to	deliver	a	coronary	stent	which	itself	is	 mounted	 onto	 a	 balloon	 which	 is	 then	 inflated,	 after	 which	 the	stent	becomes	deployed.		Further	optimisation	of	the	deployed	stent	is	 achieved	 by	 post	 dilating	 usually	 with	 a	 non-compliant	 balloon.		During	balloon	inflations	it	is	common	to	see	that	patients	go	through	reducing	angina	with	serial	balloon	inflations	in	parallel	with	a	lesser	degree	of	ST	segment	deviation.			
Thus,	 it	 is	 clear	 that	 stenting	 involves	 brief	 periods	 of	 ischaemia	during	balloon	inflation.		Several	studies	have	taken	place	to	evaluate	whether	 this	adaptation	 is	due	to	preconditioning	or	recruitment	of	collaterals.		It	must	be	borne	in	mind	that	such	studies	only	evaluate	the	 normal	 pattern	 of	 reversible	 injury	 as	 seen	 in	 coronary	angioplasty.	
In	an	earlier	study	by	Deutsch	et	al	(140),	the	effect	of	2	consecutive	90	 seconds	 balloon	 inflations	 of	 isolated	 left	 anterior	 descending	
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artery	 (LAD)	 stenosis	 in	 12	 patients	 undergoing	 elective	 PCI	 was	evaluated.	 	 Baseline	 characteristics	 before	 initial	 inflation	 were	similar	 in	 all	 12	 patients	 and	 collateral	 vessels	 in	 3	 patients	 were	visible	 before	 PCI	 took	 place.	 	 Parameters	 observed	 included	haemodynamic	 response,	 metabolic,	 electrocardiographic	 and	symptomatic	changes.		Amongst	the	usual	cardiac	medications,	these	patients	 were	 also	 given	 dipyridamole,	 which	 is	 a	 potentiator	 of	adenosine.	 	Results	 from	this	study	demonstrated	 that	anginal	pain,	ST	 segment	 elevation	 and	 myocardial	 lactate	 production	 were	 all	significantly	reduced	during	the	second	 inflation	when	compared	to	the	 first.	 	 In	 addition	 coronary	 wedge	 pressure	 during	 the	 serial	balloon	inflations	were	not	significantly	different	as	well	as	coronary	vein	 flow,	which	was	reduced	during	the	second	 inflation;	 therefore	these	 findings	 suggested	 that	 ischaemia	 resulting	 from	 the	 primary	balloon	 inflation	 may	 precondition	 against	 subsequent	 balloon	inflations	 in	 the	 absence	 of	 recruitment	 of	 collateral	 vessels.	 	 	 This	study	 may	 also	 suggest	 that	 the	 duration	 of	 ischaemia	 required	 to	trigger	preconditioning	may	be	as	low	as	90	seconds,	which	is	usually	2.5	minutes	as	suggested	by	Downey	et	al	(141).	 	Studies	employing	shorter	durations	of	 ischaemia	failed	to	demonstrate	any	protection		(118).	
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1.5.8.3	 Does	 antecedent	 angina	 protect	 against	 myocardial	
infarction?	
Aside	 from	cardiac	 surgery,	 antecedent	angina	has	been	considered	to	 mimic	 a	 form	 of	 ischaemic	 preconditioning	 in	 the	 setting	 of	 an	acute	 myocardial	 infarction	 (AMI)	 and	 this	 has	 been	 studied	extensively.	 	 Angina	 itself	 is	 a	 common	manifestation	 of	 reversible	myocardial	 ischaemia	 and	 is	 commonly	 experienced	 by	 many	patients	 before	 an	 MI.	 	 For	 angina	 to	 induce	 preconditioning,	 the	duration	 of	 ischaemia	 would	 need	 to	 be	 prolonged	 (at	 least	 2.5	minutes)	and	 take	place	within	1-2	hours	of	 the	MI	as	 suggested	 in	experimental	studies.	 	Therefore	unstable	angina	would	be	clinically	analogous	 to	 preconditioning	 as	 oppose	 to	 chronic	 stable	 angina	where	 ischaemia	 is	usually	 relatively	brief	and	does	not	necessarily	occur	 within	 the	 timeframe	 prior	 to	 an	 MI.	 	 The	 precise	pathophysiology	underlying	unstable	angina	is	yet	to	be	determined	however	 the	 formation	 and	 dispersion	 of	 platelet	 rich	 thrombi	 is	thought	 to	play	 an	 important	 role.	 	 Experimental	 evidence	 suggests	that	 ischaemia	 resulting	 from	 cyclical	 variation	 of	 coronary	 blood	flow	 as	 a	 result	 of	 repeated	 thrombi	 formation	 and	 resolution	 can	induce	 preconditioning	 as	 effectively	 as	 mechanical	 coronary	occlusion	as	applied	to	original	experimental	protocols.		As	we	know	
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from	 earlier	 studies	 i.e.	 Murrys	 original	 paper,	 preconditioning	serves	 to	 delay	 cell	 death	 rather	 than	 preventing	 it	 and	Murry	was	able	 to	 demonstrate	 that	 extending	 the	 index	 ischaemia	 to	 3	 hours	from	 40	minutes	 abrogated	 the	 effects	 of	 preconditioning.	 	 For	 the	same	 reason,	 investigators	 have	 only	 considered	 studies	 only	 after	the	 advent	 of	 thrombolysis,	 as	 reperfusion	 is	 a	 prerequisite	 for	preconditioning	to	take	place.	
On	that	note,	Muller	et	al	(143)	was	one	of	the	first	groups	to	study	the	 effect	 of	 antecedent	 angina	 on	 clinical	 outcomes	 following	 an	acute	 myocardial	 infarction	 and	 thrombolysis.	 	 775	 patients	 were	recruited	 from	 the	 Thrombolysis	 and	 Angioplasty	 in	 Myocardial	Infarction	 trial	 (TAMI)	 and	 only	 patients	 experiencing	 angina	 for	more	 than	 7	 days	were	 grouped	 in	 the	 chronic	 angina	 group.	 	 The	effects	 of	 chronic	 angina	prior	 to	 an	AMI	 on	 immediate	 and	 7	 days	angiographic	 appearances	 together	 with	 short	 term	 and	 long-term	mortality	 was	 determined.	 	 They	 were	 able	 to	 conclude	 that	 in	patients	with	antecedent	angina,	 the	 re-occlusion	 rate	of	 the	 infarct	related	artery	was	lower	(8%	v	14%)	as	well	as	in-hospital	mortality	(5%	v	7%).	 	No	difference	was	seen	in	the	two	years	mortality	data	(89%	v	90%).		Like	with	many	studies,	several	limitations	exist	with	this	 type	and	particular	study;	 firstly	these	type	of	studies	were	not	
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designed	 to	 investigate	 preconditioning,	 secondly	 patients	 suffering	with	 angina	 less	 than	 7	 days	were	 grouped	 amongst	 those	without	any	preceding	angina	-	 it	may	well	have	been	that	 if	 these	subset	of	patients	were	included	in	the	angina	group,	the	benefits	of	pre-infarct	angina	may	 have	 been	more	 pronounced	 as	 patients	 suffering	with	bouts	of	angina	 immediately	prior	 to	 their	 infarct	are	most	 likely	 to	have	 undergone	 preconditioning,	 thirdly	 collateral	 blood	 flow	 was	not	assessed	–	this	is	important	because	this	may	be	the	reason	why	patients	had	better	short	term	outcomes.		Hirai	et	al	(144)	were	able	to	demonstrate	this	in	a	group	of	patients	with	pre-infarct	angina	to	have	 better	 preserved	 left	 ventricular	 function	 when	 compared	 to	those	without	angina	but	they	also	had	a	better	collateral	circulation	at	 the	point	of	 infarction,	suggesting	that	 the	 improved	outcomes	 in	the	angina	cohort	was	a	reflection	of	better	collateral	circulation.	
Another	important	factor	is	that	patients	in	the	non-angina	arm	had	a	lower	incidence	of	multi-vessel	disease	and	lower	risk	factor	profile.		It	 cannot	 be	 deducted	 solely	 from	 this	 study	 that	 angina	preconditions	 the	 myocardium	 as	 during	 an	 acute	 coronary	occlusion,	it	may	well	be	that	collateral	vessels	are	recruited	and	also	patients	 suffering	 with	 angina	 may	 well	 have	 been	 on	 agents	 that	improve	outcomes	following	a	myocardial	infarction.		Nonetheless,	a	
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history	of	 angina	may	well	have	been	of	benefit	because	 the	2	year	outcome	 in	 the	 angina	 group	 was	 comparable	 to	 that	 of	 the	 non	anginal	group	despite	the	presence	of	multi-vessel	disease	and	higher	risk	factor	profile	(143).	
Subsequent	larger	clinical	trial	have	in	fact	demonstrated	an	adverse	event	 in	 patients	 suffering	 with	 angina	 prior	 to	 their	 infarct.	 	 For	example,	in	an	analysis	involving	more	than	eight	thousand	patients	in	 the	 International	 rt-Plasminogen	 Activator/Streptokinase	Mortality	 Trial,	 Barbash	 et	 al	 (145)	 discovered	 the	 incidence	 of	cardiogenic	 shock,	 early	 reinfarction	and	 in-hospital	mortality	were	higher	in	patients	who	suffered	with	angina	prior	to	their	MI.		Similar	to	 the	 trial	 by	 Muller	 et	 al,	 patients	 with	 angina	 had	 significantly	higher	 risk	 factors	 than	 those	 without.	 	 Furthermore,	 Ruocco	 et	 al	(146)	assessed	the	effect	of	antecedent	angina	in	over	three	thousand	patients	enrolled	in	the	Thrombolysis	in	Myocardial	Infarction	trial	II	(TIMI	II)	on	the	early	and	late	outcomes	following	an	MI.	 	Similar	to	Barbash’s	 group,	 reinfarction	 rate	was	higher	 in	 those	experiencing	pre-infarct	 angina	 compared	 to	 those	 without	 antecedent	 angina.		There	 was	 no	 difference	 in	 the	 mortality	 at	 21	 days	 amongst	 the	various	groups.	 	Authors	have	concluded	 that	 the	 latter	 two	studies	above	did	not	confirm	any	benefit	from	pre-infarct	angina	but	rather	
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exhibit	 such	 patients	 have	 a	 worse	 prognosis	 likely	 due	 to	 higher	incidence	 of	 multi-vessel	 disease	 and	 more	 unfavourable	cardiovascular	risk	factors.	
A	 crucial	 aspect	 of	 preconditioning	 is	 the	 temporal	 aspect	 of	 this	phenomenon.	 	 None	 of	 the	 aforementioned	 trials	 took	 this	 into	account;	Muller	 included	patients	 into	his	angina	arm	as	 those	with	more	 than	7	days,	Barbash’s	angina	group	divided	his	angina	group	into	those	suffering	with	angina	into	those	more	or	less	than	a	month	and	Ruocco	divided	his	angina	cohort	into	those	experiencing	angina	less	than	7	days,	8-180	days	and	more	than	180	days.		
To	address	this,	the	following	clinical	trials	of	pre-infarct	angina	were	designed	to	determine	whether	or	not	preinfarct	angina	is	the	clinical	equivalence	of	preconditioning.		In	the	TIMI	IV	trial	by	Kloner	(147),	350	 patients	 who	 experienced	 angina	 within	 48	 hours	 of	 their	infarction,	 several	 parameters	 had	 improved.	 	 Infarct	 size,	 as	determined	 by	 total	 CK	 release,	 was	 significantly	 less,	 as	 were	cardiogenic	 shock,	 severe	 heart	 failure	 and	 in-hospital	 mortality.		Importantly,	 in	 this	 study,	 angiography	was	 performed	 90	minutes	after	 initiating	 thrombolysis	 to	 determine	 collateral	 burden	 in	 the	infarct	 related	artery;	 the	authors	 concluded	no	difference	between	both	groups.		A	further	smaller	study	conducted	by	Ottani	et	al	(148)	
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involving	 only	 25	 patients	 found	 no	 difference	 in	 collateral	circulation	 at	 three	 weeks	 following	 intravenous	 thrombolysis	 and	there	 was	 also	 a	 reduction	 in	 infarct	 size	 (lower	 CK-MB	 release),	coupled	with	a	reduced	degree	of	hypokinesia	on	ventriculography	in	patients	experiencing	angina	within	24	hours	of	their	MI.			
Despite	 addressing	 the	 temporal	 aspects	 of	 antecedent	 angina,	 an	important	 limitation	 yet	 existed	 and	 this	 was	 the	 issue	 relating	 to	collateralisation.		An	important	determinant	of	infarct	size	in	relation	to	coronary	artery	occlusion	 is	 the	presence	of	collateral	vessel	and	also	patients	who	experience	angina	more	than	a	week	prior	to	their	infarct	have	a	high	incidence	of	collateral	blood	supply	to	the	infarct	related	 arterial	 territory.	 	 Therefore	 the	 estimation	 of	collateralisation	in	the	studies	by	Kloner	and	Ottani	may	actually	be	underestimated	 as	 angiography	 was	 performed	 in	 the	 absence	 of	complete	coronary	occlusion	i.e.	following	intravenous	thrombolysis.		Therefore	 the	 presence	 of	 significant	 collateral	 supply	 during	 the	peri-infarct	 period	 remains	 unknown.	 	 It	 is	 unlikely	 that	 collateral	vessels	 would	 have	 formed	 in	 the	 latter	 2	 studies	 but	 it	 is	 unclear	from	these	patients	whether	they	had	a	history	of	chronic	ischaemia	as	 this	 would	 lead	 to	 the	 formation	 of	 collaterals.	 	 Finally	 these	studies	 relied	 on	 patients	 self	 reporting	 angina	 -	 this	 reiterates	 the	
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fact	that	these	studies	are	not	designed	to	test	preconditioning	as	the	self	 reported	 symptoms	 of	 angina	 does	 not	 really	 match	 the	intermittent	 ischaemia-reperfusion	 protocols	 employed	 during	original	experimental	models.	
	
Warm	 up	 angina	 and	 preconditioning	 leading	 to	walk	 through	
angina	
Akin	to	preinfarct	angina,	preconditioning	may	also	occur	during	this	paradoxical	 phenomenon	 of	 walk	 through	 angina.	 	 In	 essence,	patients	report	 the	ability	 to	exert	 themselves	until	 they	experience	anginal	 symptoms	 (first	 wind/warm	 up/first	 hole	 angina)	 and	following	 a	 brief	 rest	 period,	 they	 are	 able	 to	 continue	 to	 exert	themselves	 without	 any	 further	 or	 minimal	 limitations	 (walk	through/second	wind	angina).		William	Heberden	first	described	this	more	 than	 two	 centuries	 ago	 in	 1772	 following	 which	 it	 was	 first	reviewed	in	the	British	Heart	Journal	in	1951	and	then	again	by	our	laboratory	 in	 1994	 by	 Marber	 et	 al	 (149).	 	 Interestingly	 1	 in	 5	patients	report	walk	through	angina	and	objective	testing	has	shown	patients	 to	 have	 enhanced	 performance	 during	 second	 effort.	 	 The	paradox	 that	 that	patients	are	resistant	 to	 further	exertional	angina	
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following	a	brief	rest	period	following	initial	period	of	effort	bears	a	resemblance	 to	 the	 paradox	 of	 preconditioning.	 	 Despite	 its	longstanding	recognition,	like	many	things	in	science,	the	mechanism	underlying	 this	 phenomenon	 remains	 indeterminate.	 	 However	several	mechanistic	principles	have	been	proposed	including:	
	




A	number	of	the	major	challenges	faced	with	preconditioning	are	its	pre-requisite	to	apply	this	prior	to	an	index	event	i.e.	an	MI.		In	reality	this	 is	unrealistic	as	an	MI	is	unpredictable	and	preconditioning	is	a	usually	 a	 short-lived	 phenomenon.	 	 This	 remained	 a	 scientific	mystery	 until	 the	 discovery	 of	 post-conditioning	 where	 repetitive	occlusion	 and	 reperfusion	 within	 minutes	 during	 early	
	 113	
revascularisation	 provided	 the	 same	 powerful	 protection	 as	preconditioning	shown	in	a	landmark	study	by	Zhao	and	co-authors	in	 2003	 (150).	 	 In	 their	 landmark	 study	 they	 used	 an	 open	 chest	canine	model,	where	dogs	were	subjected	to:		
• Control	protocol	of	60	minutes	LAD	 ligation	 followed	by	3	hours	reperfusion		
• Preconditioning	 protocol	 where	 the	 LAD	 was	 occluded	 for	 5	minutes	 then	 reperfused	 for	 10	 minutes	 prior	 to	 the	 index	ischaemia	for	60	minutes	
• Post	 conditioning	 protocol	 of	 three	 cycles	 30	 seconds	 of	reperfusion	and	occlusion	following	the	index	ischaemic	insult				 	
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Figure	1.4.	 	Protocol	used	by	Zhao	et	al	during	preconditioning	(143).		Infarct	 size	 was	 considerably	 lower	 in	 both	 the	 preconditioned	(14%)	and	postconditioned	(15%)	hearts	when	compared	to	control	(25%)	hearts.		Furthermore	polymorphonuclear	accumulation	in	the	area	 at	 risk	 myocardium	 was	 lower	 in	 comparison	 to	 the	 control	group.	 	 Other	 improved	 parameters	 included	 improved	 endothelial	function	(post	ischaemic	response	of	LAD	to	acetylcholine).		Based	on	these	 parameters,	 authors	 were	 able	 to	 conclude	 that	 post	conditioning	is	as	effective	as	preconditioning	in	reducing	infarct	size	and	preserving	endothelial	 function	and	therefore	can	be	applied	to	circumstances	 where	 ischaemia	 was	 involved	 such	 as	 coronary	intervention,	 coronary	artery	bypass	 surgery,	organ	 transplantation	
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and	 peripheral	 revascularisation.	 	 The	 same	 protection	 was	 also	identified	to	be	present	by	the	same	group	in	rats	(151).	It	 was	 not	 long	 before	 Staat	 and	 co-authors	 in	 2005	 were	 able	 to	apply	 the	 principles	 of	 post	 conditioning	 from	 bench	 to	 bedside	 in	their	pioneering	proof	of	concept	study	applied	to	humans	(152).		In	this	study,	patients	presenting	with	an	AMI	were	subjected	to	either	to	a	control	(coronary	occlusion	treated	by	direct	stenting)	arm	or	an	intervention	arm	where	within	one	minute	of	establishing	flow	down	the	infarct	related	artery,	they	were	subjected	to	further	intervention	by	means	of	4	cycles	of	one	minute	inflation	and	one	minute	deflation	using	 the	 angioplasty	 balloon.	 	 Baseline	 characteristics	 were	comparable	 in	 both	 groups	 and	 creatine	 kinase	 release	 was	measured	 over	 72	 hours	 and	 presented	 as	 the	 area	 under	 curve	 of	creatine	 kinase	 release	 AUC-CK.	 	 Analysis	 confirmed	 a	 reduction	 in	the	AUC-CK	in	the	postconditioned	group	when	compared	to	control	subjects	 (equating	 to	 a	 relative	 risk	 reduction	 of	 36%)	 thus	confirming	 the	 concept	 that	 postconditioning	 by	 coronary	angioplasty	 protects	 the	 human	 heart	 during	 an	AMI.	 	 Since	 then	 a	number	 of	 clinical	 trials	 have	 taken	 place	 to	 confirm	 that	postconditioning	 exists.	 	 Besides	 reducing	 infarct	 size,	postconditioning	 has	 also	 been	 shown	 to	 reduce	 other	 detrimental	
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effects	of	reperfusion	 injury	 including	endothelial	dysfunction,	post-ischaemic	 blood	 flow	 defects	 (no	 reflow	 phenomenon)	 and	contractile	dysfunction.			From	a	mechanistic	perspective,	both	pre	and	postconditioning	share	similar	 pathways	 and	 is	 referred	 by	 Heusch	 as	 “old	wine	 in	 a	 new	bottle”	(153).	 	 It	 is	thought	that	the	intervention	applied	at	the	time	of	 reperfusion	 must	 act	 against	 the	 known	 mediators	 of	 lethal	reperfusion	 injury,	 namely	 calcium	 paradox	 (cellular	 and	mitochondrial	 calcium	 overload),	 burst	 of	 oxidative	 stress,	endothelial	dysfunction	and	reduced	nitric	oxide	production.	 	In	our	laboratory	we	were	able	to	demonstrate	that	the	same	fundamental	pathways	 are	 activated,	 that	 include	 RISK	 pathway	 comprising	phosphatidylinositol	 3-kinase-Akt	 and	 extracellular	 signal-related	kinase.	 	 It	 has	 been	 suggested	 that	 there	 is	 upstream	 activation	 of	GPCR	 and	 downstream	 phosphorylation	 of	 eNOS	 and	 inhibition	 of	apoptosis	 promoters.	 	 As	 with	 preconditioning,	 these	 fundamental	pathways	converge	onto	the	mitochondria,	in	particular	the	MPTP	as	the	 end	 effector,	 to	 inhibit	 pore	 opening	 that	 is	 initially	 promoted	during	 the	 early	 stage	 of	 reperfusion,	 in	 response	 to	mitochondrial	calcium	overload,	oxidative	stress	and	ATP	depletion.	
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	Following	the	initial	proof	of	concept	study	by	Staat	and	co-workers,	several	 randomised	 trials	 of	 postconditioning	 in	 ST-elevation	myocardial	infarction	have	taken	place	and	most	recently	in	a	meta-analysis	involving	fourteen	randomised	controlled	trials	totalling	778	patients,	 Favaretto	 and	 colleagues	 (154)	 were	 able	 to	 conclude	postconditioning	 to	 be	 cardioprotective	 in	 terms	 of	 infarct	 size	reduction,	 however	 significant	 differences	 existed	 between	 these	trials	but	univariate	meta-regression	analysis	did	not	identify	clinical	or	 procedural	 variables	 to	 be	 associated	 with	 a	 more	 pronounced	effect	 of	 postconditioning	 effects	 on	 the	 infarct	 size	 with	 the	exception	of	cardiac	magnetic	resonance.		Further	analysis	of	6	RCTs	that	used	CMR	to	evaluate	 the	effects	of	postconditioning	on	 infarct	size	led	to	the	conclusion	that	postconditioning	had	a	limited	benefit	on	 infarct	 size	 suggesting	 that	 further	 data	 was	 necessary	 before	postconditioning	could	be	rolled	out	into	clinical	practice.	
	
So	 far,	 I	 have	discussed	benefits	of	preconditioning	 in	 experimental	models	 of	 infarction	or	have	used	pre	 infarct	 angina	 as	 a	 surrogate	marker	of	 ischaemia	preconditioning	 in	 those	 suffering	 from	an	MI.		Similarly	 discussions	 have	 taken	 place	 regarding	 postconditioning.		Both	advantages	and	disadvantages	have	been	eluded	upon	however	
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Remote	 ischaemic	 preconditioning	 (RIC)	 describes	 an	 intriguing	phenomenon	where	 reversible	 episode	 of	 sub-lethal	 ischaemia	 and	reperfusion	 applied	 in	 one	 vascular	 bed,	 tissue	 or	 organ	 confers	global	 protection,	 rendering	 remote	 tissues	 and	 organs	 resistant	 to	the	detrimental	aftermath	of	lethal	reperfusion	injury	(79).	
	
Initial	discovery	
It	was	Przyklenk	and	co-authors	that	 first	described	this	 fascinating	phenomenon	 in	 1993	 in	 their	 seminal	 paper	 “regional	 ischaemic	
preconditioning	 protects	 remote	 virgin	myocardium	 from	 subsequent	
sustained	 coronary	 occlusion”	 (79).	 	 In	 their	 groundbreaking	experiment,	 anaesthetised	 dogs	 underwent	 four	 episodes	 of	 5-minutes	circumflex	coronary	artery	occlusion	followed	by	5-minutes	reperfusion,	 followed	 by	 1	 hour	 of	 sustained	 LAD	 coronary	 artery	occlusion	 before	 4.5	 hours	 reperfusion.	 	 	 Infarct	 sizes	 of	 the	circumflex	preconditioned	group	of	dogs	were	significantly	less	than	
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that	 seen	 in	 the	 control	 group	 introducing	 the	 concept	 that	 virgin	myocardium	could	be	protected	from	subsequent	coronary	occlusion	by	brief	cycles	of	sublethal	ischaemia-reperfusion	injury	(79).		It	was	also	 noted	 by	 the	 investigators	 that	 segmental	 shortening	 in	 the	myocardium	subtended	by	the	LAD	in	the	circumflex	preconditioned	dogs	were	preserved	compared	to	control	despite	having	comparable	subendocardial	blood	flow	(79).		In	addition	to	the	initial	conclusion,	authors	 also	 suggested	 that	 RIC	 is	 mediated	 by	 factors	 that	 are	produced,	 activated	 and	 transferred	 within	 the	 heart	 following	ischaemic	 preconditioning	 to	 protect	 a	 virgin	 myocardium	 from	subsequent	sustained	ischaemia	(79).		
	
Widening	the	concept	of	RIC	
Following	 the	 initial	 discovery	 of	 RIC,	multiple	 in	 vitro	 and	 in	 vivo	experimental	models	have	since	demonstrated	 the	existence	of	 this.		Using	an	isolated	perfused	heart	model,	Dickson	et	al	(155)	collected	and	 transferred	 coronary	 effluent	 from	 2	 groups	 of	 ‘donor’	 rabbit	hearts	 (one	 group	 underwent	 a	 standard	 preconditioning	 protocol)	and	perfused	2	groups	of	 	 ‘acceptor’	rabbit	hearts	that	subsequently	underwent	40	minutes	of	global	 ischaemia.	 	The	authors	noted	 that	
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the	 preconditioned	 donor	 hearts	 and	 acceptor	 hearts	 receiving	 the	coronary	 effluent	 from	 the	 preconditioned	 donor	 hearts	 were	 all	protected	 from	 the	 detrimental	 effects	 of	 global	 ischaemia	with	 no	difference	 in	 the	 magnitude	 of	 infarct	 size	 observed	 between	 the	preconditioned	hearts	and	the	acceptor	hearts	receiving	the	effluent	(155).		Following	these	earlier	observations,	further	evolution	of	the	model	has	taken	place	and	similar	results	have	been	observed	when	the	serum	from	preconditioned	animals	have	been	applied	to	isolated	hearts	 or	 cultured	 cells	 (156-158)	 thus	 providing	 evidence	 for	 the	existence	 of	 cross-species	 protection	 RIC	 including	 treatment	 of	isolated	buffer-perfused	hearts	of	 rabbits	using	human	serum	(156,	158).	 	From	models	of	intra-organ	or	intra-myocardium	RIC,	further	experimental	 studies	 have	 now	 led	 to	 the	 discovery	 that	cardioprotection	 can	 also	 be	 achieved	when	 the	 remote	 stimulus	 is	applied	to	a	tissue	bed	or	organ	remote	from	the	heart;	Preliminary	evidence	stems	from	the	laboratory	curiosity	by	Gho	et	al	(159)	who	hypothesised	that	ischaemia	in	remote	organs	may	protect	against	an	MI.	 	They	were	subsequently	able	to	demonstrate	the	attenuation	of	MI	 size	 when	 the	 mesenteric	 artery	 or	 renal	 artery	 was	 briefly	occluded	prior	 to	 inducing	 an	MI	 by	60	minutes	 of	 coronary	 artery	occlusion	(159).		They	were	also	able	to	conclude	that	RIC	recruits	a	
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neurogenic	pathway,	as	hexamethomuin	(a	potent	ganglion	blocker)	blocks	the	protection	afforded	by	inter-organ	RIC	but	not	with	intra-organ	RIC	(159).	 	Further	experimental	work	have	since	taken	place	to	 provide	 evidence	 for	 the	 existence	 of	 RIC	 induced	 myocardial	protection	when	the	RIC	stimulus	is	applied	remotely	from	the	heart	including	 skeletal	 muscle,	 intestines	 and	 kidneys	 –	 a	 concept	 now	known	as	 inter-organ	RIC.	 	We	now	know	 that	RIC	exists	 in	organs	other	than	the	heart	to	include	the	liver,	kidney,	intestine,	brain	and	other	tissues;	this	is	summarised	in	our	recent	review	(160).				
While	these	discoveries	are	innovative,	their	translation	from	bench	to	 practice	 has	 been	 limited	 by	 its	 invasive	 nature;	 the	 intriguing	break	through	came	from	the	discovery	that	transient	limb	ischaemia	could	 also	 exert	 similar	 cardioprotection	 to	 that	 seen	 with	 remote	ischaemic	 preconditioning.	 	 	 A	 group	 led	 by	 Kloner	 in	 1997	 (161)	examined	 the	 hypothesis	 that	 the	 heart	 can	 be	 preconditioned	 at	 a	distance	by	partial	 reduction	of	blood	 flow	to	 the	hind	 limb	with	or	without	 increase	 of	 demand	 by	 electrical	 stimulation	 of	 a	 skeletal	muscle.	 	 In	 their	 seminal	 discovery,	 anaesthetised	 rabbits	 were	randomised	to	a	 time-matched	control	(30	minutes	waiting	period),	55-65%	 reduction	 of	 femoral	 arterial	 blood	 flow,	 electrical	stimulation	of	the	gastrocnemius	muscle	at	1	Hz	or	a	combination	of	
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the	latter	two.		They	were	then	subjected	to	30-minutes	of	coronary	artery	 occlusion	 followed	 by	 4	 hours	 reperfusion.	 	 They	 found	 that	the	ratio	of	 infarct	size	to	risk	zone	was	smaller	 in	the	group	where	gastrocnemius	stimulation	was	combined	with	a	reduction	of	femoral	artery	blood	flow	(161).		Oxman	and	colleagues	(162)	pioneered	this	concept	 further	 and	 subsequently	 were	 the	 first	 group	 to	demonstrate	 a	 reduction	 of	 reperfusion	 related	 arrhythmia	 in	 an	isolated	 rat	 heart	 model	 through	 application	 of	 a	 non-invasive	remote	 preconditioning	 stimulus	 (10	 minutes	 hind	 limb	 ischaemia	using	a	simple	tourniquet).		While	many	studies	use	infarct	size	as	an	end	point,	 this	particular	study	examined	the	effect	on	arrhythmias,	(as	 one	 of	 the	 cardioprotective	 properties	 of	 preconditioning	 is	 the	anti-arrhythmic	property	of	this	prodigy).		A	further	notable	example	is	perhaps	a	porcine	model	of	inter-organ	RIC	where	brief	periods	of	hind-limb	ischaemia	using	a	simple	tourniquet	reduced	MI	size;	this	opened	 doors	 to	 subsequent	 phase	 II	 trials	 in	 humans	 to	 test	 the	efficacy	 of	 cardioprotection	 by	 applying	 RIC	 to	 a	 limb.	 	 In	 an	important	study	by	Kharbanda	et	al,	15-kg	pigs	were	subjected	to	40	minutes	LAD	balloon	occlusion	preceded	by	 four	5-minutes	cycle	of	lower	 limb	 ischaemia	 that	 resulted	 in	 an	 astonishing	 reduction	 of	infarct	size	from	53%	to	26%	(163).		In	a	parallel	study	conducted	in	
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humans	 conducted	 by	 the	 same	 group,	 preconditioning	 the	 upper	limb	by	three	5-minutes	of	 ischaemia	 interspersed	with	reperfusion	using	 a	 blood	 pressure	 cuff	 inflated	 to	 200	 mm	 Hg	 reduced	 the	endothelial	 injury	 induced	by	 sustained	20	minutes	 of	 ischaemia	 in	the	 contralateral	 limb	 –	 this	 was	 demonstrated	 using	 venous	plethysmography	to	demonstrate	forearm	blood	flow	in	response	to	acetylcholine.	
While	many	of	these	experiments	were	confirmatory	studies	for	the	existence	of	RIC,	 they	too	also	explored	the	mechanism	recruited	to	allow	such	phenomenon	to	exist;	furthermore	the	possibility	of	being	able	 to	 apply	 such	 stimulus	 remotely	 and	non-invasively	has	paved	way	to	explore	RIC	in	humans	in	various	clinical	settings.	
	
1.7.1	Application	of	RIC	in	the	clinical	setting:	CABG	
With	 the	 ability	 to	 apply	 RIC	 non–invasively,	 application	 during	elective	 CABG/PCI	 procedures	 or	 during	 an	 acute	 myocardial	infarction	 has	 become	 promising.	 	 At	 present,	 with	 the	 ageing	population,	 cardiac	 surgery	 is	 increasingly	 being	 carried	 out	 in	 this	age	 group	 who	 are	 naturally	 at	 higher	 risk	 amongst	 the	 general	population	who	now	have	increased	comorbidities.	 	Previously	such	
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patients	 would	 be	 declined	 surgery,	 however,	 with	 combined	progression	 of	 anaesthetics,	 perioperative	 techniques	 and	 surgical	procedures,	 operating	 on	 such	 patients	 has	 now	 become	 feasible.		Despite	these	advances,	 there	still	remain	adverse	outcomes	related	to	periprocedural	myocardial	injury	(such	as	reduced	left	ventricular	ejection	 fraction)	 therefore	 further	 protective	 measures	 are	necessary.	 	 In	 this	 regard,	 RIC	 has	 been	 applied	 to	 such	 settings.		Many	 of	 these	 studies	 have	 developed	 the	 concepts	 introduced	 by	Kloner	(hind	limb	ischaemia)	and	MacAllister	(forearm	ischaemia)	to	apply	 this	 to	 clinical	 studies	 and	 use	 biomarkers	 as	 an	 endpoint	 in	cardiac	surgery.		Many	of	these	studies	have	shown	cardioprotective	potential	 with	 similar	 findings	 in	 patients	 undergoing	 elective	 PCI.		Although	 widely	 explored,	 discrepant	 results	 have	 been	 noted	amongst	these	studies	using	RIC	and	as	a	result	some	of	these	studies	have	 been	 reported	 as	 being	 negative	 (164).	 	 This	 can	 partly	 be	explained	 by	 the	 presence	 of	 type	 II	 errors	 including	 concomitant	therapy	with	beta-blockers	or	statins	which	have	been	shown	to	be	cardioprotective	 as	 well	 as	 anaesthetic	 regimes	 using	 propofol	 or	volatile	anaesthesia	that	can	potentially	interfere	with	RIC	(164).	
In	 recent	 larger	 clinical	 studies,	 besides	 surrogate	 markers	 of	cardioprotection,	 investigators	 have	 looked	 into	 long-term	 clinical	
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outcomes	 and	 have	 deduced	 a	 reduction	 in	 major	 adverse	cardiovascular	 outcomes	 in	 both	 elective	 CABG	 surgery	 (165)	 and	PCI	 (166).	 	More	 recently,	 in	 the	 first	 outcome	 study	 of	 its	 kind	 an	improvement	in	patients	undergoing	elective	on-pump	CABG	with	or	without	valve	surgery	was	not	observed.	 	This	may	be	partly	due	to	being	 underpowered,	 missing	 data	 and	 the	 presence	 of	 propofol	(cardioprotective	agent)(167).	
	
1.7.2	Application	of	RIC	in	the	clinical	setting:	AMI	
Similar	to	elective	procedures	noted	above,	advances	in	treatment	of	MIs	have	 led	to	a	substantial	 improvement	 in	30-day	morbidity	and	mortality	despite	ischaemic	heart	disease	maintaining	its	position	as	the	 global	 leading	 cause	 of	 death.	 	 Although	 RIC	 has	 been	 applied	prophylactically	 in	 experimental	 models,	 this	 is	 not	 a	 requisite	 for	cardioprotection;	reduction	in	 infarct	size	have	been	reported	when	the	 remote	 stimulus	 has	 applied	 during	 the	 index	 event	 (remote	ischaemic	 perconditioning)	 and	 at	 the	 time	 of	 reperfusion	 (remote	ischaemic	postconditioning).		Konstantiov		(168)	provided	the	earlier	practical	evidence	of	the	infarct	sparing	effects	in	a	swine	model	thus	providing	 the	 rationale	 for	 the	 landmark	 clinical	 trial	 of	 acute	 MIs	
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where	limb	ischaemia	was	applied	to	the	infarcting	patients	on	route	to	hospital	(169).		Clinical	evaluation	of	infarct	size	can	be	estimated	indirectly	 using	 biomarkers	 released	 from	 tissue	 and	 from	 the	resolution	 of	 ST-segment	 on	 surface	 ECG.	 	 A	more	 direct	 approach	entails	 using	 myocardial	 perfusion	 imaging	 or	 cardiac	 magnetic	resonance	 imaging	 from	 which	 the	 salvage	 index	 (proportion	 of	salvaged	 area	 at	 risk)	 can	 be	 calculated.	 	 Using	 this	 principle,	 the	important	 study	 led	by	Botker	 (169)	were	 able	 to	demonstrate	RIC	applied	 before	 hospital	 admission	 increased	myocardial	 salvage	 by	36%,	 thereby	 reducing	 final	 infarct	 size	 in	 patients	 during	 an	evolving	 MI.	 	 Furthermore,	 those	 with	 LAD	 occlusion	 as	 seen	 in	anterior	MIs	and	those	with	complete	occlusion	of	the	infarct	related	artery	 had	 an	 infarct	 size	 reduced	 to	 44%	 and	 31%	 respectively	compared	 to	 PCI	 alone.	 	 This	 translated	 to	 an	 improvement	 of	 left	ventricular	 systolic	 function	 and	 when	 followed	 up,	 these	 patients	were	 found	 to	 have	 a	 reduction	 in	MACE	 at	 4-years	 after	 the	 index	event.	 	 	 	A	 similar	 study	by	Rentoukas	et	 al	has	also	 shown	 full	 ST-segment	resolution	coupled	with	a	significant	reduction	 in	 troponin	release	 when	 RIC	 employed	 during	 a	 PPCI	 (170).	 	 Of	 the	aforementioned	 studies,	 whilst	 precedence	 has	 been	 given	 to	 the	application	 of	 non-invasive	 application	 of	 RIC	 in	 various	 clinical	
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Signal	 transduction	 from	 the	 remote	 tissue	 or	 organ	 is	 thought	 to	involve	 the	 nervous	 system	 (consisting	 of	 somatosensory	 system,	spinal	 cord	 and	 autonomic	 nervous	 system)	 that	 is	 initiated	 by	 not	only	by	local	ischaemia/reperfusion	injury	in	an	organ	other	than	the	heart	 (limb,	 mesentery),	 but	 also	 due	 local	 nerve	 injury	 or	stimulation	 by	 capsaicin	 (171,	 176,	 177),	 adenosine	 (178),	 and	bradykinin	 (173,	 179)	 to	 produce	 cardioprotection	 whilst	 RIC	 has	been	 abrogated	 in	 the	presence	 of	 sensory	nerve	blockers	 (176)	 or	local	anaesthetic	(171).	 	Interestingly,	femoral	nerve	transection	did	not	 eliminate	 limb	 RIC	 in	 a	 mice	 model	 (180).	 	 The	 nociceptive	stimulus	 is	 thought	 to	 involve	 protein	 kinase	 Cy	 (173)	 and	 is	inhibited	by	donors	of	nitric	oxide	in	rat	models	of	RIC	(178).	
It	 has	 become	 evident	 that	 RIC	 involves	 activation	 of	 peripheral	nerves	 but	 the	 way	 in	 which	 this	 signal	 is	 transferred	 to	 heart	remains	 equivocal	 (164).	 	 There	 is	 a	 suggestion	 that	 a	 neuronally	released	 signalling	 molecule	 is	 transferred	 to	 the	 heart	 humorally	(164).	 	This	 is	evident	 from	models	where	coronary	effluent	 from	a	donor-preconditioned	 heart	 has	 protected	 naïve	 hearts	 from	ischaemia	(155)	and	similarly	from	porcine	transplant	models	where	the	 preconditioned	 recipient	 receiving	 the	 denervated	 donor	 heart	
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	Stromal	 cell-derived	 factor-1α	 (SDF-1α)	 has	 recently	 become	 the	focus	 of	 intense	 interest	 and	 discussion	with	 regards	 to	 ischaemia-reperfusion	injury	with	growing	body	of	evidence	to	support	this.		It	is	 thought	 to	 acutely	 protect	 the	myocardium	 from	 the	 deleterious	effects	 of	 ischaemia	 reperfusion	 injury	 through	 activating	 cell	survival	 signalling	 pathways	 whilst	 simultaneously	 recruiting	 stem	cells	to	the	injured	site	to	reduce	myocardial	injury	and	dysfunction	(182).	 	Additionally	SDF-1α	has	been	shown	to	play	a	pivotal	role	in	stem	 cell	 proliferation,	 retention,	 survival,	 cardiomyocytes	 repair,	neoangiogenesis	 and	 ventricular	 remodelling	 following	 myocardial	infarction	 (183-186).	 	 This	 occurs	 through	 interaction	 with	 its	cognate	receptor	CXCR4,	which	is	a	G-protein	coupled	receptor;	this	SDF-1α	 –	 CXCR4	 axis	 is	 upregulated	 in	 experimental	 and	 clinical	models	 of	 MI	 leading	 to	 reduction	 of	 ischaemia	 burden	 and	preservation	 of	 ventricular	 function.	 	 Interestingly	 SDF-1α	 –	 CXCR4	axis	 exert	 these	 effects	 via	 the	 same	 Gαi	 dependent	 mechanisms	responsible	 for	 conferring	 protection	 against	 ischaemia-reperfusion	injury	 seen	 in	 other	 form	 of	 conditioning	 including	 pre,	 post	 and	remote	 ischaemic	 conditioning	 and	 involves	 activation	 of	phosphoinositide	 3	 kinase	 (PI3K),	mitogen	 activated	protein	 kinase	
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(MAPK),	 and	 Janus	 kinase	 (JAK)-signal	 transducer	 and	 activator	 of	transcription	(STAT)	signalling.		
It	 is	 therefore	 proposed	 in	 my	 thesis,	 that	 in	 addition	 to	 the	pleiotropic	effects	of	SDF-1α	mentioned	above,	it	has	a	direct	role	in	protecting	 the	 human	 myocardium.	 Evidence	 for	 this	 is	 discussed	below.	
	
1.8.1	Chemokines	and	their	structure	
Chemokines	or	chemoattractant	cytokines	such	as	SDF-1α	are	a	large	group	 of	 secreted	 proteins	 with	 a	 molecular	 weight	 between	 8-14	kDa	 that	 share	 a	 structural	 homology	 in	 up	 to	 90%	 of	 cases	 (187,	188).	 	 There	may	be	 as	many	as	40-50	human	 cytokines	 (189)	 and	their	 classification	 into	 4	 subfamilies	 is	 based	 upon	 the	 relative	position	 of	 the	 two	 N-terminal	 cysteine	 (amino	 acid)	 residues	 that	are	 bonded	 to	 two	 other	 cysteine	 residues	 via	 disulphide	 bonding	(190).	






Chemokines	 in	 general	 contain	 four	 cysteine	 residues	 in	 highly	conserved	 positions	 (191).	 	 SDF-1α	 (also	 recognised	 as	 CXCL12)	consists	of	89	amino	acids	and	belongs	to	the	CXC	chemokine	family	where	the	two	N-terminal	cysteine	residues	are	separated	by	a	single	amino	 acid.	 	 Unlike	 other	 chemokines	 of	 the	 CXC	 sub-family	which	
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are	clustered,	SDF-1,	coded	by	the	CXL	gene,	is	uniquely	localised	on	chromosome	10	(192)	and	is	expressed	in	many	cell	types	including	the	 heart,	 bone	marrow,	 liver,	 kidney,	 thymus,	 skeletal	muscle	 and	brain	 (193-195).	 	 The	 gene	 encoding	 SDF-1α	was	 first	 cloned	 from	mouse	 bone	 marrow	 stromal	 cells,	 hence	 the	 name	 ‘stromal	 cell	derived	 factor	 –	 1	 α’	 (33,	 196).	 	 Furthermore,	 the	 CXC	 chemokines	may	be	subdivided	into	either	ELR+	or	ELR-	based	upon	the	presence	of	 the	 sequence	 of	 a	 particular	 amino	 acid	 (glutamic	 acid-leucine-arginine);	SDF1/CXCL12	 is	an	example	of	 the	 former	and	 is	capable	of	 recruiting	monocytes	 and	 lymphocytes	 (186).	 	 In	 addition	 to	 cell	homing,	chemokines	contribute	an	important	role	in	apoptosis,	gene	transcription,	mitogenesis	and	degranulation	(189).	 	They	have	also	been	implicated	in	multiple	disease	processes	including	cancers	(197,	198),	 infection	 with	 HIV	 (199)	 and	 multiple	 inflammatory	 states	(200,	 201).	 	 Deficiency	 of	 SDF-1α	 or	 CXCR4	 receptor	 in	 mice	experimental	models	 has	 been	 shown	 to	 cause	 embryonic	 lethality	due	 to	 serious	 structural	 defects	 including	 anomalies	 in	gastrointestinal	blood	vessel	formation	and	ventricular	septal	defects	(193,	 202,	 203).	 	 Additionally,	 production	 of	 blood	 cells	within	 the	bone	 marrow	 (haematopoiesis)	 have	 been	 shown	 to	 become	compromised	 with	 decreased	 bone	 marrow	 colonisation	 of	
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haemopoeitic	 stem	 cells,	 development	 deficiencies	 of	 B	 cells	 and	decreased	myelopoeisis	(185).			
Various	isoforms	of	SDF-1	exist	in	humans	(and	mice)	including	SDF-1α	(89	amino	acids/3	exons)	and	SDF-1β	(93	amino	acids/4	exons)	that	 are	 encoded	 by	 the	 same	 gene	 on	 chromosome	 10	 but	 are	produced	 by	 alternative	 splicing	 (204).	 	 Other	 spliced	 variants	 of	SDF-1	exist	 in	humans	including	SDF-1ζ,	SDF-1δ,	SDF-1ε	(205,	206),	however	the	functional	diversity	of	these	SDF-1	variants	are	yet	to	be	fully	understood.		
SDF-1α	 is	 cleaved	 by	 several	 exopeptidases,	 such	 as,	 dipeptidyl	peptidase-4	(DPP4),	matrix	metalloproteinase	(MMP)-2,	and	9	(206).	Proteolysis	of	SDF-1	by	DPP4	takes	place	at	position	2-3	whereas	that	by	 MMP	 occurs	 at	 position	 4-5;	 this	 leads	 to	 the	 release	 of	 the	 N-terminal	 tetrapeptide,	culminating	 in	the	 loss	of	binding	of	SDF-1	at	its	 binding	 site	 on	 the	 CXCR4	 receptor	 and	 inactivation	 of	 the	molecule	 (207).	 	 Although	 several	 exopeptidases	 exist,	 DPP4	 is	thought	 to	 prevail	 in	 this	 manner	 (208).	 	 Interestingly,	 when	compared	to	SDF-1α,	the	other	isoforms	of	SDF-1	are	more	resistant	to	the	proteolytic	degradation	(209).	
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SDF-1α	 exerts	 its	 action	 through	 interaction	 with	 specific	 CXCR4	chemokine	 receptors	 found	 on	 cell	 surfaces	 of	 specific	 cell	 types	including	 cardiomyocytes,	 vascular	 and	 haematopoietic	 progenitor	
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The	binding	of	SDF-1	to	CXCR4	results	in	G-protein	coupled	receptor	activation	 through	homo-	or	hetero-	dimerization	(213).	 	This	 leads	to	 Gai	 protein	 pathway	 activation	 culminating	 in	 the	 regulation	 of	several	signalling	cascades	including	and	not	limited	to	the	activation	
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Binding	of	SDF-1	to	GPCR	CXR4	induces	a	variety	signalling	pathways	in	different	cell	 types;	 in	cardiomyocytes,	the	activation	of	PI3K	and	AKT	pathways	lead	to	enhanced	cell	survival	whilst	in	bone	marrow	stem/progenitor	 cells,	 activation	 of	 the	 various	 pathways	 result	 in	the	 activation	 and	 release	 of	 BM	 stem/progenitor	 cells	 into	 the	peripheral	 blood	 and	 homing	 to	 sites	 of	 tissue	 injury	 where	 they	participate	in	tissue	repair	and	neoangiogenesis	(186).	
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It	 has	 now	 been	 proposed	 that	 activation	 of	 the	 second	 SDF-1	receptor	may	also	regulate	MAPK,	PI3K,	Jak-STAT	cascades	leading	to	the	homing	of	progenitor	cells	at	injured	sites	(216).	
	
CXCR7	receptor		
The	 initial	 belief	was	 that	 SDF-1	was	 an	 exclusive	 ligand	 for	 the	G-protein	 coupled	 receptor,	 CXCR4,	 highlighting	 its	 unique	 biological	role.	However,	 further	studies	have	demonstrated	the	 interaction	of	this	 chemokine	with	 another	 receptor,	 CXCR7/RDC1	 (217),	making	the	biological	role	of	SDF-1	more	complex	and	difficult	to	understand		in	stem	cell	homing	as	seen	when	SDF-1	interacts	with	CXCR4	(218,	219).			
It	has	now	been	shown	 that	CXCR7	receptors	are	present	 in	a	wide	variety	of	cell	 types	 including	activated	endothelial	cells,	 foetal	 liver	cells,	 T	 cells,	 B	 cells	 and	 renal	multi-potent	 progenitors	 (217,	 220).		However	 the	 function	 of	 this	 receptor	 remains	 unclear	 and	controversial	in	that	some	authors	suggest	that	it	is	a	non-functioning	decoy	 receptor	 and	 is	 unable	 to	 activate	 intracellular	 signalling	cascades	whereas	others	suggest	 that	 it	 is	a	 true	signalling	receptor	with	 the	 capacity	 to	 activate	 certain	 pathways	 involving	 mitogen-
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We	 now	 know	 that	 several	 chemokines	 become	 upregulated	 in	experimental	models	of	myocardial	 infarction	 (225).	 	These	 include	both	CXC	 	 (interleukin-8	 (226-229),	 growth	 related	oncogene	alpha	(227)	 +	 IP-10)	 and	 CC	 (CCL2	 (230,	 231)	 and	 macrophage	inflammatory	 protein-1	 α/β	 (232))	 subtypes	 of	 the	 chemokine	family.	 	 In	particular	experimental	models	where	SDF-1	was	 shown	to	be	upregulated	include	studies	by	Ma	J	(233),	Abbott	JD	(234)	and	Pillarisetti	K	(235).			To	demonstrate	these	two	experimental	models	of	MI	are	employed,	namely	the	ischaemia-reperfusion	injury	model	and	 the	 permanent	 myocardial	 infarction	 model	 (236,	 237).	 	 Key	differences	are	summarised	in	table	3	below:	
Ischaemia-reperfusion	model	 Permanent	MI	model	Large	 release	 of	 reactive-oxygen	species	 resulting	 in	 reperfusion	injury	 Smaller	 release	 of	 reactive-oxygen	species	Larger	inflammatory	response	 Smaller	inflammatory	response	Accelerated	 collagen	 deposition	resulting	 in	 improved	 tissue	healing	 (determined	 by	inflammatory	response)	





Furthermore,	 in	 keeping	 with	 experimental	 models	 of	 MI,	chemokines	 including	 SDF-1	 have	 been	 shown	 to	 be	 elevated	 in	serum	in	patients	with	MI	(238).	 	This	highlights	 the	significance	of	chemokines	in	the	pathophysiology	of	myocardial	infarction.			
	
Upregulation	of	chemokines	in	the	infarcted	heart	




Figure	 1.8	 demonstrates	 the	 potential	 SDF-1α/CXCR4	 receptor	
interaction	 and	 potential	 role	 in	 myocardial	 ischaemia.		Myocardial	 ischaemia	 leads	 to	 the	 upregulation	 and	 release	 of	 the	hypoxia	 signal,	 hypoxia	 inducible	 factor	 1-alpha	 (HIF	 1-α),	 which	then	 upregulates	 and	 release	 stem	 cell	 mobilising	 signals	 such	 as	SDF-1	 α	 and	 vascular	 endothelial	 growth	 factor	 (VEGF).	 	 These	signals	 reach	 the	 bone	 marrow	 resulting	 in	 the	 proliferation	 and	increased	expression	of	CXCR4	receptors	of	stem/progenitor	cells	(as	well	as	degradation	of	SDF).	 	This	creates	a	change	 in	bone	marrow	SDF	gradient	leading	to	the	release	of	the	stem/progenitor	cells	into	the	peripheral	blood	and	towards	the	 local	SDF	gradient	originating	in	the	myocardium.		By	homing	into	the	damaged	myocardium,	they	modulate	myocardial	repair	and	angiogenesis.				
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1.8.4	 SDF-1/CXCR4:	 Therapeutic	 application	 in	 experimental	
models	













Effects	Rat	(241)	 SDF-1	 over-expressed	fibroblasts	+	G-CSF	 CD	117/34+	Endothelial	cells	 Improved	 LV	function,	 improved	wall	 thickness	 and	mass	Mouse	(234)	 SDF-1α	 over-expression	(adenovirus)	 Lin-/GFP+	BM	cells	 Increased	 stem	 cell	homing	Rat	(242)	 Non	 viral	 SDF-1α	transfection	 in	 skeletal	myoblast	 CD	117/34/31+	 Increased	 vessel	density,	 improved	LV	EF/FS,	 increased	posterior	 wall/septal	thickness	Mouse	(243)	 SDF-1α	 infused	 into	 left	ventricular	cavity	 	 Reduced	infarct	size	Mouse	(244)	 Local	 delivery	 of	 SDF-1α	into	 ischaemic	myocardium	 GFP+,	vWF+	 Reduced	 infarct	 area,	improved	 LVFS	 and	vessel	density	Rat	(245)	 Intra-myocardial	 delivery	of	 protease	 resistant	 S-SDF-1	(S4V)	 CXCR4+	 c-Kit+	 Improved	 capillary	density/LVEF	Rat	(246)	 MSCs	 overexpressing	 SDF-1	 GFP+,	 α-actin	 SM	cells,	connexion	45+	cells	
Improved	 cell	survival,	LVFS	and	LV	dimensions.	 Reduced	apoptosis		Mouse	(247)	 Intramyocardial	 injection	of	SDF-1α	 	 Reduced	 scar	 tissue,	improved	 LVEF	 and	neoangenesis.	Cardioprotection	(AKT)	Rat	(248)	 Intramyocardial	 delivery	of	SDF-1α/EPCs/cSA	 CD31+	BrdU+	 Improved	LV/coronary	 flow,	neovascularisation.	Reduced	inflammation.	Rat	(249,	250)	 Adenoviral	 mediated	overexpression	 of	 SDF-1α	(AdV-SDF-1)	 c-Kit+	 Increased	angiogenesis/anti-fibrosis/LVEF	Mouse	(251)	 Genetic/pharmacological	inhibition	 of	 SDF-1	breakdown		+	G-CSF	 CD45/CD34/CXCR4+,	 c-Kit+,	Sca-1+	 Improved	 cardiac	remodelling/neovascularisation	
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Mouse	(252)	 Intramyocardial	 delivery	of	 lentiviral	 engineered	MSCc	 overexpressing	 SDF-1	α	
GFP+,	 BM	cells,	CXCR4+,	 c-Kit+,	CD31+	
Improved	 LVEF,	vascular	 density	 and	reduced	apoptosis		
Table	1.4.		Summary	of	experiments	that	have	demonstrated	the	
role	 of	 SDF	 in	 directing	 bone	 marrow	 stem	 cells	 to	 infarcted	
myocardium.	
	
Furthermore,	 the	 same	 axis	 has	 been	 modified	 in	 experimental	studies	to	further	elucidate	its	role	in	MI.	This	can	be	illustrated	by		
	
• Delivering	 SDF-1α	 at	 the	 site	 of	 infarction	whilst	 simultaneously	inhibiting	cleavage	of	SDF-1α	
• Upregulating	 CXCR4	 receptors	 in	 cardiomyocytes	 and	 cardiac	stem	cells	
• Mobilising	 CXCR4+	 cells	 into	 peripheral	 circulation	 from	 bone	marrow	
• Upregulating	CXCR4	in	bone	marrow	stem	cells		
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In	 a	 rabbit	 model	 of	 ischaemia-reperfusion	 by	 Misao	 et	 al	 (253),	granulocyte-colony	 stimulating	 factor	 (G-CSF)	 administered	following	an	MI	was	associated	with	an	increase	in	SDF-1α	level	thus	directing	 stem	 cells	 towards	 infarcted	 tissue;	 this	 led	 to	 a	 more	favourable	left	ventricular	ejection	fraction,	end	diastolic	dimensions	and	 scar	 burden.	 This	 benefit	 was	 ameliorated	 in	 the	 presence	 of	CXCR4	receptor	blocker	(AMD100)	implying	that	the	SDF-1	α/CXCR4	receptor	 interaction	was	 central	 in	mediating	G-CSF	mediated	 stem	cell	recruitment	to	the	site	of	tissue	infarction.		Hu	et	al	(243)	on	the	other	hand	utilised	in	vitro	and	in	vivo	models	of	IRI	to	demonstrate	the	 same	 axis;	when	pre-treated	with	 SDF-1α,	 the	 degree	 of	 infarct	size	 and	 apoptosis	 was	 reduced	 whilst	 there	 was	 an	 increased	resistance	 to	hypoxic	cell	 injury	via	activation	of	ERK	1/2	and	AKT.		Saxenas	 group	 had	 demonstrated	 the	 preservation	 of	 cardiac	function	 in	 a	 mice	 model	 of	 infarction	 when	 SDF-1α	 was	administered	 into	several	peri-infarct	zones.	 	They	 too	were	able	 to	observe	 increased	 phosphorylation	 of	 AKT	 together	 with	upregulation	 VEGF	 in	 response	 to	 SDF-1α	 thereby	 providing	potential	mechanisms	for	the	observed	effects	(247).		Several	authors	have	also	demonstrated	increased	mobilisation	of	c-kit+	cells	during	adenoviral	delivery	of	SDF-1α	resulting	in	increased	cardiac	function	
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thought	 to	 be	 through	 the	 angiogenic	 and	 anti-fibrotic	 property	 of	SDF	(249,	250).			
All	these	studies	suggest	SDF-1α	mediated	cardioprotection	is	due	to	the	activation	of	downstream	cell	survival	pathways	and	induction	of	neovascularisation	 rather	 than	 myocardial	 regeneration	 for	 which	evidence	remains	incomplete	(186).	 	One	limitation	of	using	SDF-1α	is	 the	 proteolytic	 degradation	by	 exopeptidases	 thereby	 limiting	 its	full	therapeutic	potential	in	myocardial	ischaemia.		To	overcome	this,	researchers	 have	 bioengineered	 SDF-1α	 (S-SDF-1/SDV)	 to	 create	 a	protein	 that	 retains	 its	 chemoattractant	 property	 whilst	 being	resistant	 to	 proteolysis.	 	 Segers	 et	 al	 (245)	were	 able	 to	 show	 that	when	 this	 bioengineered	 version	 is	 injected	 into	 infarcted	 tissue,	stem	 cells	 are	 recruited	 resulting	 in	 improved	 myocardial	contractility.	 	Using	a	similar	concept,	Zaruba	and	co-workers	(251)	used	 a	 ‘novel	 therapeutic	 concept’	 of	 pharmacological	 and	 genetic	inhibition	of	exopeptidases	such	as	DPPIV	in	conjunction	with	G-CSF	to	recruit	stem	cells	to	infarcted	myocardium	in	mice	to	demonstrate	preservation	 of	 cardiac	 function	 through	 reduced	 cardiac	remodelling	and	increased	angiogenesis.	
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Many	 experimental	 studies	 have	 demonstrated	 chemokines,	 with	SDF-1α	 in	 particular,	 being	 an	 important	 regulator	 in	 MI.	 I	 will	therefore	 evaluate	 the	 effect	 of	 this	 chemokine	 in	 a	 human	 atrial	trabecular	model.	
	
1.9	Stretch	Preconditioning	
The	 notion	 that	 the	 heart	 becomes	 dilated	 (stretched)	 during	simulated	ischaemia	led	authors	to	theorise	that	the	beneficial	effects	of	 ischaemic	 preconditioning	 may	 be	 reproduced	 by	 mechanically	stretching	 the	 heart	 (a	 term	 often	 referred	 to	 as	 ‘stretch	preconditioning’)	 possibly	 through	 activation	 of	 mechanosensitive	ion	channels.		Ovize	and	co-workers	were	probably	one	of	the	earlier	investigators	 to	 demonstrate	 this.	 	 In	 their	 experimental	 model,	stretch	 preconditioning	 was	 achieved	 in	 canine	 hearts	 by	 rapidly	volume	 overloading	 the	 hearts	 prior	 to	 a	 period	 of	 simulated	ischaemia.	 	 When	 compared	 to	 control	 hearts,	 the	 stretched	 heart	significantly	 attenuated	 infarct	 size.	 	 This	 protection	was	 abolished	when	 Gd3+,	 an	 inhibitor	 of	 stretch	 activated	 channel,	 was	 injected	into	 the	 left	 atrium	 prior	 to	 stretching	 the	 heart.	 	 Intriguingly,	 the	extend	of	myocardial	necrosis	remained	unaffected	(254).			
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In	 order	 to	 sought	 the	mechanism,	 the	 same	 authors	 used	 a	 rabbit	model	 to	 determine	 whether	 there	 were	 any	 cross	 talks	 between	these	 mechanoreceptors	 and	 effectors	 of	 known	 preconditioning	(K+ATP	 	 +/-	adenosine	 receptors	 through	activation	of	protein	kinase	C)	 and	 they	were	 able	 to	 conclude	 this	was	 indeed	 the	 case	 (107).		Furthermore,	 isolated	 hearts	 stretched	 by	 a	 transient	 rise	 in	 left	ventricular	 end	 diastolic	 pressure	 recovered	 better	 from	 an	ischaemic	insult	when	compared	to	their	counter-part.	






1.	 	 To	 confirm	 the	 ability	 to	 precondition	 human	muscle	 using	 the	atrial	trabecular	model	of	superfusion.		Although	this	model	has	been	established	 since	 the	 early	 90’s,	 it	 was	 important	 to	 confirm	 the	ability	to	 ‘work	the	model’.	 	This	would	allow	the	use	of	such	model	to	investigate	the	protection	of	human	muscle.	
	
2.	 	 To	 characterise	 the	 model	 to	 achieve	 aim	 (1).	 	 This	 would	 be	achieved	 by	 altering	 various	 components	 of	 the	 preconditioning	protocol	 that	 include	 stabilisation	 time,	 duration	 of	 index	 hypoxia	and	reperfusion	time.	 	Established	preconditioning	protocols	will	be	used	 and	 altered	 according	 to	 the	 ability	 to	 achieve	 successful	preconditioning	in	human	muscle.			
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3.		To	investigate	whether	stretching	atrial	trabeculae	whilst	reaching	the	peak	of	the	Frank-Starling	curve	induces	preconditioning.		There	is	 data	 from	 animal	 studies	 to	 support	 stretching	 as	 a	preconditioning	mimetic.	
	
4.	 	 To	 investigate	 the	 ability	 for	 SDF-1α	 to	 chemically	 precondition	human	 muscle.	 	 As	 discussed	 in	 the	 introductory	 section	 to	 this	thesis,	 SDF-1α	 been	 shown	 in	 animal	 hearts	 to	 protect	 it	 from	ischaemia-reperfusion	 injury	 via	 mechanisms	 analogous	 to	 other	forms	of	conditioning.	
	

























Isolated	human	atrial	trabeculae	were	used	in	the	investigation	into	the	protection	of	human	muscle	 from	hypoxia-reoxygenation	 injury.		This	superfusion	model	is	described	along	with	the	Western	blotting	technique	 used.	 	 The	 use	 of	 the	 model	 within	 the	 Hatter	Cardiovascular	Institute	has	been	described	earlier	(section	1.5.8.1).	
	
3.2	Critical	analysis	of	the	superfusion	model	
This	 ex-vivo	 model	 is	 a	 unique	 robust	 and	 reproducible	 model	 for	evaluating	 the	 cardioprotective	 potential	 of	 both	 pharmacological	and	 non-pharmacological	 effects	 on	 the	 isolated	 human	 atrial	trabeculae	harvested	from	right	atrial	appendage.	
This	 setup	 is	 a	 functional	model	 that	 uses	 the	 developed	 force	 as	 a	measure	and	recovery	of	function	therefore	is	a	surrogate	marker	of	muscle	 injury.	 	 Data	 from	 this	 unique	 model	 has	 been	 reproduced	with	both	positive	 controls	using	 ischaemic	preconditioning	as	well	as	negative	controls	of	simulated	ischaemia-reperfusion	injury.	 	The	
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effect	 of	 postconditioning	 has	 also	 been	 analysed	 using	 this	 model	(256).			
There	are	several	advantages	of	this	human	model:	
1. Avoidance	 of	 the	 confounding	 factor	 of	 collateral	 blood	 flow	experienced	with	in-vivo	models	(127);	2. Eliminates	 the	effects	of	alterations	 in	preloads	and	afterloads.		Authors	 have	 suggested	 in	 the	 past	 that	 brief	 period	 of	ischaemia	results	in	transient	stretch	(through	dilatation)	of	the	heart	 that	 may	 be	 responsible	 for	 preconditioning	 the	 human	heart	(254);	3. Eliminates	 any	 ethical	 considerations	 that	 may	 be	 involved	whilst	utilising	experimental	drugs;	4. 	In	experiments	involving	whole	hearts,	altered	cavity	geometry	occurs	 when	 there	 is	 a	 modulation	 of	 coronary	 perfusion	pressure,	 tissue	 oedema	 and	 ischaemic	 contracture	 (as	encountered	during	and	following	ischaemia).		These	may	affect	the	measurement	of	contractile	function	(257)	and	5. The	natural	milieu	of	the	cardiomyocytes	remains	unaltered.	
An	 important	 consideration	 of	 this	 model	 is	 that	 the	 human	myocardium	used	 is	atrial	rather	than	ventricular.	 	This	 is	based	on	
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Variability	 exists	 amongst	 published	 data	 with	 respect	 to	 what	 is	considered	 the	 appropriate	 maximum	 diameter	 for	 effective	oxygenation	 of	 superfused	 isolated	muscle	 preparation.	 	 It	was	 the	pioneering	work	of	Hill	and	colleagues	who	derived	a	formula	based	on	 ‘biophysical	 principle’	 to	 determine	 the	 maximum	 diameter	 of	superfused	 tissue	 that	 can	 be	 adequately	 oxygenated	 in	 an	 isolated	muscle	preparation	(259).		Using	this	formula,	Prasad	and	colleagues	were	 able	 to	 demonstrate	 the	 adequate	 oxygenation	 of	 isolated	superfused	human	papillary	muscle	of	diameter	less	than	0.932	mm	in	 an	 atmosphere	 of	 95%	O2	 5%	CO2	with	 the	 temperature	 at	 37oC	whilst	being	paced	at	1	Hz	(260).	 	Page	and	colleagues	on	the	other	hand	 demonstrated	 that	 cylindrical	 cat	 papillary	 muscle	 with	 a	diameter	 of	 1.12	mm	would	 be	 adequately	 oxygenated	 (261).	 	 In	 a	separate	 experiment,	 Snow	 and	 colleagues	 demonstrated	preservation	of	rabbit	papillary	muscle	core	with	a	diameter	of	1.22	mm	when	 it	was	 paced	 at	 0.8	Hz	 at	 25oC;	 however	 this	will	 not	 be	relevant	 to	 studies	 conducted	 here	 (262).	 	 In	 an	 interesting	 set	 of	experiments	 conducted	 by	 Paradise	 and	 colleagues	 where	 rat	papillary	 muscle	 diameter	 and	 oxygen	 tension	 were	 altered,	 they	summarised	 that	 it	would	be	only	possible	 to	adequately	oxygenate	
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muscle	 with	 diameters	 that	 were	 less	 than	 0.48	 mm	 when	oxygenated	adequately	at	37oC	and	paced	at	1	Hz	(258).		However	it	is	 well	 established	 from	 several	 experimental	 models	 utilising	specimens	obtained	 from	human	ventricle	 that	 is	1-2	mm	muscle	 is	adequate	in	superfusing	isolated	muscle	(263,	264).	
During	 this	 study,	 all	 human	atrial	 trabeculae	were	equal	 to	or	 less	than	 1.2	mm	 in	 diameter.	 	When	 isolating	 the	 individual	 trabecula	from	 the	 atrial	 appendage,	 the	 thinnest	 were	 isolated	 first.	 	 An	assumption	was	made	 in	 that	 the	 human	 atrial	 appendages	 in	 this	study	were	adequately	oxygenated	and	majority	of	the	studies	above	would	 advocate	 this.	 	 If	 the	 diameter	 of	 the	muscle	were	 such	 that	core	hypoxia	existed,	 then	 this	would	affect	all	groups	equally.	 	The	results	 obtained	 in	 the	 experiment	 would	 remain	 valid	 since	 the	study	compares	the	responses	of	clusters	of	 trabeculae	that	were	of	equal	characteristics	at	baseline.	
Based	 on	 the	 above	 and	 experiences	 of	 previous	 researchers	 using	this	model,	a	cut	off	value	of	1.2	mm	was	arrived.		On	the	principles	of	diffusion,	one	would	expect	atrial	trabeculae	greater	than	1.2	mm	in	diameters	 not	 react	 in	 the	 same	 way	 to	 simulated	 ischaemia-reperfusion	or	hypoxic	preconditioning	when	compared	 to	 tissue	of	smaller	 diameter.	 	 However,	 there	 is	 evidence	 from	 models	 using	
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ventricular	papillary	muscle	obtained	 from	explanted	heart	 that	are	1-2	mm	in	diameter	that	have	been	successfully	preconditioned	(129,	263,	264).		With	the	notion	that	smaller	diameter	trabeculae	may	be	better	diffused	with	gases	and	solutes,	all	trabeculae	with	diameters	up	 to	1.2	mm	have	been	 included	and	 their	baseline	 function	value	are	similar	without	any	statistical	difference	between	groups.	
Finally,	 there	 is	 most	 likely	 to	 be	 a	 core	 of	 necrosis	 in	 this	experimental	model.		Contraction	is	most	likely	due	to	an	outer	layer	of	viable	cardiomyocytes.		Following	a	long	experimental	protocol	of	at	 least	180	minutes,	 it	 is	 likely	 that	 the	numbers	of	viable	cells	are	reduced	even	further.		This	precludes	further	experimentation	at	the	end	of	 the	protocol	 (such	as	Western	blot	 analysis).	 	Therefore	 this	atrial	 trabecular	 model	 demonstrates	 indirect	 evidence	 through	 a	functional	 recovery	 model	 without	 any	 exhibition	 of	 mechanistic	pathways	 as	 demonstrated	 in	 cellular	 mechanisms	 of	preconditioning.	
Despite	the	above	limitations,	this	experimental	model	is	unique,	has	several	advantages	and	is	reproducible	by	different	researcher	albeit	different	protocols	(108,	133,	134,	136,	265,	266).		Despite	the	initial	model	 of	preconditioning	was	based	on	a	different	model	 (74),	 this	translational	model	 enables	us	 to	determine	whether	data	obtained	
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from	 animal	 studies	 can	 be	 applied	 to	 human	 models	 therefore	allowing	us	to	better	our	understanding	of	preconditioning	and	study	the	effect	of	novel	proteins	such	as	SDF-1α	may	have	on	myocardial	injury.				
	
3.5	Study	subjects	
Patients	 recruited	 in	 this	 study	 were	 undergoing	 elective	 coronary	artery	 bypass	 graft	 (CABG)	 surgery,	 valve	 repair	 or	 replacement	surgery	 and	 replacement	 of	 the	 aortic	 arch	 at	 the	 Heart	 Hospital,	University	 College	 London	 NHS	 Foundation	 Trust,	 London.	 	 All	patients	recruited	had	given	prior	written	consent	using	the	consent	form	as	shown	(see	appendix).			








• Experienced	 a	 troponin	 positive	 event	 within	 6	 weeks	 of	undergoing	surgery	
• They	had	a	history	of	arrhythmias	e.g.	atrial	fibrillation	or	flutter,	ventricular	arrhythmias	within	6	weeks	or	on	any	anti-arrhythmic	medications	such	as	amiodarone	
• They	 had	 any	 forms	 of	 heart	 failure	 (ejection	 fraction	 less	 than	50%)	or	active	pulmonary	oedema	




3.6	 Human	 atrial	 trabecula	 model	 of	 simulated	 hypoxia-
reperfusion	injury	
3.6.1	Specimen	collection	and	transport		
During	the	surgery,	prior	to	insertion	of	the	venous	cannula	(usually	follows	arterial	cannulation	of	the	aorta),	a	purse	string	suture	would	be	 placed	 around	 the	 base	 of	 the	 right	 atrial	 appendage	 to	 enable	harvesting	of	the	sample.		At	this	point,	the	surgeon	would	be	aware	to	 manipulate	 the	 appendage	 with	 caution	 as	 rigid	 or	 excessive	handling	of	the	tissue	would	quite	often	affect	the	functionality	of	the	trabeculae	 therefore	 invalidate	 any	 experiments.	 	 A	 clamp	 (side	biter)	 would	 then	 be	 placed	 above	 the	 purse	 string	 suture	 and	 a	scissor	 would	 be	 used	 to	 carefully	 dissect	 out	 the	 right	 atrial	appendage	by	the	cardiothoracic	surgeon.		The	sample	would	then	be	placed	 immediately	 in	 a	 50	 mL	 FalconTM	 tube	 containing	approximately	 45	 mL	 of	 modified	 Tyrode’s	 buffer	 (comprising	 in	mmol/L	 118.5	 NaCl,	 4.8	 KCl,	 24.8	 NaHCO3,	 1.2	 KH2PO4,	 1.44	MgSO4.7H2O,	 1.8	 CaCl2.2H2O,	 10.0	 glucose	 and	 10.0	 pyruvic	 acid),	which	was	pre-oxygenated	with	a	gas	mixture	consisting	of	95%	O2	+	5%	 CO2	 to	 maintain	 a	 physiological	 pH	 between	 7.35-7.45	 and	 a	partial	pressure	of	oxygen	and	carbon	dioxide	above	55	kPa	and	4.0-6.0	kPa	respectively.	 	Temperature	was	maintained	<4°C	by	placing	
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the	 FalconTM	 in	 a	 flask	 containing	 ice	 which	 was	 then	 transported	back	to	the	laboratory	as	soon	as	possible.			
On	the	morning	of	 the	experiment,	 the	organ	bath	system	would	be	set-up	with	the	water	 jackets	switched	on	and	the	buffer	circulating	to	eliminate	any	delays	in	conducting	the	experiment	on	return	from	the	Heart	Hospital.		In	a	separate	polystyrene	box	containing	ice,	a	50	ml	FalconTM	tube	containing	the	modified	Tyrode’s	solution	would	be	bubbled	 with	 95%	 O2	 +	 5%	 CO2	 gas	 mixture	 for	 a	 minimum	 of	 5	minutes	 prior	 to	 placement	 in	 a	 transport	 flask	 containing	 ice.	 	 On	arrival	 to	 the	 Heart	 Hospital,	 the	 flask	 containing	 the	 Tyrode’s	solution	would	 be	 placed	 immediately	 into	 a	 4°C	 fridge	 next	 to	 the	operating	theatre.		The	flask	would	then	be	removed	from	the	fridge	within	minutes	of	the	surgeon	harvesting	the	right	atrial	appendage.		This	 enabled	 the	 temperature	 to	 be	 regulated	 at	 the	 preferred	 4°C.		The	transport	between	the	Hatter	Cardiovascular	Institute	and	Heart	Hospital	 was	 approximately	 1.1mile	 journey;	 walking	 would	 take	approximately	 20	minutes	whereas	 cycling	would	 take	 10	minutes.		At	 the	set-up	of	 the	experiments,	 samples	were	 transported	on	 foot	but	 later	 a	 pushbike	 was	 utilised	 to	 minimise	 transport	 times	 to	maximise	yield	in	terms	of	surviving	trabeculae.	
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The	 importance	 of	 temperature	 regulation	 and	 transport	 times	 has	been	 highlighted,	 as	 these	 are	 some	 of	 the	 variable	 factors	 that	influence	whether	or	not	trabeculae	survived.	
	
3.6.2	Dissecting	atrial	trabeculae		






The	 dish	 itself	 contained	 modified	 Tyrode’s	 buffer	 that	 was	continuously	 oxygenated	 with	 95%	 O2	 +	 5%	 CO2	 gas	 mixture	 and	placed	on	a	bed	of	ice	to	maintain	temperature	of	4°C.	 	The	edges	of	the	 inner	surface	of	 the	atrial	appendage	were	secured	onto	 the	gel	bed	 to	 enable	 exposure	 of	 the	 atrial	 trabeculae	 that	were	dissected	out.	 	 Individual	 trabecula	 (>2mm	 length,	 <1.2mm	 diameter)	 were	identified	under	a	light	microscope	(Olympus	SZ40)	using	a	separate	light	source	(Photonic	PL2000)	then	isolated	by	tying	a	surgical	knot	at	 either	 end	 of	 the	 trabecula	 with	 a	 7-0	 silk	 suture.	 	 Using	 a	microscope	 facilitated	 enhanced	 identification	 of	 trabeculae,	minimised	manual	 manipulation	 and	 also	 allowed	measurement	 of	trabeculae	 prior	 to	 their	 dissection.	 	 Once	 excised,	 the	 trabeculae	were	 suspended	 vertically	 in	 a	 25ml	 water-jacketed	 organ	 bath	between	 two	 platinum	 pacing	 electrodes	 (Radnoti	 Glass	Technologies,	 USA)	 containing	 modified	 Tyrode’s	 buffer	 bubbled	with	 a	 gas	 mixture	 containing	 95%	 O2	 +	 5%	 CO2	 to	 maintain	 a	physiological	pH	between	7.35-7.45	and	maintain	pO2	>	55	kPa	and	CO2	 between	 4.0-6.0	 kPa.	 	 The	 inferior	 end	 of	 the	 trabecula	 was	attached	to	a	fixed	post	in	the	organ	bath	using	a	7-0	silk	suture	and	the	 opposite	 superior	 end	 was	 attached	 to	 a	 force	 transducer	 also	using	 a	 7-0	 silk	 suture.	 	 Where	 there	 were	 multiple	 trabeculae	
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The	 suspended	 trabeculae	 in	 non-toxic	 perspex	25	ml	organ	baths	were	continuously	bathed	in	modified	Tyrode’s	buffer	delivered	from	









large	 glass	 beaker	 that	 would	 be	 re-circulated	 using	 a	 peristaltic	
















Trabeculae	were	suspended	vertically	in	the	organ	bath	as	described	above.	 	 The	 initial	 phase	 was	 the	 stabilisation	 phase	 followed	 by	simulated	 ischaemia	 then	 ending	 with	 reoxygenation	 (simulated	reperfusion).	 	 The	 duration	 of	 individual	 component	 varied	throughout	 my	 research	 period.	 	 Through	 characterisation	 of	 the	human	 trabecular	 model,	 the	 optimum	 timing	 of	 the	 individual	components	was	 determined	which	was	 then	 applied	 to	 the	 rest	 of	the	experiments	conducted.		This	is	discussed	below.	
With	 the	 muscle	 suspended	 and	 paced	 at	 1	 Hz	 at	 37°C,	 the	 force	transducer	would	be	reset	to	zero.		A	small	stretch	would	be	applied	to	 the	 muscle	 to	 create	 a	 resting	 muscle	 tension	 of	 0.1g	 and	 the	muscle	would	be	left	for	30	minutes.		A	sample	of	the	effluent	would	be	 taken	 to	 ensure	 the	 pH,	 O2,	 CO2	 and	HCO3-	were	within	 normal	physiological	 levels.	 	 A	 good	 healthy	 sample	 would	 be	 seen	contracting	 immediately	and	 this	would	 improve	over	 time	prior	 to	application	of	various	experimental	protocols.		A	surrogate	marker	of	the	 quality	 of	 specimen	 was	 noted	 by	 also	 recording	 the	 rate	 in	
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change	 in	 force	 (dF/dt)	 for	 each	 set	 of	 experiment	 conducted;	 the	smaller	dF/dt,	the	stiffer	the	muscle	and	poorer	the	quality.			
The	muscle	was	 gradually	 stretched	 using	 a	micromanipulator	 in	 a	stepwise	manner	over	a	period	of	15	minutes	until	maximum	force	of	contraction	was	achieved	through	the	Frank-Starling	law	of	the	heart.		




Fig	 3.4.	 	 Demonstrating	 response	 of	 human	 muscle	 to	 stretch	
and	final	stabilisation	phase.		






Figure	 3.5.	 Graph	 taken	 from	 an	 actual	 experiment	
demonstrating	a	typical	Frank-Starling	behavior	of	human	atrial	
trabeculae.	





















chambers	containing	normoxic	and	hypoxic	buffers.		Three	way	taps	controlled	 the	 flow	 to	each	organ	bath.	 	There	were	also	 smaller	1-litre	 chambers	 connected	 to	 individual	 baths	 allowing	 a	 different	agent	to	be	tested	on	a	particular	trabecula.		For	example,	at	any	one	time	there	could	be	a	sham	experiment	running,	alongside	a	positive	control	 (hypoxic	 preconditioning),	 negative	 control	 (simulated	ischaemia-reperfusion)	 and	 one	 being	 chemically	 preconditioned	(SDF-1α).		Each	organ	bath	itself	was	connected	to	a	drain	controlled	by	a	valve	that	enabled	rapid	replacement	by	a	different	buffer.	
Ischaemia	 for	 at	 least	 60	 minutes	 was	 simulated	 by	 replacing	 the	oxygenated	 glucose	 and	pyruvate-containing	Tyrode’s	 buffer	with	 a	hypoxic	 pyruvate-free	 and	 glucose-free	 buffer	 (comprising	 in	mmol/L	 118.5	 NaCl,	 4.8	 KCl,	 24.8	 NaHCO3,	 1.2	 KH2PO4,	 1.44	MgSO4.7H2O,	 1.8	 CaCl2.2H2O,	 7.0	 choline	 chloride)	 that	was	 bubbled	with	95%	N2	+	5%	CO2.		Field	stimulation	was	increased	from	1	Hz	to	3	 Hz	 to	 enable	 depletion	 of	 ATP	 levels.	 	 Oxygen	 tension	 was	maintained	 between	 6-8	 KPa	 whilst	 the	 pH	 was	 maintained	 at	 a	lower	level	between	7.30-7.35.		The	induction	of	simulated	ischaemia	was	 immediately	apparent	on	the	recording	chart,	as	 indicated	by	a	reduction	 in	 force	 amplitude	 and	 increase	 in	 contractile	 frequency.		During	this	period	the	resting	tension	would	also	rise	up	to	the	point	
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As	 described	 earlier,	 the	 trabeculae	 were	 suspended	 vertically	 in	modified	 Tyrodes	 buffer	 in	 a	 25	ml	 perspex	 organ	 bath	 between	 a	force	transducer	and	a	 fixed	hook	and	paced	by	field	stimulation	by	platinum	pacing	electrodes	that	were	on	either	side	of	the	trabeculae.		The	pacing	was	driven	by	an	isolated	stimulator	(Harvard	apparatus)	triggered	 by	 a	 computerised	 clock.	 	 The	 amplitude	 (voltage)	 and	duration	(pulse	width)	of	the	square	wave	pulse	could	be	altered	by	adjusting	the	appropriate	dial	on	the	stimulator.		The	pulse	width	for	all	experiments	were	set	at	5ms	and	amplitude	was	set	at	least	twice	the	 threshold	 needed	 by	 individual	 trabeculae	 for	 mechanical	contraction	 to	 take	 place.	 	 Through	 the	 force	 transducer,	 amplifier	and	 PowerLab	 software,	 spikes	 were	 seen	 which	 represented	 the	developed	 force.	 	 Prior	 to	 the	 start	 of	 each	 experiment,	 the	 entire	system	 would	 be	 reset.	 	 In	 particular,	 a	 known	 weight	 would	 be	applied	 to	 the	 force	 transducer	 to	 ensure	 that	 the	 appropriate	developed	force	was	being	recorded	(calibration	of	force	transducer).		At	 the	 end	of	 each	experiment,	 the	 entire	 system	would	be	drained	and	 circulated	 with	 distilled	 water	 before	 being	 flushed.	 	 Every	 3	months,	the	system	would	undergo	an	acid	wash	as	recommended	by	the	manufacturers.	
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3.9	Application	of	protocols	and	infusion	of	compounds	
Through	this	system,	various	protocols	could	be	applied.		This	would	include	 different	 stabilisation,	 simulated	 ischaemia	 and	 reperfusion	times.	 	 Similarly	 a	 range	 of	 protocols	 of	 ischaemic	 preconditioning	could	 be	 applied	 by	 alternating	 between	 the	 oxygenated	 normoxic	buffers	 or	 oxygen	 and	 substrate	 deplete	 hypoxic	 buffer.	 	 Various	compounds	 could	 also	 be	 investigated	 upon	 through	 separate	infusion	from	1-litre	chambers	that	were	connected	individual	25ml	organ	baths.	 	Recirculation	of	effluent	was	via	a	separate	pump	that	collected	 the	 effluent	 and	 re-circulated	 back	 into	 these	 1-litre	chambers.	
A	 randomisation	 technique	 was	 applied	 to	 the	 experiments	 to	eliminate	any	bias.		The	dissected	trabeculae	were	allocated	to	a	bath	depending	on	the	outcome	of	a	shuffled	pack	of	cards	numbered	one	through	 to	 four.	 	 The	 bath	 in	 turn	 had	 a	 predetermined	 protocol	applied	to	it	at	the	beginning	of	the	experiment.	
	
3.10	Measure	of	cardioprotection:	Recovery	of	function	
The	 developed	 force	 of	 contraction	 was	 recorded	 on	 an	 Excel	spreadsheet	at	15-minute	 time	 intervals	 throughout	 the	experiment	
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by	a	built	in	programme	within	Lab	Chart.		Baseline	force	at	t=0	was	taken	at	1	minute	prior	to	subjecting	tissue	to	simulated	ischaemia	to	allow	for	any	error	that	may	arise	whilst	switching	between	buffers.		This	represented	the	maximum	contractility	of	the	trabeculae.		At	the	end	of	the	protocol,	the	developed	force	was	also	noted	and	this	was	divided	 by	 the	 baseline	 value	 to	 calculate	 the	 recovery	 of	 function,	which	was	expressed	as	a	percentage	of	the	baseline.			
	
3.11	Measure	of	stability	
During	various	stages	of	 the	experiment	 there	was	a	group	of	atrial	trabeculae	that	would	be	allowed	to	contract	for	the	entire	duration	of	the	experiment	(minimum	210-minutes)	in	one	of	the	organ	baths,	superfused	with	oxygenated	modified	Tyrode’s	solution	and	paced	at	1Hz	with	no	 further	experimental	manipulation	 following	the	 initial	stabilisation	 phase.	 	 This	 was	 to	 ensure	 that	 the	 atrial	 trabeculae	were	 stable	 and	 more	 importantly	 provided	 reassurance	 that	 the	organ	bath	system	was	in	good	working	order.	
Over	time	there	was	a	gradual	decline	 in	function	over	the	duration	of	 the	 experimental	 protocol.	 	 Encouragingly,	 this	 compares	favourably	with	 the	 decline	 in	 contractility	 observed	 in	 other	 atrial	
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• The	trabeculae	had	to	be	of	a	certain	‘quality’	to	be	included	in	the	study.	 	 Those	 that	 failed	 to	 reach	 a	 baseline	 contractility	 of	 0.5g	were	excluded.	 	This	was	determined	based	on	experiences	 from	previous	researchers	at	The	Hatter	Cardiovascular	Institute	
• 	Damaged	 trabeculae	 were	 excluded.	 	 This	 may	 have	 occurred	during	the	harvesting	process	where	part	of	the	trabeculae	would	be	excised	or	during	the	isolation	process	itself	in	the	laboratory.		Any	 trabeculae	 that	 needed	 separating	 from	 other	 trabeculae	would	also	be	excluded	as	the	dissecting	process	would	inevitably	damage	the	muscle	
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• Trabeculae	greater	than	1.2mm	thickness	were	excluded	based	on	the	principle	of	adequate	oxygenation	and	diffusion	of	oxygen	 to	muscle	core	




This	widely	used	analytical	method	detects	 specific	proteins	 from	a	sample	of	homogenate.		During	this	technique,	proteins	are	separated	based	 on	 their	 type	 and	 molecular	 weight	 through	 gel	electrophoresis.	 	 This	 is	 then	 transferred	 to	 a	 membrane	 that	produces	a	band	for	each	protein.		This	membrane	is	then	incubated	with	 synthetic	 antibodies	 that	 bind	 with	 these	 specific	 proteins	 of	interest.		The	unbound	antibodies	are	then	washed	off	leaving	behind	the	 bound	 antibody	 of	 interest	 that	 is	 detected	 by	 developing	 the	film.		The	thickness	of	the	band	corresponds	to	the	amount	of	protein	present	(268).		
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	Protein	 quantification	 was	 determined	 using	 the	 detergent-compatible	 Pierce	 Bicinchoninic	 acid	 (BCATM)	 based	 assay	 reagent	system	 (Rockford,	 USA).	 	 This	 colorimetric	 assay	 reduces	 ionized	copper	 to	 produce	 a	 purple	 coloured	 BCA-copper	 complex;	 the	quantity	 produced	 is	 proportional	 to	 the	 protein	 content.	 	 A	spectrophotometer	 set	 at	 a	 wavelength	 of	 562nm	 was	 used	 to	estimate	 the	 protein	 content.	 	 A	 standard	 curve	 using	 increasing	concentrations	of	bovine	serum	albumin	(BSA)	was	produced		(0,	10,	20,	 30,	 40	 μL	 of	 2μg/ml	 and	 25μL	 of	 4μg/ml).	 	 The	 relationship	between	 light	 absorbance	 and	 protein	 concentration	 was	 linear	ranging	 from	 20-2000	 μg/ml.	 	 The	 protein	 concentration	 in	 each	specimen	could	therefore	be	obtained	by	plotting	the	absorbance	on	a	standard	curve.		This	made	certain	that	there	was	equal	loading	of	the	polyacrylamide	gel.	
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Sodium	 dodecylsulphate-polyacrylamide	 gels	 were	 prepared	 (SDS-PAGE).		Gel	mixtures	were	introduced	between	two	glass	plates	that	were	prepared	by	cleaning	them	with	70%	ethanol.		The	plates	were	separated	 by	 spacers	 loaded	 onto	 a	 gel	 loading	 self-sealing	 system.		The	lower	proportion	of	the	SDS-PAGE	gel	was	a	12.5%	running	gel	that	 was	 essentially	 one	 large	 sized	 gel	 (12ml	 distilled	 water,	 9ml	
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running	gel	base	[containing	1.5M	TRIS,	0.4%	SDS	in	distilled	water,	adjusted	with	HCl	to	a	pH	of	8.8],	15ml	of	30%	acrylamide	and	mixed	prior	 to	 the	 addition	 of	 40μL	 TEMED,	 200μL	 10%	 ammonium	persulphate	(269)).	 	Once	the	running	gel	was	allowed	to	set	 for	30	minutes	 an	 upper	 5%	 stacking	 gel	 (7ml	 distilled	 water,	 3ml	 of	stacking	 gel	 base	 [0.5M	TRIS,	 0.4%	 SDS	 in	 distilled	water,	 adjusted	with	 HCl	 to	 a	 pH	 of	 6.82],	 2ml	 of	 30%	 acrylamide,	 20μL	 8%	bromophenol	blue,	24μL	TEMED	and	120μL	10%	APS)	was	prepared.		Wells	 were	 formed	 in	 the	 upper	 stacking	 gel	 by	 inserting	 a	 24-pronged	 comb	 between	 the	 glass	 plates	 at	 the	 top	 prior	 to	introduction	 of	 the	 stacking	 gel.	 	 This	 was	 allowed	 to	 set	 for	 10	minutes.	
	
3.13.4	Electrophoresis	technique	
The	 gel	 plates	 were	 mounted	 onto	 a	 water-cooled	 electrophoresis	system.		Running	buffer	(comprising	of	1L-distilled	water,	TRIS	3.03	mmol/L,	SDS	1.0g/L	and	glycine	14.42	g/L)	was	added	to	both	ends	of	 the	 plates	 ensuring	 that	 the	 electrodes	 were	 covered.	 	 A	 dual	colour	molecular	weight	marker	(BioRad,	UK)	was	pipetted	 into	the	first	well	followed	by	45	μg	of	protein	sample	(prepared	as	described	
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in	protein	extraction)	into	each	subsequent	well.		The	gels	were	then	allowed	 to	 run	 at	 120	 volts	 constantly	 until	 the	 protein	 marker	showed	good	separation	(usually	2-4	hours).	
	
3.13.5	Protein	transfer	
Following	electrophoresis,	gels	were	removed,	cut	to	size	and	placed	on	 Whatmann	 filter	 paper	 that	 was	 then	 rolled	 to	 ensure	 any	 air	bubbles	were	eliminated.	 	A	nitrocellulose	membrane	(Hybond	ECL,	Amersham,	 UK)	 was	 also	 trimmed	 to	 the	 same	 size	 as	 the	 gel	 and	placed	on	top	and	rolled	again.		A	second	Whatmann	filter	paper	was	placed	on	top	of	the	nitrocellulose	membrane	and	gently	flattened	to	expel	 any	 trapped	 air	 bubbles.	 	 This	 whole	 sandwich	 was	 then	mounted	 on	 a	 transfer	 cassette	 and	 placed	 vertically	 in	 a	 transfer	buffer	 containing	 transfer	 tank	 (transfer	 buffer	 consisted	 of	 700ml	distilled	water,	200ml	methanol,	100ml	of	10	times	strength	transfer	buffer	 stock	 solution	 [comprising	 1L	 distilled	 water,	 glycine	 144.2	g/L	 and	 TRIS	 30.3	 g/L]).	 	 The	 transfer	 system	 was	 run	 at	 0.1	 mA	overnight	for	a	minimum	duration	of	16	hours.		On	the	following	day,	the	membranes	were	removed	and	stained	with	Ponceau	Red	(Sigma	
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Chemicals,	 Poole,	UK)	 to	 ensure	 adequate	 transfer	 of	 proteins	 from	the	gel.	
	
3.13.6	Immunoblotting	
The	membranes	were	 placed	 on	 trays	with	 a	 rocking	 platform	 and	washed	with	TBS-Tween	 (comprising	1L	distilled	water	adjusted	 to	pH	7.6	with	HCl,	NaCl	8.0g,	TRIS	2.42g,	Tween-20	[polysorbate-20]	1	ml)	for	5	minutes.		Subsequently	a	wash	in	blocking	buffer	(5g	Marvel	–	dried	skimmed	milk	powder	in	TBS-Tween)	was	performed	for	one	hour	 to	 minimise	 interference	 from	 non-specific	 binding	 of	antibodies	 to	 other	 proteins.	 	 Three	 further	 5-minute	washes	were	performed	with	washing	buffer	 following	which	 the	membrane	was	probed	 for	 a	minimum	of	 2	hours	with	 the	primary	 antibody	being	analysed.		Dilutions	of	1:1000	were	used	for	the	phosphorylated	and	total	 kinase	 antibodies.	 	 The	 antibodies	 were	 diluted	 in	 a	 5%	 BSA	solution.	 	 Three	 further	 5-minute	 washes	 were	 performed	 in	 TBS-Tween	prior	to	probing	with	the	secondary	antibody	for	a	minimum	of	 1	 hour	 (same	 dilution	 as	 their	 primary	 antibody)	 using	 blocking	buffer	 as	 a	diluent.	 	A	 final	 three	5-minute	washes	were	performed	prior	 to	 the	 membranes	 being	 incubated	 with	 enhanced	
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chemiluminescent	 (ECL)	 Western	 blotting	 detection	 reagent	 (GE	Healthcare,	UK)	to	produce	the	horseradish	peroxidase	signal.	
	
3.13.7	Protein	band	quantification	
Within	 a	 dark	 developing	 environment,	 the	 nitrocellulose	membranes	 were	 exposed	 against	 Amersham	 Hyperfilm	 ECL	 and	subsequently	developed	using	Kodax	GBX	developer	and	fixer	(Sigma	chemicals,	Poole,	UK).		Once	the	films	were	dried,	they	were	digitally	scanned	 and	 stored	 for	 analysis.	 	 Image	 J	 	 (National	 Institute	 of	Health,	USA)	was	used	to	obtain	densitometry	readings	of	the	bands.		Values	of	absolute	phosphorylation	of	proteins	were	obtained	along	with	values	normalized	against	the	total	protein.			
	
3.14	Immunohistochemistry	for	SDF	receptor	and	mechanism	








All	 data	 presented	 are	 presented	 as	 mean	 value	 ±	 SEM.		Indistinguishable	 to	 previous	 researchers	 with	 the	 same	 model,	 a	factorial	 one-way	 ANOVA	 was	 used	 for	 comparison	 between	 more	than	 two	 groups	 in	 the	 functional	 recovery	 experiments.	 	 In	 cases	where	 a	 significant	 F-value	 was	 obtained,	 Fisher’s	 protected	 least	significance	 difference	 (PLSD)	 post	 hoc	 was	 applied	 to	 test	 for	significance.	 	 A	 p-value	 of	 <0.05	 was	 taken	 to	 specify	 significance.		With	western	blotting,	protein	band	quantification	are	expressed	as	mean	value	±	SEM.		The	differences	between	groups	have	been	tested	
	 197	









Chapter	 4:	 	 Characterisation	 -	Establishing	 the	 human	 atrial	trabecular	superfusion	model	
4.1	Introduction	
To	test	the	hypothesis	that	SDF-1α	may	protect	human	myocardium	from	 ischaemia-reperfusion	 injury,	 it	 was	 necessary	 to	 ensure	 that	the	 trabecular	 model	 was	 a	 ‘functioning’	 model.	 	 Previous	investigators	 in	 the	 Hatter	 Cardiovascular	 Institute	 have	 employed	the	 same	model	 with	 various	 stabilisation	 techniques,	 hypoxia	 and	re-oxygenation	 durations,	 in	 addition	 to	 different	 preconditioning	protocols	 as	 tabulated	 below.	 	 It	 was	 therefore	 crucial	 to	 adopt	 a	protocol	 that	would	function	prior	to	studying	the	effects	of	SDF-1α	was	studied	upon.			
	












90	 120	 120	 3+12	
SD	Morris	 90	 120	 120	 3+7	
CS	Carr	 90	 120	 120	 3+7	
P	Rees	 90	 120	 120	 3+7	
ME	S-Dick	 90	 120	 120	 3+7	
V	
Sivaraman	
75	 120	 120	 4+16	
	
Table	4.1.	Protocol	used	by	previous	investigators	at	The	Hatter	









































Muscle	 was	 stabilised	 as	 described	 earlier.	 	 Atrial	 trabeculae	 were	suspended	 between	 a	 fixed	 glass	 hook	 and	 a	 force	 transducer	 then	superfused	 in	modified	Tyrode’s	 solution	 at	 37°C	whilst	 being	 field	stimulated	 at	 1	 Hz.	 	 During	 the	 first	 part	 of	 stabilisation	 muscle	 a	force	of	0.1g	was	applied	and	muscle	 left	 for	30	minutes.	 	This	was	followed	by	a	stretch	over	15	minutes	 to	 the	peak	of	Frank-Starling	curve	followed	by	a	final	45	minutes	of	stabilisation.		At	this	point	a	
preconditioning	 protocol	 was	 applied.	 	 The	 muscle	 was	 then	subjected	 to	 a	 period	 of	 90	minutes	 simulated	 hypoxia	 followed	by	
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120	minutes	re-oxygenation.	 	This	is	depicted	in	the	diagram	below.		Therefore	 trabeculae	 were	 randomly	 assigned	 to	 the	 following	groups:	
	
1. Controls	(n≥5):		Atrial	trabeculae	were	subjected	to	90	minutes	of	stabilisation,	 90	minutes	 of	 simulated	 ischaemia	 (index	hypoxia)	and	120	minutes	of	simulated	reperfusion	(reoxygenation)	
	
2. Hypoxic	 preconditioning	 (n≥8):	 	 Atrial	 trabeculae	 were	subjected	 to	 the	 same	 protocol	 as	 the	 hypoxia-reoxygenation	control	 in	 addition	 to	 a	 preconditioning	 protocol	 consisting	 of	3	
minutes	hypoxia,	12	minutes	reoxygenation	prior	to	the	index	90	minutes	hypoxia.	
	























Trabeculae	 in	 all	 groups	 were	 comparable	 at	 baseline	 in	 terms	 of	average	 baseline	 force	 of	 contraction	 as	 shown	 in	 the	 table	 below.		Baseline	data	was	collected	at	the	end	of	the	90	minutes	stabilisation	period.	
	
Group	 Number	 Average	 contraction	
in	grams)	Sham	 1	 1.5	Control	 5	 0.86±0.09	Precondition	3+12	 8	 0.86±0.13	
	






Figure	 4.2.	 	 Graph	 showing	 recovery	 of	 function	 from	 onset	 of	
hypoxia.	
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To	 determine	 whether	 increasing	 the	 preconditioning	 protocol	






1. Controls	(n≥5):		Atrial	trabeculae	were	subjected	to	90	minutes	of	stabilisation,	 90	minutes	 of	 simulated	 ischaemia	 (index	hypoxia)	and	120	minutes	of	simulated	reperfusion	(reoxygenation).	
	
2. Hypoxic	 preconditioning	 (n≥4):	 	 Atrial	 trabeculae	 were	subjected	 to	 the	 same	 protocol	 as	 the	 hypoxia-reoxygenation	control	in	addition	to	a	longer	preconditioning	protocol	consisting	of	4	minutes	hypoxia,	10	minutes	re-oxygenation	prior	 to	 the	index	90	minutes	hypoxia.	
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Trabeculae	 in	 all	 groups	 were	 comparable	 at	 baseline	 in	 terms	 of	average	 baseline	 force	 of	 contraction	 as	 shown	 in	 the	 table	 below.		Baseline	data	was	collected	at	the	end	of	the	90	minutes	stabilisation	period.	
Group	 Number	 Average	 contraction	
in	grams)	Sham	 1	 1.5	Control	 5	 0.86±0.09	Precondition	4+10	 4	 0.79±0.10	











































































1. Controls	(n≥5):		Atrial	trabeculae	were	subjected	to	90	minutes	of	stabilisation,	 90	minutes	 of	 simulated	 ischaemia	 (index	hypoxia)	and	120	minutes	of	simulated	reperfusion	(reoxygenation).	
	
2. Hypoxic	 preconditioning	 (n≥4):	 	 Atrial	 trabeculae	 were	subjected	 to	 the	 same	 protocol	 as	 the	 hypoxia-reoxygenation	control	in	addition	to	a	longer	preconditioning	protocol	consisting	of	4	minutes	hypoxia,	16	minutes	re-oxygenation	prior	 to	 the	index	90	minutes	hypoxia.	
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A	 total	 of	 10	 patients	 were	 included	 for	 this	 set	 of	 experiments	including	 9	 males	 and	 1	 females,	 ages	 ranging	 from	 51	 to	 76,	inclusive.	 	33	atrial	trabeculae	were	isolated	from	these	appendages	of	which	10	were	included	in	the	study.		23	trabeculae	were	excluded	according	to	the	exclusion	criteria	mentioned	in	section	3.12.	
	
4.7.2.2	Baseline	functional	data	







Group	 Number	 Average	 contraction	
in	grams)	Sham	 1	 1.50	Control	 5	 0.86±0.19	Precondition	4+16	 4	 0.82±0.23	























































































To	determine	 the	appropriate	 stabilisation	 time	 following	 isolation	of	
trabeculae.			
	
Previous	 investigators	 have	 mostly	 used	 90	 minutes	 stabilisation	times	prior	to	any	form	of	intervention.	 	The	purpose	of	this	section	was	to	determine	whether	this	period	could	be	shortened	to	enable	maximum	 time	 to	 conduct	 experiment	 on	 the	 trabeculae.	 	 Stability	was	determined	by	assessing	whether	there	was	a	change	in	levels	of	Akt	 and	 Erk	 with	 time	 prior	 to	 evaluating	 the	 effect	 of	 SDF-1α	 on	functional	recovery.	
	
4.8.1	Experimental	protocol	









4.	 	Sample	 left	 in	circulating	buffer	 for	60	minutes	with	1µM	insulin	(1nM	in	cell	studies).	
5.		Sample	left	in	circulating	buffer	for	120	minutes.	




A	 total	 of	 4	 patients	 were	 included	 for	 this	 set	 of	 experiments	including	4	males	and	0	 females,	 ages	 ranging	 from	46	 to	78	years,	inclusive.	 	There	were	equal	numbers	of	patients	undergoing	either	CABG	 or	 aortic	 valve	 surgery.	 	 The	 mean	 weight	 of	 the	 atrial	
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60 mins + insulin
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4.8.2.4	Ratio	of	phosphorylated	kinase	to	total	kinase	present	

















All	 experiments	 conducted	 with	 the	 90	 minutes	 hypoxia	 duration	have	failed	to	demonstrate	the	ability	for	hypoxic	preconditioning	to	protect	human	tissue.	 	The	question	was	whether	the	90	minutes	of	hypoxia	 injured	 the	muscle	 to	 such	an	extent	 that	prevents	 it	being	successfully	 preconditioned.	 	 Therefore	 protocol	 that	 consisted	 of	shorter	durations	of	index	hypoxia	was	examined	in	this	section.		The	objective	was	 to	cause	enough	hypoxic	 injury	 to	allow	muscle	 to	be	preconditioned	successfully.	
	
4.9.1	Experimental	protocol	
The	 same	 standard	 stabilisation	 technique	 was	 used	 here	 as	 with	other	 experiments.	 	 Different	 index	 hypoxia	 durations	 were	employed	 upon	 here.	 	 All	 muscles	 were	 then	 reoxygenated	 for	 2	hours.		Trabeculae	were	randomly	assigned	to	one	of	2	protocols	(see	figure	25):		
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1. Control	with	45	minutes	index	hypoxia	(n≥4):		Atrial	trabeculae	were	 subjected	 to	 90	 minutes	 of	 stabilisation,	 45	 minutes	 of	
simulated	 ischaemia	 (index	 hypoxia)	 and	 120	 minutes	 of	simulated	reperfusion	(reoxygenation)	
	
2. Control	with	60	minutes	index	hypoxia	(n≥5):		Atrial	trabeculae	were	 subjected	 to	 90	 minutes	 of	 stabilisation,	 60	 minutes	 of	
simulated	 ischaemia	 (index	 hypoxia)	 and	 120	 minutes	 of	simulated	reperfusion	(reoxygenation).	
	
























Trabeculae	 in	 all	 groups	 were	 comparable	 at	 baseline	 in	 terms	 of	average	 baseline	 force	 of	 contraction	 as	 shown	 in	 the	 table	 below.		Baseline	data	was	collected	at	the	end	of	the	90	minutes	stabilisation	period.	
Group	 Number	 Average	 contraction	
in	grams)	Sham	 1	 1.5	Control	45	 4	 0.75±0.10	Control	60	 5	 0.73±0.10	
	





Index	 hypoxia	 duration	 of	 45	 and	 60	 minutes	 using	 the	 above	protocol	produced	a	significant	difference	in	the	recovery	of	function,	64.3	±	2.5%	and	32.0	±	6.6%	respectively,	p<0.05.		
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The	stabilisation	technique	varied	during	this	set	of	experiments.		In	previous	 experimental	 protocols,	 the	 suspended	 atrial	 trabeculae	would	undergo	stabilisation	by	applying	0.1g	stretch	at	the	beginning	of	the	protocol	to	stimulate	muscle	contraction	then	being	left	for	30	minutes.		The	muscle	would	then	be	stretched	over	15	minutes	to	the	peak	 of	 Frank-Starling	 curve	 before	 allowing	 a	 final	 stabilisation	phase	of	45	minutes.	 	 It	was	following	this	stabilisation	phase	when	experimental	intervention	would	be	applied.	
In	 this	 experimental	 set	 the	 muscle	 was	 stretched	 immediately	 to	0.5g	and	a	second	stretch	applied	into	20	minutes	of	the	protocol	as	the	 resting	 tension	 of	 the	 muscle	 would	 declining	 with	 a	corresponding	reduction	 in	 the	developed	 force.	 	The	muscle	would	then	 be	 left	 for	 the	 remainder	 of	 the	 stabilisation	 phase.	 	 This	 is	depicted	in	the	diagram	below.		Trabeculae	were	randomly	assigned	to	the	following	groups:	
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1. Limited	 stretch	 (n≥6):	 	 Atrial	 trabeculae	 were	 subjected	 to	 90	minutes	of	stabilisation	during	which	0.5g	stretch	was	applied	at	the	 start	 of	 the	 experiment	 followed	 by	 a	 second	 stretch	 at	 20	minutes	 into	 the	 protocol.	 	 This	 was	 followed	 by	 60	minutes	 of	simulated	ischaemia	(index	hypoxia)	and	60	minutes	of	simulated	reperfusion	(reoxygenation).	
	
2. Hypoxic	 preconditioning	 (n≥6):	 	 Atrial	 trabeculae	 that	 were	stretched	 by	 a	 limited	 number	 of	 times	 were	 subjected	 to	 a	preconditioning	protocol	consisting	of	4	minutes	hypoxia	and	16	
minutes	reoxygenation	prior	to	the	index	hypoxia	of	60	minutes.	
	


























Trabeculae	 in	 all	 groups	 were	 comparable	 at	 baseline	 in	 terms	 of	average	 baseline	 force	 of	 contraction	 as	 shown	 in	 the	 table	 below.		Baseline	data	was	collected	at	the	end	of	the	90	minutes	stabilisation	period.	
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Group	 Number	 Average	 contraction	
in	grams)	Sham	 1	 1.5	Control	 6	 0.94	±	0.11	Precondition	4+16	 6	 0.78±0.10	
	




The	 effect	 of	 stretch	 on	 the	 ability	 to	 precondition	 human	 atrial	
trabeculae.	


























































































To	 determine	 whether	 human	 muscle	 can	 be	 preconditioned	 under	
optimised	stabilisation	and	hypoxia	times	established	earlier.	
	
This	 final	 section	 of	 the	 human	 atrial	 characterisation	 explores	whether	 atrial	 trabeculae	 can	 now	 be	 preconditioned	 having	determined	what	 is	 assumed	 to	be	an	optimised	stabilisation	phase	and	a	hypoxia	time	that	is	sufficient	to	cause	muscle	injury	yet	leave	it	with	 the	 capacity	 to	undergo	preconditioning	 and	have	 enhanced	recovery	when	compared	to	control	specimens.	
	
4.11.1	Experimental	protocol	
The	 same	 standard	 stabilisation	 technique	 was	 used	 here	 as	 with	other	experiments.		The	index	hypoxia	duration	was	60	minutes.		All	muscles	 were	 then	 reoxygenated	 for	 2	 hours.	 	 Trabeculae	 were	randomly	assigned	to	one	of	2	protocols	(see	figure	30):	
			
1. Control	 (n≥11):	 	Atrial	 trabeculae	were	 subjected	 to	90	minutes	of	 stabilisation,	 60	 minutes	 of	 simulated	 ischaemia	 (index	
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hypoxia)	 and	 120	 minutes	 of	 simulated	 reperfusion	(reoxygenation)	
	
2. 	Hypoxic	 preconditioning	 (n≥10):	 	 Atrial	 trabeculae	 were	subjected	 to	 a	 preconditioning	 protocol	 consisting	 of	6	minutes	
hypoxia	 and	 4.5	 minutes	 reoxygenation	 prior	 to	 the	 index	hypoxia	of	60	minutes.	
	






















Trabeculae	 in	 all	 groups	 were	 comparable	 at	 baseline	 in	 terms	 of	average	 baseline	 force	 of	 contraction	 as	 shown	 in	 the	 table	 below.		Baseline	data	was	collected	at	the	end	of	the	90	minutes	stabilisation	period.	
Group	 Number	 Average	 contraction	
(grams)	Sham	 1	 1.5	Control		 11	 0.75±0.06	Precondition	 10	 0.74±0.07	
	





Preconditioning	 using	 the	 above	 protocol	 resulted	 in	 a	 significant	improvement	 in	 the	 recovery	 of	 function	 compared	 to	 the	 control	experiments,	47.6	±	3.7	%	and	26.9	±	1.8	%	respectively,	p<0.05.	
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of	 SDF-1α	 in	 the	 protection	 of	











There	 were	 41	 patients	 included	 in	 this	 set	 of	 experiments.	 	 All	patients	 met	 the	 inclusion	 criteria	 as	 described	 earlier.	 	 The	 table	below	outlines	the	profile	of	patients	that	were	included	in	this	part	of	the	study.		















Human	SDF-1α	(research	grade)	was	obtained	from	Miltenyi	Biotec,	Germany.	 	 They	 were	 supplied	 as	 100mcg	 vials	 and	 produced	 in	E.Coli.	 	 The	 ED50	 according	 to	 the	 manufacturers	 was	 between	 5-50ng/mL.		A	working	concentration	of	25ng/ml	was	chosen	based	on	previous	experimental	data	obtained	from	animal	models	(271,	272).		As	per	manufacturer	instructions,	reconstitution	was	suggested	with	deionized	sterile-filtered	water	to	a	final	concentration	between	0.1-
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Therefore	 for	 each	100μg	vial,	 16	 experiments	 (100/6.25)	 could	be	conducted.			
	
Using	 a	 pipette,	 62.5	 μl	 of	 the	 stock	 solution	 was	 transferred	 to	aliquots	 and	 stored	 at	 -20°C.	 	 To	 eliminate	 any	 errors,	 only	 15	experiments	 were	 conducted	 with	 each	 100μg	 vial	 and	 remainder	discarded.	 	 During	 the	 initial	 stabilisation	 phase,	 the	 frozen	 aliquot	would	be	removed	from	the	freezer	and	left	at	room	temperature	to	thaw	taking	around	5-minutes	to	complete	the	process.	 	When	SDF-
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1α	 was	 added	 directly	 into	 the	 organ	 bath	 using	 a	 pipette,	 the	aliquots	 were	 washed	 out	 repeatedly	 with	 circulating	 buffer	 to	ensure	all	the	contents	were	added.		
	
5.4.2	AMD	3100	octahydrochloride	
The	SDF-1α	inhibitor,	AMD	3100	(research	grade)	was	obtained	from	Tocris	 Bioscience,	 United	 Kingdom.	 	 They	 were	 supplied	 as	 10mg	vials.	 	 The	 IC50	 according	 to	 the	manufacturer	was	 between	 0.02	 –	0.13	μΜ	 for	CXCR4	 receptors.	 	A	working	 concentration	of	 5	μg/ml	was	 based	 on	 previous	 experimental	 data	 obtained	 from	 animal	models	 (272).	 	 As	 per	 manufacturer	 datasheet,	 reconstitution	 was	suggested	with	deionized	sterile-filtered	water	and	the	stock	solution	stored	 aliquoted	 in	 tightly	 sealed	 vials	 at	 -20°C	 or	 below	 and	 used	within	one	month.	














This	study	evaluated	 the	effect	of	SDF-1α	given	30	minutes	prior	 to	the	 index	 hypoxia	 on	 functional	 recovery	 of	 atrial	 trabeculae.	 	 The	dose	 of	 25	 ng/ml	 SDF-1α	was	 chosen	 based	 on	 previous	 literature	that	illustrated	the	effective	dose	(Huang	2011).		The	protocols	used	in	this	experiment	are	depicted	in	figure	X	and	are	as	follows:	
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1. Sham	 (n≥1):	 	 Atrial	 trabeculae	 were	 allowed	 to	 contract	 for	 a	minimum	of	2-hours	following	the	stabilisation	phase	in	the	organ	bath	 where	 they	 were	 superfused	 with	 oxygenated	 modified	Tyrode’s	 solution	 and	 paced	 at	 1	 Hz	 without	 any	 further	experimental	manipulation.		
	
2. Controls	(n≥11):		Atrial	trabeculae	were	subjected	to	90	minutes	of	 stabilisation,	 60	 minutes	 of	 simulated	 ischaemia	 (index	hypoxia)	 and	 60	 minutes	 of	 simulated	 reperfusion	(reoxygenation)	
	
3. SDF-1α	 (n≥11):	 	 Atrial	 trabeculae	 were	 subjected	 to	 the	 same	protocol	as	control	with	SDF-1α	administered	30	minutes	prior	to	index	hypoxia	 (60	minutes	 into	 stabilisation).	 	This	 ensured	 that	all	CXCR-4	receptors	were	saturated.			
	
4. SDF-1α	 +	 AMD-3100	 5μg/ml	 (n≥4):	 	 Atrial	 trabeculae	 were	subjected	 to	 the	 same	 protocol	 as	 control	 with	 AMD-3100	administered	 10	 minutes	 prior	 to	 the	 addition	 of	 SDF-1α	 	 (50	minutes	 into	 stabilisation).	 	 This	 ensured	 that	 all	 CXCR-4	receptors	were	antagonised.			
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5. SDF-1α	 +	 AMD-3100	 10μg/ml	 (n≥10):	 	 Atrial	 trabeculae	 were	subjected	 to	 the	 same	 protocol	 as	 control	 with	 AMD-3100	administered	 10	 minutes	 prior	 to	 the	 addition	 of	 SDF-1α	 	 (50	minutes	 into	 stabilisation).	 	 This	 ensured	 that	 all	 CXCR-4	receptors	were	antagonised.			
	
























Figure	 5.2.	 	 Protocols	 used	 in	 SDF1α	 experiments.	 	 Vertical	























A	 total	 of	 41	 patients	 were	 included	 in	 this	 set	 of	 experiments,	 6	female	and	35	male.		The	ages	ranged	from	45	to	79.	
	
5.5.2.2	Baseline	functional	data	
Trabeculae	 in	 all	 groups	 were	 comparable	 at	 baseline	 in	 terms	 of	average	 baseline	 force	 of	 contraction	 as	 shown	 in	 the	 table	 below.		Baseline	data	was	collected	at	the	end	of	the	90	minutes	stabilisation	period.	
Group	 Number	 Average	 contraction	





















































































































SDF-1α + AMD 5










As	mentioned	previously	Dr	Jose	Vincencio	conducted	this	part	of	my	study.		The	purpose	was	to	confirm	the	presence	of	SDF-1α	receptors	on	human	tissue.		The	method	is	described	in	chapter	3,	section	3.14	immunuhistochemistry.	 	 Rat	 and	 mice	 whole	 heart	 and	cardiomyocyte	 (CM),	 are	 known	 to	 contain	 CXCR4	 receptors	 were	used	as	a	positive	controls.	
	
5.6.2 Western	blots	




























As	 mentioned	 earlier	 Dr	 Jose	 Vincencio	 conducted	 this	 part	 of	 my	study.	 	 The	 purpose	 was	 to	 confirm	 the	 activation	 of	 the	 RISK	pathway.	 	 The	 method	 is	 described	 in	 chapter	 3,	 section	 3.14	immunuhistochemistry.	 	Insulin,	which	is	known	to	activate	Akt	and	Erk	was	used	as	a	positive	control.	
	
5.7.2 Western	blots	










The	present	study	confirms	(1)	the	presence	and	location	of	SDF-1α	receptors	(CXCR4)	 in	human	adult	cardiomyocytes	(2)	 the	ability	of	SDF-1α	 to	 attenuate	 the	detrimental	 effects	of	 IRI	 on	human	 tissue,	(3)	 using	 the	 specific	 receptor	 blocker,	 AMD3100,	 can	 attenuate	benefits	 conferred	 by	 chemically	 preconditioning	 by	 SDF-1α,	 (4)	AMD3100	 itself	 has	 no	 effect	 on	 the	 functional	 recovery	 of	 human	trabeculae	subjected	to	IRI	compared	to	control,	(5)	preconditioning	effects	of	 SDF-1α	 could	 at	 least	be	partly	 explained	by	 activation	of	prosurvival	 kinases	 such	 as	 Erk	 1/2	 and	 (6)	 the	 ability	 to	 protect	human	atrial	 trabeculae	 from	 the	detrimental	 effects	of	 IRI	 through	hypoxic	preconditioning.			
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6.2 Human	 trabeculae	 can	 be	 preconditioned	with	 simulated	
ischaemia.	
The	present	study	confirms	(a)	isolated	human	atrial	muscle	may	be	 protected	 from	 a	 hypoxic	 insult	 (simulated	 ischaemia)	 by	preconditioning	with	substrate-free	hypoxic	Tyrode’s	solution	and	rapid	pacing,	(b)	a	stabilisation	time	of	60	minutes	is	sufficient	in	the	 atrial	 trabecular	 model	 of	 preconditioning	 and	 (c)	 an	 index	ischaemic	 insult	 of	 60	minutes	 is	 adequate	 to	 induce	 injury	 and	also	 allow	 a	 preconditioning	 protocol	 to	 be	 applied	 to	demonstrate	protection	 i.e.	 in	our	 study	our	 trabeculae	was	able	to	withstand	60	minutes	hypoxia	and	delay	cell	death	induced	by	hypoxic	preconditioning.	
There	 are	 now	 several	 clinical	 studies	 that	 suggest	preconditioning	 occurs	 in	 humans,	which	 are	 described	 in	more	detail	in	the	introduction	to	this	thesis	in	section	1.5.8.			
	
6.3 Difficulties	encountered	with	preconditioning.	
During	 this	 study	 it	 was	 essential	 to	 demonstrate	 the	 ability	 to	precondition	human	atrial	 trabeculae	 in	order	 to	have	a	positive	control	 for	 experiments	 against	 lethal	 reperfusion	 injury.		
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Previous	 investigators	 at	 the	Hatter	Cardiovascular	 Institute	had	demonstrated	the	existence	of	this	in	several	studies	as	outlined	in	the	 introduction.	 	 With	 advances	 in	 clinical	 pharmacotherapy,	many	of	which	have	preconditioning	properties,	it	was	essential	to	establish	that	preconditioning	continued	to	exist	in	human	heart.	
Previously	 the	 experiments	 conducted	 at	 this	 Institute	 consisted	of	75	minutes	stabilisation	time	followed	by	90	minutes	simulated	ischaemia	 with	 subsequent	 2	 hours	 re-oxygenation.		Preconditioning	 applied	 prior	 to	 index	 hypoxic	 insult	 ranged	between	 3	 -	 4	minutes	 of	 simulated	 ischaemia	 followed	 by	 7-16	minutes	 of	 reoxygenation.	 	Most	 authors	 used	 3+7	 protocol	 and	were	able	to	successfully	precondition	human	muscle.	
In	 this	 study,	 the	 initial	 protocol	 implemented	 consisted	 of	 90	minutes	 simulated	 ischaemia	 followed	 by	 120	 minutes	reoxygenation	to	achieve	a	functional	recovery	between	25-35%;	this	 was	 consistent	 with	 previous	 studies	 at	 the	 Hatter	Cardiovascular	 Institute.	 	 However,	 preconditioning	 with	 a	protocol	consisting	of	3	minutes	simulated	ischaemia	followed	by	12	minutes	 reoxygenation	based	on	previous	 investigators	 failed	to	 precondition	 trabeculae.	 	 Subsequent	 protocols	with	 stronger	preconditioning	 stimulus	 (4+10	 and	 4+16)	 also	 failed	 to	
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successfully	 precondition	 human	 muscle.	 	 The	 reason	 for	increasing	 the	 stimulus	 was	 partly	 based	 on	 previous	 work	 on	human	diabetic	heart	preconditioning	at	this	Institute	where	with	an	established	protocol	(4+16)	failed	to	precondition	muscle	and	a	stronger	stimulus	(7+16)	was	required	 to	be	able	 to	successfully	precondition	 (267).	 	 Besides	 increasing	 the	 preconditioning	hypoxia	time,	the	reoxygenation	time	was	also	increased	as	it	was	felt	 that	 the	 trabeculae	 may	 gain	 benefit	 by	 the	 process	 of	catabolite	 washing	 that	 would	 have	 accumulated	 during	 the	hypoxic	episode.	
There	 may	 be	 several	 considerations	 why	 it	 may	 have	 been	difficult	to	precondition	trabeculae.	 	During	recruitment,	patients	had	to	meet	strict	exclusion	criteria	outlined	in	section	3.5.1.	and	trabeculae	 were	 excluded	 according	 to	 criteria	 in	 section	 3.12.		Despite	 reaching	 the	 expected	 baseline	 contractility	 of	 0.5g	 it	 is	possible	 that	during	the	harvesting	process,	handing	of	 the	atrial	appendage	 may	 have	 caused	 mechanical	 injury	 that	 was	 not	apparent	 macroscopically	 but	 somehow	 prevented	 them	 from	being	 preconditioned.	 	 Furthermore	 there	 was	 a	 time	 delay	between	harvesting	 the	appendage	and	 	 	 isolating	 the	 trabeculae	to	 starting	 the	 experiment.	 	 A	 solution	 to	 overcome	 time	 delay	
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could	 be	 to	 have	 a	 laboratory	 within	 the	 hospital	 next	 to	 the	cardiac	 theatres	 so	 that	 harvested	 appendage	 could	 be	 placed	immediately	 in	warm	 oxygenated	 buffer	 and	 trabeculae	 isolated	with	minimal	 interruption.	 	Transport	to	the	 laboratory	from	the	hospital	 is	 likely	to	incur	some	thermal	injury	with	cooling	down	to	 4°C	 which	 is	 necessary	 to	 reduce	 the	 metabolic	 rate	 of	 the	cardiomyocytes.		
Other	 important	 considerations	 are	 the	 diabetic	 status	 and	 drug	history	 of	 the	 patients.	 	 It	 has	 been	 established	 that	 diabetic	patients	 require	 an	 enhanced	 preconditioning	 stimulus	 to	 be	preconditioned;	 this	 is	 at	 least	 partly	 due	 to	 down-regulation	 of	the	PI3K-Akt	signalling	pathway	(267).		Many	patients	recruited	in	this	 study	 were	 not	 diabetic	 as	 this	 was	 an	 exclusion	 criterion	(section	3.5.1).	 	However,	with	a	high	prevalence	of	undiagnosed	diabetes	 in	 the	UK,	 it	 is	possible	 that	patients	were	not	aware	of	their	 glycaemic	 status.	 	 Also	 no	 formal	 tests	were	 carried	 out	 to	exclude	 this.	 	With	 increasing	 prevalence	 of	 diabetes,	 this	 partly	may	 explain	 why	 the	 trabeculae	 in	 this	 study	 failed	 to	 get	preconditioned	 with	 an	 established	 standard	 protocol	 but	required	a	higher	stimulus.		It	may	have	been	a	useful	exercise	to	exclude	diabetes	biochemically	prior	to	recruitment	into	study.	
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Many	 patients	 recruited	 in	 this	 study	 were	 on	 several	 cardiac	drugs	that	may	have	a	direct	preconditioning	effect.	 	These	drugs	include	statins,	beta-blocking	drugs	and	ACEi.		In	an	isolated	atrial	trabecular	 model	 by	 Dr	 Rees	 at	 the	 Hatter	 Cardiovascular	Institute,	 high	 dose	 atorvastatin	 administered	 12	 hours	 before	cardiac	 surgery	 has	 been	 shown	 to	 improve	 functional	 recovery	when	compared	to	patients	on	chronic	statin	therapy	(273).	 	It	is	known	 from	 earlier	 studies	 that	 bradykinin	 is	 a	 trigger	 for	preconditioning	(274).	 	 In	a	subsequent	experiment	by	Morris	et	al,	 pretreatment	 with	 an	 ACEi	 combined	 with	 a	 subthreshold	preconditioning	stimulus	lead	to	an	improved	function	recovery	in	isolated	 human	 atrial	 trabeculae	 as	 seen	 with	 a	 standard	preconditioning	 stimulus	 (108).	 	 Other	 drugs	 that	 have	preconditioning	 effects	 would	 include	 opioid	 analgesia	 given	 at	anaesthetic	induction	–	this	has	also	been	shown	in	a	human	atrial	trabecular	 model	 to	 precondition	 muscle	 (133).	 	 Similarly	anaesthetic	 preconditioning	 with	 volatile	 anaesthesia	 is	 a	 well-described	phenomenon	and	has	been	shown	to	provide	protection	against	ischaemia-reperfusion	injury	(275).		All	patients	recruited	in	this	study	were	subjected	to	volatile	anaesthesia.		If	these	drugs	were	 to	 precondition	 the	 heart	 then	 the	 functional	 recovery	
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following	 standard	 hypoxia-reoxygenation	 protocol	 would	 have	been	higher,	which	was	not	 the	case	 in	 this	 study.	 	An	argument	against	this	could	be	that	the	beneficial	effects	of	these	agents	may	not	have	been	apparent	as	 in	classical	preconditioning,	 there	 is	a	temporal	 relationship	between	 the	preconditioning	 stimulus	 and	index	 hypoxia.	 (1st	 window	 of	 PC	 has	 passed).	 	 Blockers	 of	preconditioning	 include	 sulphonylureas	 (diabetic	 drug),	 which	does	 not	 apply	 in	 this	 study.	 	 Briefly	 it	 is	 thought	 to	 block	preconditioning	 by	 blocking	 ATP-sensitive	 K+	 channels	 (KATP	channels)	(106-107).	
Given	the	inability	to	precondition	human	tissue,	the	next	part	of	the	 study	was	 therefore	 to	 re-characterise	 the	human	 trabecular	model	despite	its	use	since	1990’s.		The	first	characterisation	step	established	 whether	 a	 stabilisation	 time	 of	 90	 minutes	 was	necessary.		This	was	evaluated	by	assessing	the	ratios	of	activated	Akt	 or	 Erk	 to	 total	 Akt	 or	 Erk.	 	 Insulin	 was	 used	 as	 a	 positive	control	 as	 it	 has	 been	 established	 to	 activate	 both	 these	 kinases	(276).		Finding	from	this	part	of	the	study	suggested	high	ratio	of	kinases	 at	 10	 and	 30	 minutes	 with	 a	 reduction	 at	 60	 minutes.		There	 was	 no	 significant	 difference	 at	 120	 minutes.	 	 At	 60	minutes,	 addition	 of	 insulin	 increased	 kinase	 ratios	 confirming	
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there	 was	 still	 capacity	 for	 muscle	 to	 be	 preconditioned.		Therefore	a	stabilisation	time	of	90	minutes	was	chosen	to	allow	muscle	to	settle	 for	at	 least	45	minutes	 following	achievement	of	the	peak	of	the	Frank-Starling	curve.	
We	then	investigated	different	hypoxia	times.			Although	a	hypoxia	time	of	90	minutes	was	achieving	a	functional	recovery	similar	to	previous	 investigators,	 it	 may	 have	 been	 that	 this	 exceeded	 the	level	 of	 damage	 caused	 to	 cardiomyocytes	 to	 enable	 them	 to	 be	preconditioned.	 	 90	minutes	 hypoxia	 times	may	 have	 caused	 so	much	damaged	to	the	CM	that	the	efficacy	of	PC	was	diminished.	Index	hypoxia	times	of	45	and	60	minutes	were	chosen.		With	a	45	minutes	 hypoxia	 time,	 insufficient	 muscle	 injury	 was	 caused	therefore	 a	 longer	hypoxia	 time	of	60	minutes	was	 trialed.	 	This	produced	 similar	 injury	 levels	 to	 that	 of	 90	 minutes	 hypoxia	therefore	a	hypoxia	time	of	60	minutes	were	taken	as	part	of	the	protocol.		What	has	been	established	from	Murrys	original	study	is	that	 preconditioning	 act	 to	 delay	 rather	 than	 prevent	 cell	 death.		In	their	earlier	observation,	rate	of	ATP	depletion	was	equivalent	in	 control	 and	preconditioned	 cell	 but	 cell	 death	was	 reduced	 in	the	preconditioned	cells	implying	they	were	more	resistant	to	the	detrimental	 effects	 of	 hypoxia.	 	 However,	 when	 a	 prolonged	
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ischaemia	time	was	applied,	the	benefits	of	preconditioning	were	abolished	 confirming	 preconditioning	 acts	 to	 delay	 cell	 death.		What	is	also	known	from	previous	studies	that	there	is	a	temporal	aspect	 to	 preconditioning;	 that	 is,	 there	 is	 a	 limit	 to	 how	much	ischaemia	 cells	may	 resist	 or	withstand.	 	Murrys	 original	 canine	study	consisted	of	40	minutes	circumflex	occlusion	followed	by	4	days	of	reperfusion.		Nao	et	al	(80)	demonstrated	this	in	a	similar	canine	 model	 to	 Murry	 where	 the	 protection	 conferred	 by	preconditioning	 was	 maintained	 with	 60	 minutes	 of	 coronary	occlusion	but	lost	with	90	minutes	of	occlusion.		This	may	indeed	be	one	of	many	reasons	why	in	this	study,	human	muscle	failed	to	be	preconditioned	with	90	minutes	hypoxia.	
The	next	question	was	whether	the	gradual	stretching	during	the	stabilisation	 period	 affected	 the	 ability	 to	 precondition	 isolated	human	 trabeculae.	 	 Dr	 Rees	 established	 a	 similar	 model	 at	 the	Hatter	Cardiovascular	Institute	where	a	single	stretch	was	applied	at	 the	 outset	 of	 the	 experiment	 and	 left	 to	 stabilise	 before	protocols	 were	 applied.	 	 This	 was	 the	 case	 irrespective	 of	 the	length	or	width	of	trabeculae.		A	criticism	was	how	the	same	force	can	be	applied	to	different	trabeculae	and	how	would	one	ensure	the	peak	of	the	Frank-Starling	curve	was	achieved?	What	is	known	
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is	 overstretching	 atrial	 muscle	 could	 have	 a	 negative	 inotropic	effect	 (270).	 	 Bearing	 this	 in	 mind,	 a	 comparison	 was	 made	between	multiple	stretches	and	minimal	stretches	(that	consisted	of	 a	 stretch	 at	 the	 beginning	 and	 again	 20	 minutes	 into	 the	experiment).	 	 The	 finding	 from	 this	 part	 of	 the	 study	 confirmed	there	was	no	significant	difference	in	functional	recovery	between	the	 control	 and	 preconditioned	 (4+16)	 trabeculae	 whether	 they	were	 stretched	 multiple	 times	 or	 minimally.	 	 These	 findings	contradict	 earlier	 studies	 on	 stretch-induced	 preconditioning.		Ovize	 and	 colleagues	 were	 the	 first	 authors	 to	 propose	 that	preconditioning	 triggered	 by	 brief	 ischaemia	 lead	 to	 transient	stretching	or	dilatation	(stretching),	questioning	whether	if	it	was	the	effect	of	stretch	that	induced	the	protective	effects	rather	than	ischaemia	per	se.		This	was	confirmed	in	their	canine	model	where	acute	 volume	 overloading	 their	 heart	 leads	 to	 reduced	 infarct	sizes.		Furthermore	they	proposed	that	the	protection	afforded	by	stretch	 was	 mediated	 by	 stretch-activated	 channels	 that	 was	abolished	 in	 the	 presence	 of	 Gd3+,	 which	 is	 a	 potent	 blocker	 of	stretch-activated	channels	(254).		Nakagawa	et	al	used	an	isolated	perfused	heart	Langendorff	model	to	demonstrate	that	stretch	(a	form	 of	 non-ischemic	 stress),	 induced	 by	 transiently	 increasing	
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left	 ventricular	 end	 diastolic	 pressure	 (LVEDP)	 for	 5	 minutes	preconditioned	 rats	 hearts	 as	 demonstrated	 by	 improved	haemodynamic	 parameters	 of	 LVEDP	 and	 left	 ventricular	developed	pressure	(LVDP).		Importantly	coronary	blood	flow	did	not	 alter	 during	 the	 increase	 in	 LVEDP	 hence	 the	 term	 ‘non-ischaemic	stress’	(277).		In	another	study	by	Gysembergh	et	al,	an	in-vivo	rabbit	model	was	used	to	demonstrate	preconditioning	by	stretch	 where	 this	 was	 induced	 by	 transient	 volume	 overload.		The	 same	 authors	 went	 on	 to	 describe	 the	 similarities	 in	mechanistic	 that	 exist	 between	 ischaemic	 preconditions	 and	stretch	 preconditioning	 such	 as	 downstream	 activation	 of	 PKC,	adenosine	receptors	and/or	K+ATP	channels	(107).			
There	may	be	several	explanations	why	stretching	the	trabeculae	did	 not	 precondition	 the	 heart;	 the	 studies	 mentioned	 above	involve	whole	hearts	compared	to	 isolated	atrial	 trabeculae	used	in	this	study.		Secondly	the	stretch	induced	was	rapid;	in	the	study	by	 Nakagawa	 et	 al	 (253),	 LVEDP	 was	 rapidly	 increased	 from	 a	baseline	of	10	mmHg	to	either	30	or	60	mmHg.		In	comparison,	the	trabeculae	were	stretched	gradually	over	15	minutes	to	the	peak	of	 the	 Frank-Starling	 curve	 with	 each	 stretch	 with	 the	micromanipulator	not	exceeding	a	force	of	0.1g	and	0.05g	towards	
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the	peak.	 	 It	 could	be	 that	a	 sudden	 large	 stretch	 is	necessary	 to	activate	 the	 stretch-activated	 channels.	 	 This	 could	 be	 related	 to	work	by	Downey	 and	 colleagues	 (274)	who	proposed	 that	 there	was	a	summative	interaction	of	preconditioning	triggers	such	that	a	particular	threshold	must	attained	to	achieve	analogous	to	‘all	or	none’	phenomenon	seen	with	action	potentials.	 	This	concept	has	been	 illustrated	 in	 this	 laboratory	 using	 an	 isolated	 atrial	trabecular	 model	 where	 two	 separate	 stimuli	 (elevated	bradykinin	 by	 ACEi	 or	 sublethal	 hypoxia)	 were	 inadequate	 to	provoke	 a	 preconditioning	 response	 when	 administered	separately,	 but	 in	 combination,	 a	 full	 protective	 response	 was	detected	(108).				





These	experiments	demonstrate	 that	 SDF-1α	protects	human	 tissue	from	 lethal	 reperfusion	 injury.	 	 The	 key	 findings	 in	 this	 part	 of	 the	study	 are	 as	 follows:	 (1)	 the	 presence	 and	 location	 of	 SDF-1α	receptors	(CXCR4)	 in	human	adult	cardiomyocytes	(2)	 the	ability	of	SDF-1α	 to	 attenuate	 the	detrimental	 effects	of	 IRI	 on	human	 tissue,	(3)	 using	 the	 specific	 receptor	 blocker,	 AMD3100,	 can	 attenuate	benefits	 conferred	 by	 chemically	 preconditioning	 by	 SDF-1α,	 (4)	AMD3100	 itself	 has	 no	 effect	 on	 the	 functional	 recovery	 of	 human	trabeculae	 subjected	 to	 IRI	 compared	 to	 control	 and	 (5)	preconditioning	effects	of	 SDF-1α	could	at	 least	be	partly	 explained	by	activation	of	prosurvival	kinases.			
In	 this	 study	we	demonstrate	 that	SDF-1α	at	25	ng/ml,	 for	 the	 first	time,	 protects	 human	 atrial	 trabeculae	 subjected	 to	 simulated	ischaemia-reperfusion	 injury.	 	 This	 finding	 is	 consistent	 with	published	data	obtained	from	animal	models	where	SDF-1α	has	been	shown	 to	 confer	 myocardial	 protection	 in	 MI	 related	 to	 the	modulation	 of	 ischaemia-reperfusion	 injury	 rather	 than	 stem	 cell	recruitment	(278).	 	Saxena	et	al	demonstrated	intracardiac	injection	of	SDF-1α	into	the	myocardium	adjacent	to	the	ischaemic	zone	at	the	
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time	 of	 ligation	 of	 left	 anterior	 descending	 artery	 in	 mice	 hearts	resulted	 in	 significantly	 better	 cardiac	 function	 after	 an	MI	 through	activation	 of	 cell	 survival	 kinase,	 protein	 kinase	 B/Akt	 within	endothelial	cells	and	myocytes	of	mice	hearts	(247).			
In	 a	 separate	 murine	 model	 of	 ischaemic	 preconditioning,	 Hu	 and	colleagues	were	able	 to	demonstrate	 increased	 levels	of	myocardial	SDF-1α	 mRNA	 (cardiac	 myocytes	 and	 fibroblasts).	 	 In	 isolated	myocytes,	 increased	 phosphorylation	 of	 both	 Erk	 1/2	 and	 Akt	 and	decreased	phosphorylation	of	JNK	and	p38	were	noted	when	CXCR4	receptors	were	activated	with	SDF-1α	(243).			
It	is	important	to	understand	that	pre-ischaemic	exposure	of	SDF-1α	to	the	myocardium,	as	was	the	case	with	this	study,	 is	 less	clinically	relevant	unless	ischaemia	is	planned	such	as	during	cardiac	surgery	or	 transplantation.	 	 However	 there	 have	 been	 studies	 that	 have	examined	 the	 role	 of	 SDF-1α	 targeting	 specifically	 the	 reperfusion	phase	 i.e.	 post-ischaemia	 that	 would	 be	 more	 clinically	 relevant	following	 an	 MI	 (278).	 	 In	 this	 experimental	 study	 by	 Jang	 et	 al,	Langendorff	 isolated	 rat	hearts	 infused	with	varying	 concentrations	of	SDF-1α	10	mins	prior	to	reperfusion	reduced	the	area	of	necrosis	relative	 to	 the	 area	 at	 risk	 in	 a	 dose	 dependent	manner.	 	 This	was	abolished	 in	 the	 presence	 of	 AMD-3100	 given	 10	 minutes	 prior	 to	
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SDF-1α.	 	Similar	results	were	noted	with	pre-ischaemic	exposure	 to	SDF-1α.	 	 Interestingly,	 authors	 noted	 the	 infarct	 sparing	 effect	was	greater	 than	 that	 seen	 with	 ischaemic	 pre	 and	 post-conditioning.		These	 findings	 are	 similar	 to	 this	 study	 where	 pre-ischaemic	exposure	to	SDF-1α	lead	to	improved	functional	recovery	and	effects	abolished	 when	 AMD-3100	 was	 administered	 10	 minutes	 prior	 to	SDF-1α.	
	
Another	 important	 finding	 in	 the	 present	 study	 is	 the	phosphorylation	of	Erk	1/2	by	SDF-1α	in	cardiomyocytes.		This	again	is	consistent	with	many	experimental	 finding	such	as	work	done	by	Hu	et	al	noted	an	increase	in	phosphorylation	of	Erk	1/2	and	Akt	in	isolated	 rat	 cardiomyocytes	 when	 CXCR4	 receptor	 were	 activated	with	 SDF-1α	 	 (221).	 	 In	 a	 separate	 study	by	 Jang	 et	 al,	 the	 effect	 of	SDF-1α	on	myocardial	protection	during	 the	 reperfusion	phase	was	studied.		This	was	performed	using	a	Langendorff	model	where	SDF-1α	was	added	to	the	reperfusion	buffer	following	LAD	ligation	in	rat	hearts	to	demonstrate	a	reduction	in	area	of	necrosis:	area	at	risk	in	a	dose	dependent	manner.	 	 Furthermore,	 the	 involvement	of	Akt	 and	Erk	were	demonstrated	during	post	conditioning	of	rat	hearts	(278).		Interestingly,	Akt	phosphorylation	was	not	demonstrated	with	SDF-
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6.5.1	 Effectiveness	 of	 hypoxia	 at	 inducing	 preconditioning	
compared	to	true	ischaemia.	
Important	differences	exist	between	 true	 ischaemia	seen	 in	real	 life	compared	 to	 experimental	 models	 where	 in	 this	 study	 hypoxia	 or	‘simulated	ischaemia’	is	emulated.		In	our	study	this	was	achieved	by	using	hypoxic	substrate	free	buffer	in	conjunction	with	rapid	pacing.			
The	degree	 of	metabolite	 accumulation	 in	 true	 ischaemia	 is	 greater	than	 that	observed	 in	experimental	models	and	 the	pH	change	may	not	be	to	the	same	degree	(279).		Therefore	it	may	not	be	possible	to	
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extrapolate	 the	 findings	 from	this	study	where	preconditioning	was	produced	 by	 simulated	 ischaemia	 to	 circumstances	 of	preconditioning	with	 ischaemia.	 	However,	 there	 is	now	a	wealth	of	evidence	 from	 experimental	 models	 that	 simulated	 ischaemia	 is	 as	effective	 as	 ischaemia	 in	 eliciting	protection.	 	These	 include	models	consisting	of	 cell	 culture	models,	 global	and	regional	 ischaemia.	 	To	illustrate	 this,	 Lasley	 et	 al	 demonstrated	 the	 comparable	effectiveness	 of	 preconditioning	 using	 ischaemia	 and	 hypoxia	 in	 a	Langendorff	model	using	rat	hearts	where	the	hearts	were	subjected	to	 either	 5	 minutes	 of	 hypoxia	 or	 ischaemia.	 	 Lasley	 observed	 the	same	 post-ischaemic	 functional	 recovery	 in	 both	 groups	 and	proposed	 that	 reduced	 oxygen	 delivery	 to	 the	 tissue	 was	 more	important	 than	metabolite	 accumulation	 to	 induce	 preconditioning.		In	 a	 similar	model	 by	 Engleman	 et	 al,	 the	 effect	 of	 preconditioning	with	 hypoxia	 was	 compared	 against	 rat	 hearts	 without	preconditioning	 on	 cell	 necrosis	 (assessed	 by	 LDH	 release)	 and	functional	 recovery.	 	 Preconditioning	 with	 10	 minutes	 of	 hypoxia	ensued	a	reduction	in	cell	necrosis	and	improved	functional	recovery	suggesting	 hypoxia	 is	 an	 effective	 preconditioning	 stimulus	 (280).		Using	a	cell	culture	model,	Webster	et	al	have	also	demonstrated	the	
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ability	 to	 successfully	 precondition	 neonatal	 rat	 myocytes	 using	hypoxia	(281).	
	
6.5.2	 Improvement	 of	 functional	 recovery	 equating	 to	 reduced	
cell	death.	
This	 study	 uses	 force	 of	 contraction	 as	 a	measure	 and	 recovery	 of	function	as	a	surrogate	marker	of	muscle	injury.		It	does	not	measure	the	 degree	 of	 necrosis.	 	 Experimental	 protocol	 used	 in	 this	 study	were	as	long	as	230	minutes.		It	is	probable	that	there	was	an	area	of	central	 necrosis	 with	 contractions	 being	 due	 to	 the	 outermost	cardiomyocytes	 and	 by	 the	 end	 of	 the	 protocol	 there	 is	 almost	certainly	 likely	 to	 be	 a	 further	 reduction	 of	 viable	 cells.	 	 Therefore	further	 experiments	 such	 as	 Western	 blotting	 to	 evaluate	 survival	kinases	 is	 difficult,	 thus	 this	model	 provides	 only	 indirect	 evidence	through	functional	recovery	in	relation	to	preconditioning.		However,	other	 in	 vitro	 experiments	 by	 Jenkins	 et	 al	 have	 demonstrated	 an	infarct	 sparing	 effect	 with	 preconditioning	 where	 improvement	 of	global	 left	 ventricular	 function	 mediated	 through	 preconditioning	was	 proportional	 to	 a	 reduction	 in	 infarct	 volume	 (282).		Furthermore	earlier	investigators	including	Pryzklenk	et	al	(79)	and	
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Cohen	et	al	(75)	were	able	to	associate	improved	recovery	of	systolic	shortening	 to	 a	 reduction	 in	 infarct	 size	 in	 an	 in	 vivo	 model	 of	regional	ischaemia.		To	date	there	is	no	direct	evidence	in	an	isolated	trabecular	model	 that	 improved	 functional	 recovery	 is	 related	 to	 a	reduction	in	infarct	volume	but	given	the	body	of	evidence,	it	is	likely	to	be	the	case.			





At	present,	 to	 the	best	of	my	knowledge,	 there	are	no	 clinical	 trials	exploring	 the	 role	 of	 SDF-1α	 in	 the	 context	 of	 a	 myocardial	ischaemia-reperfusion	 injury	 model.	 	 Kim	 et	 al	 have	 assessed	 the	release	 of	 SDF-1α	 in	 cardiac	 surgery	 patient	 and	 have	 noted	 their	release	 specifically	 during	 myocardial	 ischaemia	 but	 not	 during	reperfusion	whilst	also	noting	an	inverse	relationship	between	SDF-1α	release	and	organ	dysfunction	(284).	





The	present	study	demonstrates	that	preconditioning	continues	to	be	effective	 in	 human	 tissue	 even	 after	 3	 decades	 since	 the	 initial	discovery,	despite	advances	 in	medical	 therapy	 that	have	 important	preconditioning	effects.			SDF-1α/CXCR4	axis	may	play	a	central	role	in	preconditioning	 the	myocardium	 in	human	and	other	 species.	 	 It	demonstrates	 that	 preconditioning	 may	 be	 mediated	 through	activation	of	Erk	1/2	kinases	that	has	been	shown	in	all	other	forms	of	 conditioning.	 	With	 limited	 numbers	 of	 patients	 recruited	 in	 this	study,	the	findings	must	be	reviewed	with	this	in	mind.		This	study	is	the	 first	 to	demonstrate	 that	SDF-1α	has	 the	ability	 to	precondition	human	myocardium.	





Given	 the	 challenges	 encountered	 during	 this	 research	 period	 for	preconditioning,	it	would	be	suggested	that	future	patients	recruited	should	all	have	biochemical	exclusion	of	diabetes	mellitus.	
If	time	was	permitted,	it	would	also	be	interesting	to	explore	whether	with	 the	 optimal	 stabilisation	 and	 hypoxia	 times,	 atrial	 trabeculae	could	 be	 preconditioned	 with	 the	 same	 preconditioning	 protocol	used	 earlier	 that	 failed	 with	 the	 longer	 duration	 of	 hypoxia	 and	reoxygenation	times.			
Only	 a	 single	 dose	 of	 SDF-1α	 was	 used	 based	 on	 published	experimental	 studies.	 	 It	 would	 be	 valuable	 to	 perform	 a	 dose	response	curve	in	human	tissue	with	SDF-1α	as	well	as	AMD-3100.	
Finally,	 the	 use	 of	 specific	 inhibitors	 of	 the	 RISK	 pathway	 in	 the	presence	of	 SDF-1α	 to	demonstrate	protection	 is	mediated	 (at	 least	partially)	through	this	pathway	would	be	a	valuable	demonstration.	
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PATIENT INFORMATION SHEET-CONFIDENTIAL 
 
 
An investigation into the effects of potential cardioprotective therapies on human 
heart muscle 
We are undertaking research to identify agents that will have a significant effect of protecting the heart during coronary artery bypass graft 
surgery or limit the damage caused by a heart attack. Research has shown that it is possible to protect animal hearts from the damaging 
effects of a heart attack using a variety of interventions. In contrast however there is little experience in man. We seek to investigate whether 
protection can occur using samples of human heart muscle.  
 
What does the study involve? 
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findings are presented at meetings or published in medical journals. 
 
What if you change your mind? 







 THE HATTER INSTITUTE & CENTRE FOR CARDIOLOGY  
(Division of Medicine) 
 
University College London Medical School 
Centre for Cardiology 
University College London Hospitals 
51-67 Chenies Mews 
London WC1E 6DB 
 
Tel:      020 7380 9888 
Fax:     020 7388 5095 
Email: hatter-institute@ucl.ac.uk 
 
Professor DM Yellon PhD, DSc, Hon FRCP, FESC, FACC 
Director of Institute & Director of the Centre for Cardiology 
Dr JM Walker: Consultant Cardiologist & Clinical Director, Dr PMI Sutton: Associate Director & Sen Lecturer, Dr P Taggart: Reader in Medicine,  
Dr RH Swanton: Consultant Cardiologist, Professor J Betteridge: Professor of Endocrinology & Metabolism, Dr CCT Smith: Sen Lecturer,  




INFORMED CONSENT FORM 
 
 
Study Title:   An investigation into the effects of potential cardioprotective therapies on human heart muscle 
 
Name of Principal investigator:  Professor Derek M Yellon 
 
1. HAVE YOU RECEIVED THE INFORMATION SHEET ABOUT THIS STUDY?    YES/NO 
 
2. HAVE YOU HAD AN OPPORTUNITY TO ASK QUESTIONS AND DISCUSS THE STUDY? 
                    YES/NO 
 
3. HAVE YOU RECEIVED SATISFACTORY ANSWERS TO YOUR QUESTIONS?    YES/NO 
 
4. HAVE YOU RECEIVED ENOUGH INFORMATIONJ ABOUT THE STUDY?  YES/NO 
 
5. DO YOU UNDERSTAND THAT YOU ARE FREE AT ANY TIME TO WITHDRAW FROM THE 
 STUDY?          YES/NO 
 






I have explained the above study to the patient 
 




I have had the nature  and purpose of the study explained to me and agree to participate 
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Introduction
ST-segment elevation myocardial infarction (STEMI) is a con-
sequence of atherosclerotic plaque rupture and thrombotic oc-
clusion of the coronary artery causing downstream ischaemia
and, eventually, cell death. The most effective therapeutic strat-
egy for STEMI is timely reperfusion by primary percutaneous
coronary intervention (PPCI). Such reperfusion is a prerequi-
site for myocardial salvage, leading to smaller infarct sizes and
improved clinical outcomes [1, 2]. However, reperfusion can
itself inflict further injury, termed ischaemia-reperfusion injury
(IRI). Despite PPCI, a recent study found 30-day, 1-year, and
5-year mortality following STEMI to be 7.9 %, 11.4 %, and
23.3 %, respectively [3]. Consequently, novel strategies to mit-
igate the deleterious effects of IRI are paramount.
Stromal derived factor-1α (SDF-1α or CXCL12) is a che-
mokine that has demonstrated cardioprotective activity in
mice [4]. We recently demonstrated that exogenous SDF-1α
improved functional recovery of ex vivo rat cardiac papillary
muscle subjected to hypoxia and reoxygenation (simulated
IRI) [5]. This effect was abrogated by pre-treatment with
AMD3100, a highly specific antagonist of the SDF-1α recep-
tor, CXCR4.
However, it is not known whether SDF-1α can similarly
protect human heart tissue and whether any such protection is
afforded via CXCR4. We address this question using isolated
human atrial trabeculae subjected to simulated IRI.
Methods
Human Atrial Trabeculae Hypoxia-Reoxygenation
Experiments
The study received Local Research Ethics Committee approv-
al and was carried out in accordance with the University
College London Hospitals NHS Trust guidelines. A right atri-
al appendage sample was harvested from 47 patients with
chronic stable angina undergoing cannulation for cardiopul-
monary bypass for CABG.All patients were aged 18–80 years
and there were no significant differences in their baseline
characteristics (see Table 1). Patients with diabetes, impaired
renal or ventricular function, dilated left atria, unstable angina,
or a history of arrhythmias or on rhythm stabilising medica-
tions were excluded.
Trabeculae were randomly allocated to [1] control (n = 11),
[2] hypoxic preconditioning (n = 10), [3] SDF-1α pre-treat-
ment (n = 11), [4] AMD3100 + SDF-1α pre-treatment
(n = 10), and [5] AMD3100 pre-treatment (n = 5). Two sep-
arate trabeculae were collected for immunofluorescent stain-
ing. The sample was placed in ice-cold buffer prior to careful
dissection of the trabeculae. Isolated trabeculae (≤1.2 mm in
diameter and ≥2.0 mm in length) were suspended in a heated
(37 °C) organ bath with one end connected to a force trans-
ducer. Samples were superfused with oxygenated modified
Tyrode’s buffer (95 % O2/5 % CO2) at 37 ± 0.5 °C and
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pH 7.4 ± 0.5 [5]. The muscle was electrically paced at 1 Hz
and stretched until the maximum force of contraction (the
peak of the Frank-Starling curve) was achieved. The muscle
was subsequently allowed to stabilise for 90 min before being
subjected to 60 min of hypoxia by superfusion with
equiosmolar, glucose-free hypoxic modified Tyrode’s buffer
(95 % N2/5 % CO2), pH 7.4 ± 0.5 and electrical stimulation at
3 Hz. Themuscle was reoxygenated for 60min with normoxic
buffer and 1 Hz stimulation, to simulate reperfusion. Hypoxic
preconditioning, consisting of 4.5 min hypoxia and pacing at
3 Hz followed by 6 min reoxygenation and pacing at 1 Hz,
was applied immediately prior to the index hypoxic period as
a positive cardioprotective control [5]. SDF-1α (25 ng/ml),
AMD3100 (10 μg/ml) or saline vehicle were administered
for 30 min and 40 min respectively prior to index hypoxia,
concentrations that were based on previous publications [4, 5].
Immunohistochemistry
In a separate group of experiments, isolated human atrial tra-
beculae were frozen and mounted in OCT before being cut
into 5 μm sections at −20°C in a microtome-cryostat and
transferred to slides. Sections were fixed with HistoChoice
(Sigma-Aldrich, UK) for 20 min at room temperature and
washed with PBS, before blocking with 5 % BSA/PBS for
60 min. Immunofluorescent co-staining of CXCR4 and
cardiomyocytes was performed using rabbit monoclonal
anti-CXCR4 (ab124824) and mouse anti-cardiac troponin T
(ab8295) from Abcam (Gillingham, UK). Anti-rabbit Alexa
Fluor 488 and anti-mouse Alexa Fluor 555 secondary antibod-
ies were purchased from Abcam. Cardiomyocyte co-stained
samples were incubated in anti-CXCR4 and anti-cardiac tro-
ponin T, diluted in 1 % BSA/PBS 1:100 and 1:10 respectively,
overnight at 4°C. Following washing and incubation with the
appropriate secondary antibody diluted 1:400 in the same
buffer for 60 min at room temperature, samples were washed
again and coverslips mounted using fluorescence mounting
medium (Dako, Ely, UK). 0.1 μg/ml Hoechst 33,258 nuclear
stain (Life Technologies, Paisley, UK) was added with the
secondary antibodies to all sections. Preparation of control
sections was identical and they were incubated either with
1 % BSA/PBS only (unstained control) or with the relevant
secondary antibody in the absence of any primary antibody.
After drying, Alexa 488 and Alexa 555 fluorescence was











Mean age (years) 61 64.8 64.6 63.4 61.6
Gender (male) 9 (82 %) 10 (100 %) 10 (91 %) 7 (70 %) 4 (80 %)
Good LV (>50 %) 11 (100 %) 10 (100 %) 11 (100 %) 10 (100 %) 5 (100 %)
eGFR >55 mL/min 11 (100 %) 10 (100 %) 11 (100 %) 10 (100 %) 5 (100 %)
Rhythm
Sinus 11 (100 %) 10 (100 %) 11 (100 %) 10 (100 %) 5 (100 %)
Surgery
CABG 7 (64 %) 4 (40 %) 7 (64 %) 5 (50 %) 1 (20 %)
AVR 4 (36 %) 5 (50 %) 0 (0 %) 5 (50 %) 4 (80 %)
CABG + AVR 0 (0 %) 1 (10 %) 4 (36 %) 0 (0 %) 0 (0 %)
Medications
β-blocker 8 (73 %) 4 (40 %) 7 (64 %) 2 (20 %) 1 (20 %)
ACE inhibitor 5 (45 %) 5 (50 %) 5 (45 %) 3 (30 %) 1 (20 %)
Calcium channel blocker 2 (18 %) 0 (0 %) 1 (9 %) 1 (10 %) 1 (20 %)
Nitrate 2 (18 %) 2 (20 %) 1 (9 %) 1 (10 %) 1 (20 %)
Statin 8 (73 %) 2 (20 %) 7 (64 %) 5 (50 %) 3 (60 %)
MRA 1 (9 %) 1 (10 %) 0 (0 %) 0 (0 %) 0 (0 %)
Diuretic 2 (18 %) 1 (10 %) 1 (9 %) 0 (0 %) 0 (0 %)
Anti-arrhythmic 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Trabecular dimensions
Length (mm) 4.31 5.16 5.05 3.86 4.6
Diameter (mm) 0.97 1.01 1.09 1.18 0.89
LV, left ventricle; eGFR, estimated glomerular filtration rate; CABG, coronary artery bypass graft surgery; AVR, aortic valve replacement; ACE,
angiotensin converting enzmye; MRA, mineralocorticoid receptor antagonist
*Data expressed as number (%) or mean




imaged using a 40× oil immersion objective, by sequential
scanning using the 488 nm and 543 nm lines of a Leica SP5
confocal microscope and collecting emitted light at 500–
530 nm and 580–650 nm respectively. Control experiments
were performed to confirm the absence of fluorescence bleed-
through or non-specific staining with secondary antibodies
alone.
Statistics
The final force of contraction in the human atrial trabeculae
hypoxia-reoxygenation experiments was expressed as a
percentage of baseline contractility to give recovery of function.
Values are expressed as mean ± SEM. Comparisons between
more than 2 groups were made using 1-way analysis of variance
(ANOVA). Fisher’s protected least significant difference post
hoc test was used for between-group comparisons. Differences
were considered statistically significant when P < 0.05.
Results
In control trabeculae, the mean recovery of function after hyp-
oxia and reoxygenation was 27 ± 2 % [1]. Recovery of
Fig. 1 The SDF-1α-CXCR4 axis
protects humanmyocardium from
hypoxia-reoxygenation injury: a
Recovery of contractile function
during simulated ischaemia and
reperfusion applied to isolated
human atrial trabeculae is
improved by pre-treatment with
exogenous SDF-1α to a level
similar to that conferred by
hypoxic preconditioning. N = 11
atrial trabeculae in the control and
SDF-1α pre-treatment groups, 10
in the hypoxic preconditioning
and AMD3100 + SDF-1α pre-
treatment groups, and 5 in the
AMD3100 pre-treatment group.
*SDF-1α vs. control, †AMD +
SDF-1α vs. SDF-1α (*P < 0.05,
**P < 0.005, ***P < 0.001). b,
Immunofluorescent staining of
isolated human atrial trabeculae
demonstrating the distribution of
CXCR4 (green) in relation to
cardiomyocytes (red). c,
Immunofluorescent staining
using secondary antibody in the
absence of primary antibody.
Representative images fromN = 2
independent experiments, 50 μm
scale bar
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function in samples pre-treated with SDF-1αwas significantly
increased (53 ± 3 %, P < 0.05 vs. control, Fig. 1), which was
similar to that in control trabeculae subjected to hypoxic pre-
conditioning (48 ± 4 %, P < 0.05 vs. control).
The role of signalling via CXCR4 was investigated by pre-
treating trabeculae with the specific CXCR4 inhibitor,
AMD3100, which abrogated the protective effect of SDF-1
(30 ± 2 %, P < 0.05 vs. SDF-1α alone). AMD3100 alone had
no effect on functional recovery (25 ± 4 %). Furthermore,
immunofluorescent staining confirmed the presence of
CXCR4 receptors on cardiomyocytes in human atrial trabec-
ulae (Fig. 1).
Discussion
SDF-1α is a small CXC chemokine that is expressed by sev-
eral organs and tissues, including endothelial cells and
cardiomyocytes in the heart [6]. Its cognate receptors
CXCR4 and CXCR7 are similarly present in a range of tis-
sues, including cardiomyocytes. The SDF-1α/CXCR4 axis
has garnered considerable interest due to its role in stem cell
homing, angiogenesis and ventricular remodelling after myo-
cardial infarction, and has been used to target stem cells to
ischaemic tissue, thereby improving LV dimensions and func-
tion [7].
We and others have previously demonstrated a
cardioprotective role for SDF-1α on both infarct size in iso-
lated perfused rat hearts and recovery of function in isolated
rat papillary muscle [5, 8]. Both of these beneficial effects
were abolished by AMD3100, all of which evidences a
cardioprotective role for the SDF-1α/CXCR4 axis.
Elsewhere, the application of exogenous SDF-1 has been
shown to reduce apoptosis in isolated cardiomyocytes and
SDF-1 infused into the murine LV cavity in vivo produced
significantly smaller infarct sizes after IRI, both effects that
were abrogated by AMD3100 [9].
This ex vivo functional model of hypoxia and reoxygena-
tion translates the aforementioned findings to human myocar-
dium for the first time, in the native milieu of the functional
heart. This study confirms [1] the ability of exogenous SDF-
1α to protect human atrial trabeculae from the detrimental
effects of simulated IRI; [2] the role of CXCR4 in this mech-
anism, as evidenced by attenuating the benefits of SDF-1α
using the specific receptor blocker AMD3100; and [3] the
presence and distribution of CXCR4 in human adult
cardiomyocytes and endothelial cells.
There is evidence that the cardioprotective utility of SDF-
1α/CXCR4 may be conferred by activating intracellular pro-
survival kinases, although the specific mechanism remains
unknown [5]. However, it is thought to converge on the mito-
chondrial permeability transition pore (mPTP) and effect
protection by delaying its opening and consequent necrotic
cell death [10]. The exact mechanism of protection afforded
by SDF-1α/CXCR4 should be the focus of further investiga-
tion in both basic and clinical studies.
In summary, our findings support the hypothesis that exog-
enous SDF-1α is a preconditioning mimetic, herein shown to
exert acute protection against the deleterious effects of hypox-
ia and reoxygenation and that this protection, in the isolated
human atrial trabeculae, occurs via the CXCR4 receptor.
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ischemia (MI) and ischemia-reperfusion. The mitochondrial enzyme
thiosulfate sulfurtransferase (TST) has a putative role in removal of
H2S and inhibition may provide an alternative means of therapeuti-
cally increasing H2S bioavailability. This study investigated the
hypothesis that deletion of TST in mice (Tst -/-) would reduce infarct
size and improve outcome following MI.
Methods TST expression was assessed by qRT-PCR and Western
blotting. Tst -/- and wild-type (WT) mice were anaesthetised for
assessment of cardaic structure and function by high frequency ultra-
sound and for measurement of blood pressure. MI was induced by
coronary artery ligation in vivo , or ex vivo in perfused hearts, when
30 mins ischemia was followed by 120 min reperfusion.
Results qRT-PCR and Western blots confirmed the presence of TST
in the murine heart and also deletion in Tst -/-. Tst -/- mice survived to
adulthood, had no change in blood pressure relative to WTand and
had normal cardiac structure and function. Expression of the H2S
synthesising enzyme, cystathionine gamma-lyase (CSE), was reduced
in Tst-/- relative to WT hearts (n = 5, p < 0.01). Following MI the
incidence of cardiac rupture was increased in Tst-/- mice (66%, vs
20% in WT). Studies in isolated hearts revealed increased infarct size
in Tst-/- (88 ± 2% area at risk, vs 65 ± 6% in WT, n = 6, p = 0.01).
Discussion TST is present in the heart and deletion does not
influence structure or function. Tst -/- mice have reduced cardiac
CSE expression, suggesting reduced H2S synthetic capacity. This
may underlie the increased susceptibility of Tst -/- mice to myo-
cardial injury and increased mortality.
Conclusion TST may act with CSE to regulate H2S availability.
Alteration in the balance of these enzymes has no overt physio-
logical effect, but is associated with reduced capacity of the heart
to resist ischaemic stress.
This study was supported by a BHF 4 PhD studentship to BE
and by a BHF Centre of Research Excellence Award.
222 SRC-DEPENDENT TYROSINE PHOSPHORYLATION OF HIC-
5 REGULATES HIC-5 SUBCELLULAR LOCALISATION AND
ACTIN CYTOSKELETON DYNAMICS IN RAT VASCULAR
SMOOTH MUSCLE CELLS IN RESPONSE TO
NORADRENALINE AND ENDOTHELIN-1
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223 A NOVEL IMMUNOGLOBULIN G AUTOANTIBODY
AGAINST LOW DENSITY LIPOPROTEIN (LDL) WITH
PATHOGENIC FUNCTIONS
Ramzi Khamis*, Kevin Woollard, Joseph Boyle, Shang-Hung Chang, Gareth Hyde,
Michael Johns, Dorian Haskard. Imperial College London
10.1136/heartjnl-2014-306118.223
Introduction IgG autoantibodies reacting with different forms of
modified LDL are found in blood and have been associated with
cardiovascular events related to atherosclerosis. However there is
a controversy as to whether such antibodies are pathogenic. We
set out to generate monoclonal autoantibodies reacting with
LDL for further mechanistic studies.
Methods/Results We fused splenocytes from a LDL receptor defi-
cient (Ldlr-/- ) atherosclerotic mouse with the Sp2/0 myeloma cell
line, and screened hybridoma culture supernatants by ELISA for reac-
tivity with solid-phase LDL. We selected a monoclonal IgG2b anti-
body, designated LO9. Sequencing of the LO9 variable heavy (VH)
and variable light (VL) regions revealed numerous somatic mutations
in the complementarity determining regions (CDR) of both the VH
and VL. Together with the IgG2b subclass, these indicate that LO9 is
not a natural antibody but has developed from an adaptive immune
response. To investigate interaction of LO9 with LDL we performed
in vitro binding assays. LO9 reacted with LDL directly adherent to
ELISA plates, but not with LDL immobilised by polyclonal anti-
apoB. Less reactivity was noted with Cu++ oxidised-LDL and malon-
dialdehyde-conjugated LDL (MDA-LDL). LO9 binding to adherent
LDL was not inhibited by fluid-phase LDL in excess and the LO9
epitope was not abolished by organic solvents, suggesting that it is
not lipid. In functional assays, addition of macrophages to LO9
bound to adherent LDL in vitro led to significant TNF release, an
effect that was blocked by inhibition of Fc gamma receptors (FcgRs),
and which was not seen when macrophages were incubated with
adherent LDL alone. Expression of the LO9 epitope on adherent
LDL was greatly increased by incubation with conditioned medium
(CM) from activated macrophages, consistent with the LDL epitope
being further revealed by the action of macrophage-derived factors.
Expression of the LO9 epitope in atherosclerosis was confirmed by
immunohistochemical staining of human and mouse lesions.
Following intra-venous injection of LO9 labelled with a near
infra-red dye (LO9–750), fluorescence molecular tomography
imaging demonstrated specific localisation to a region of interest
covering the aortic arch of Ldlr-/- mice but not wild type ani-
mals. Confocal microscopy of extracted aortae en face confirmed
that LO9 localised in atherosclerotic regions beneath endothe-
lium and in the vicinity of macrophages.
Conclusions We believe LO9 is the first example of an autoanti-
body that reacts with an allosteric epitope on LDL, revealed by
adhesion to a surface and/or by the action of factors derived
from activated macrophages. Binding of LO9-like antibodies to
LDL trapped on matrix in the arterial wall could lead to promo-
tion of atherosclerosis via ligation of macrophage FcgRs and
release of TNF and other proinflammatory mediators.
224 STROMAL DERIVED FACTOR 1 ALPHA IS A MEDIATOR
OF CONDITIONING IN HUMAN AND RAT MYOCARDIUM
Derek M Yellon, Abdul Malik*, Jack MJ Pickard, Daniel Bromage, Sean M Davidson,
Vivek Sivaraman, Zhenhe He. Hatter Cardiovascular Institute
10.1136/heartjnl-2014-306118.224
Background We have recently demonstrated that stromal cell-
derived factor 1a (SDF-1a) limits myocardial infarct size (IS) in a
murine model of ischaemia-reperfusion injury (IRI) via its receptor
CXCR4. This study aimed to investigate the role of SDF-1a in the
cardioprotection conferred by remote ischaemic conditioning
(RIC) using three different human and animal models.
Methods 1) In vivo RIC: Rats were anaesthetised with sodium
pentobarbitone (60mg/kg i.p.), intubated and ventilated. Animals
were randomly allocated to receive intravenously either a specific
inhibitor of CXCR4, AMD3100 (10µg/ml), or vehicle (0.9% sal-
ine). Animals then underwent either a RIC protocol (3 × 5 min
hind limb ischaemia) or a sham procedure for the same time
period. Complete cessation of blood flow in the RIC group was
confirmed by Doppler measurement. All groups were subjected to
30 min left coronary artery occlusion and 2h reperfusion (IR),
after which the heart was removed and analysed for IS as a propor-
tion of area at risk (IS/AAR%). 2) Ex vivo RIC: Coronary effluent
was collected from isolated perfused rat hearts following either
stabilisation (Ceff) or during a preconditioning protocol (3 × 5
min, IPCeff). Recipient hearts were perfused with effluent for 10
min (± 5 µg/ml AMD) prior to 35 min LCA occlusion and 60 min
reperfusion. Infarct size was measured as above. 3) Isolated human
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